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1. Introduction 
 
1.1. Cimicifuga racemosa rhizome extract  
 
1.1.1. Cimicifuga racemosa  
 
Cimicifuga racemosa extracts (L.) Nutt. (synonym for Actaea racemosa L., black cohosh) 
obtained from the rootstock are commonly used to treat menopausal complaints. 
Cimicifuga racemosa belongs to the buttercup family (Ranunculaceae) and is native to 
the Eastern part of the United States and Canada. In traditional Chinese medicine and 
in folk medicine it has been used against a wide range of symptoms for example, against 
headache [1]. 
                            
Figure 1. Cimicifuga racemosa 
Pictures of Cimicifuga racemosa at the cultivation site in Uttwill in Switzerland (Vitaplant AG, 
photographs by Malena Rabenau).  
 
In Europe, Cimicifuga racemosa gained importance in the last decades; it is 
monographed for treatment of climacteric symptoms by the German Commission E since 
1989, the WHO since 2002 and the ESCOP since 2012. Moreover, the HMPC granted 
Cimicifuga racemosa extracts with well-established use status [2,3]. Several clinical 
studies support the effective treatment of Cimicifuga racemosa extracts against 
menopausal complaints, which was summarized in a recent meta-analysis comparing 
Cimicifuga racemosa to placebo [4]. In this meta-analysis, a statistical difference of 
p<0.0001 in favor of Cimicifuga racemosa extracts was found. In the HMPC monograph, 
three different herbal preparations are listed: two ethanolic, and one isopropanolic dry 
extract [2]. Ze 450 is an ethanolic (60%, v/v) Cimicifuga racemosa dry extract that was 
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produced by a standardized procedure and this extract was exclusively investigated in 
this study.  
The extract from the rhizome of Cimicifuga racemosa contains many different 
components. It consists of triterpene glycosides [5–7], mainly xylosides, like actein, 23-
epi-26-deoxyactein and cimiracemoside C [8,9], besides phenolic acids, predominantly 
derivatives of hydroxycinnamic acid [10], including caffeic, ferulic and cimicfugic acid [7], 
and flavonoids [11] are represented. Moreover, it is suggested that mostly the phenolic 
compounds, especially ferulic, isoferulic and caffeic acid mediate antioxidant effects 
[12,13]. It is important to point out that, according to current knowledge, the rootstock 
does not contain phytoestrogens. In earlier studies the isoflavone and phytoestrogen 
formononetin was related to effects mediated by Cimicifuga racemosa extract [14], 
however, in more recent studies, formononetin was not detected [15–17]. 
 
1.1.2. Therapeutic use and mechanism of action  
 
Ze 450 is approved for the treatment of peri-menopausal complaints in many European 
countries. Climacteric symptoms include sweating, insomnia, mood disorders, 
headache, vaginal dryness, and most frequently hot flushes [18,19]. It is well known that 
during menopausal transition estrogen depletion or fluctuation of estrogen level lead to 
alterations in CNS gene expression, neurotransmitter synthesis, and to an impairment of 
hypothalamic neuronal activity, including mitochondrial dysfunction and an imbalanced 
redox homeostasis (Figure 2) [20]. Those alterations promote inflammatory processes 
and oxidative stress [21]. The mentioned changes may largely contribute to the 
development of hut flushes via narrowing of the thermoregulatory set point [22]. In line 
with the general view of menopausal complaints being caused by hormonal 
dysregulation, hormone replacement therapy (HRT) is mainly used to treat menopausal 
complaints [21], but it is limited due to adverse side effects, like headache, uterine 
bleeding and enhanced risks for venous thromboembolic disease, breast cancer, stroke, 
and coronary artery disease [23,24]. Besides, the need for alternative treatment 
strategies is supported by the wish of women suffering from menopausal symptoms for 
hormone-free treatments [25,26]. Therefore, Cimicifuga racemosa extracts are an 
effective [4,27,28] and safe alternative [29] with a good tolerability and no known 
interactions [2]. Additionally, menopausal women with osteoporosis [30–34], metabolic 
disturbances [35,36] and myeloma [37] may benefit from Cimicifuga racemosa 
treatment. 
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Figure 2. Scheme of estrogen-mediated effects in pre- and post-menopause 
Estrogen mediates protective effects on metabolism. In premenopausal women, physiological 
estrogen levels contribute to a balanced brain redox homeostasis with normal activity of ETC 
(electron transport chain). Depletion of estrogen in the postmenopause leads to a decrease of 
mitochondrial respiration and an increase in ROS formation and consequently a dysbalanced 
redox homeostasis, which may contribute to climacteric complaints, like hot flushes (OXPHOS: 
oxidative phosphorylation, mROS: mitochondrial ROS). 
Besides estrogen depletion mediated processes, mounting evidence suggests additional 
effects, such as increased oxidative stress, which may contribute to the development of 
metabolic disorders that do not respond to HRT [38,39].  
Until now, very little is known about the exact mechanism of action of Cimicifuga 
racemosa extracts. In vitro, it was demonstrated that Cimicifuga racemosa extract binds 
to serotonergic receptors (5HT(1A), 5-HT(1D), and 5-HT(7)), and regulates signal 
transduction as a partial agonist [40,41]. This regulation might be responsible for the 
effective reduction of hot flushes since 5 HT(1A) and 5 HT(7) receptors are present in 
the hypothalamus, and they are involved in thermoregulation [42]. Moreover, another 
study identified Nω-methylserotonin as a serotonergic component of rhizomes of black 
cohosh [41]. In vivo, in ovariectomized rats, serving as a model of post-menopause, it 
was demonstrated that Cimicifuga racemosa extract reduced hot flushes [43], weight 
gain and serum triglycerides [36], which are indicators for beneficial metabolic effects.  
Besides this, it was found that components of the Cimicifuga racemosa extract passed 
the blood-brain-barrier and were involved in thermoregulation in ovariectomized rats [44]. 
Moreover, black cohosh mediates neurobiological effects, for example, it increased the 
μ opioid receptor binding potential in brain regions involved in emotional and cognitive 
function in postmenopausal women [45].  
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Recent studies further revealed that Cimicifuga racemosa extract rather exerted anti-
estrogenic than estrogenic effects, since black cohosh did not impact hormone level in a 
study with peri- and postmenopausal women [46]. 
Furthermore, Cimicifuga racemosa extract exerted anti-estrogenic effects in breast 
cancer cells in vitro [47] and can be used in patients with uterine myoma [37], endometrial 
cancer [33] and breast cancer treated with tamoxifen [48]. Cimicifuga racemosa extract 
has shown to be beneficial in some types of cancer, as it showed a reduced risk for 
recurrence of breast cancer [49] and endometrial cancer [33]. Moreover, Cimicifuga 
racemosa extract rather mediated protective effects against breast cancer [50]. 
Recent in vitro studies revealed that AMP-activated kinase A (AMPK) was activated by 
Cimicifuga racemosa extract and ameliorated metabolic disorders in ob/ob mice and 
ovariectomized rats, indicating that effects of black cohosh extract on the bioenergetic 
metabolism may significantly contribute to therapeutic effects against menopausal 
complaints [35,36]. In contrast to metformin, Ze 450 mediated beneficial effects on 
cumulative weight gain and decreased average daily food and water intake in the 
mentioned study [35]. Additionally, Ze 450 improved HOMA-IR index as an indicator of 
insulin resistance [35].  
These recently emerging results highlight a potential role of Ze 450 on the energy 
metabolism in vitro and in vivo, proposing a novel therapeutic concept in the treatment 
of menopausal complaints that focuses on the metabolism rather than estrogen 
replacement. In a retrospective study, women treated with HRT or Cimicifuga racemosa 
were compared. In this study, body weight, metabolic serum parameters (lipids, glucose, 
insulin, HOMA-IR) and menopausal symptoms were assessed. In line with previous 
findings, Cimicifuga racemosa extract improved climacteric complaints. Notably, women 
treated with HRT or Cimicifuga racemosa extract did not gain weight, which points out 
beneficial effects of Cimicifuga racemosa extract on energy metabolism [52], since 
menopausal women accumulate risks for metabolic disease, including a significant 
weight gain [53]. In the current study, effects of Ze 450 on cellular metabolism were of 
particular interest with a special focus on mitochondria, since they are key organelles 
regulating cellular energy metabolism and thermoregulation. 
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1.2. Model systems of oxidative stress  
 
1.2.1. Ferroptosis/Oxytosis 
 
Oxidative stress plays a key role in the pathogenesis and progression of many metabolic, 
immunological and neurological diseases [54–57]. In this context, research was 
conducted in the field of oxidative stress-mediated cell death. Besides apoptosis, 
caspase-independent forms of cell death, like oxytosis or ferroptosis [58–60] contribute 
to the mentioned diseases. Well-established in vitro model systems of oxidative cell 
toxicity were used to study cellular and mitochondrial contribution to oxidative damage. 
HT22 cells lack expression of NMDA receptors and, consequently, glutamate-induced 
cell death is not mediated through glutamate-induced excitotoxicity through rapid calcium 
influx (Chapter 1.2.2.). Inhibition of the xCT (cysteine/glutamate antiporter) by erastin or 
glutamate provokes cellular depletion of glutathione, thereby disrupting the glutathione 
peroxidase 4 (GPX4) redox homeostasis [60]. GPX4 is an antioxidant enzyme, which 
catalyzes the detoxification of lipid-hydroperoxides [61]. 1S, 3R-RSL-3 (RSL-3) is 
capable to induce oxidative cell death by covalent binding and inactivation of GPX4. 
Either erastin or glutamate, as well as RSL-3 exposure, lead to massive ROS formation 
via lipid-peroxidation due to 12/15 lipoxygenases and subsequent mitochondrial 
impairments in neuronal and non-neuronal cells [59,62]. Loss of mitochondrial 
membrane potential, depletion of ATP generation via oxidative phosphorylation, 
enhanced mitochondrial fission [63] and mitochondrial ROS formation [64] mark the so-
called “point of no return”, meaning that cells with massively impaired mitochondria 
cannot survive (Figure 3) [65]. 
Upon mitochondrial outer membrane permeabilization, AIF is released and translocates 
to the nucleus [66], triggering DNA fragmentation and subsequent induction of cell death 
[67]. 
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Figure 3. Oxytosis/Ferroptosis  
The xCT transporter mediates the exchange of cysteine and intracellular glutamate across the 
plasma membrane. Milimolar concentrations of glutamate and micromolar concentrations of 
erastin inhibit the xCT antiporter reducing the intracellular cysteine required for the synthesis of 
glutathione (GSH). Depletion of GSH, in turn, reduces the activity of GPX4 (glutathione 
peroxidase 4) resulting in activation of 12/15 lipoxygenases (LOX) and ROS formation. Increase 
in ROS production mediates mitochondrial impairment and apoptosis-inducing factor (AIF) 
translocation from the mitochondria to the nucleus leading to DNA fragmentation and 
subsequently cell death (mROS: mitochondrial ROS; ψTm: mitochondrial membrane potential). 
 
1.2.2. Excitotoxicity 
 
Glutamate is an important neurotransmitter and signaling molecule, which is involved in 
neuronal plasticity and learning [68]. The neurotransmitter is primarily located 
intracellularly but can reach concentrations in a 10 µM range during synaptic 
transmission. In physiological conditions, voltage-dependent NMDA receptors are 
blocked by Mg2+, but after stimulation by glutamate, depolarization of the post-synaptic 
membrane removes the Mg2+ blockage and allows for Ca2+ influx [68,69]. However, 
excessive glutamatergic signaling followed by massive Ca2+ influx and disruption of the 
Ca2+ homeostasis causes excitotoxic cellular damage, which has been linked to a variety 
of neurodegenerative diseases, for example, stroke and traumatic brain injury [70]. In 
excitotoxicity, calcium dysregulation due to post-synaptic activation of glutamate 
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receptors (AMPAR, NMDAR, and metabotropic glutamate receptors) [69] triggers 
neuronal cell death (Figure 4). In particular, NMDAR mediated calcium and sodium influx 
contribute to a further increase in intracellular calcium levels [71] accompanied by 
dysregulation of the calcium extrusion via the sodium-calcium exchanger [72]. Upon 
excitotoxic signaling mitochondrial uptake of calcium leads to massive mitochondrial 
ROS formation, loss of mitochondrial membrane potential by opening of the 
mitochondrial permeability transition pore, thereby resulting in neuronal cell death 
[73,74]. 
  
Figure 4. Excitotoxicity  
Illustration of excitotoxic cell death in neurons. NMDAR: N-methyl-D-aspartate receptor; mGluR: 
metabotropic glutamate receptor, AMPAR: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid receptor; IP3R: inositol trisphosphate receptor ;VDCC: voltage-dependent calcium channels; 
NCX: sodium-calcium exchanger; Na+: sodium, Ca2+: calcium; ROS: reactive oxygen species; 
nNOS: neuronal nitric oxide synthase; NO: nitric oxide; mPTP: mitochondrial permeability 
transition pore; Cyt c, cytochrome c; DNA: deoxyribonucleic acid; ER: endoplasmic reticulum.  
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1.3. Cellular energy metabolism  
 
Mitochondria are considered as crucial organelles in energy metabolism since 
mammalian cells primarily rely on energy supply via oxidative phosphorylation. Besides 
this, ATP production is provided by the degradation of nutrients via anaerobic glycolysis 
(Figure 5) [75]. Under certain physiological and pathophysiological conditions, the 
importance of glycolytic metabolism increases [75].  
    
Figure 5. Main pathways of energy supply  
Glucose is metabolized to pyruvate via the glycolytic pathway. Under aerobic conditions (sufficient 
oxygen supply), ATP is supplied by mitochondria due to oxidative phosphorylation (OXPHOS). 
Under anaerobic conditions, pyruvate is metabolized to lactate by recycling NAD+ for glycolysis. 
Normally, the main energy demand is covered by mitochondrial use of acetyl-CoA via the 
tricarboxylic acid cycle (TCA) and following oxidative phosphorylation (OXPHOS). 
 
Oxidative phosphorylation  
Mitochondria are critical organelles for maintaining cellular energy homeostasis. In the 
tricarboxylic cycle, NADH is produced, which is essential for oxidative phosphorylation 
and ATP production. Five different mitochondrial complexes (I-V) are involved in energy 
production, by generating an electron and pH gradient along the inner mitochondrial 
membrane (Figure 6). Finally, complex V uses the energy provided by the proton 
electrochemical gradient to synthesize ATP from ADP in the mitochondrial matrix. 
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Mitochondria are considered as a major source of ROS upon electron leakage as a side 
product of oxidative phosphorylation [76]. Mitochondrial ROS are important mediators of 
cellular and mitochondrial damage and mitochondrial ROS production is often elevated 
under certain pathologic conditions, including oxidative stress [65]. Hence, protecting 
mitochondria has been proposed as a promising therapeutic strategy in the treatment of 
a variety of diseases, including metabolic diseases related to oxidative stress. 
 
Figure 6. Scheme of the electron transport chain (ETC) 
Oxidative phosphorylation is driven by a proton (black line) and an electron (dashed black line, 
indicates transport of electrons) gradient: NADH dehydrogenase (CI) uses NADH for electron 
entry and proton supply for the pH gradient. Succinate is metabolized by CII to fumarate; thereby 
electrons from CI and CII reactions were transferred to Ubiquinone (UbQ). Next, electrons were 
transferred from reduced ubiquinone to cytochrome c (Cyt c) via CIII. CIV transfers an electron 
from cytochrome c to a dioxygen molecule, which is converted to water. Moreover, complex IV 
increases the electrochemical potential by transferring protons to the IMS. Subsequently, ATP is 
produced by complex V driven from the pH and electron gradient. Inhibitors of the ETC are 
represented in red: rotenone inhibits CI, antimycin A inhibits CIII and oligomycin inhibits CV. 
Pyruvate and malate are involved in CI activity by supply of NADH, succinate is a substrate for 
CII (IMS: intermembrane space, IMM: inner mitochondrial membrane, MM: mitochondrial matrix, 
UbQ: Ubiquinone, Cyt c: cytochrome c). 
 
Anaerobic glycolysis  
In cases of low oxygen supply, glycolytic pyruvate is metabolized to lactate by lactate-
dehydrogenase restoring NAD+, this metabolic pathway is named anaerobic glycolysis, 
but glycolysis takes place in the presence or absence of oxygen. Under anaerobic 
conditions, pyruvate is metabolized to lactate (Figure 5), while during aerobic conditions 
it is metabolized to acetyl-CoA and used in the TCA cycle and following OXPHOS (Figure 
5). In cancer or fast proliferating cells, pyruvate is preferentially metabolized to lactate 
independent of the presence or absence of oxygen, and this phenomenon is called the 
Warburg effect or aerobic glycolysis (Figure 7) [75,77].  
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Figure 7. Molecular signaling pathways promoting the Warburg effect 
Metabolic reprogramming in cancer cells is promoted by enhanced glycolysis. AMPK, cMyc, and 
HIF1α are key players in cellular energy regulation contributing to this bioenergetic shift. The 
mentioned regulators (AMPK, cMyc, and HIF1α) enhance glycolytic gene expression. cMyc and 
HIF1α increase LDHA expression and LDHA activity, leading to preferred metabolism of pyruvate 
to lactate and limited influx of pyruvate in mitochondrial energy production. HIF1α enhances the 
activity of PDK1 and following inhibition of PDH, resulting in decreased OXPHOS (GLUT: glucose 
transporters, TCA: tricarboxylic acid cycle, OXPHOS: oxidative phosphorylation, AMPK: AMP-
activated protein kinase HIF1α: hypoxia-inducible factor α, PDH: pyruvate dehydrogenase, PDK1: 
pyruvate dehydrogenase kinase 1). 
 
Since aerobic glycolysis is less effective in energy production compared to oxidative 
phosphorylation, larger amounts of glucose are required to fulfill the energy demand of 
fast proliferating cells. Much research was done investigating the mechanism beyond the 
altered energy supply in tumor cells. For instance, glucose transporters [78] and 
hexokinase [79,80] expression were enhanced to support glycolysis. Besides this, the 
Warburg effect is regulated by the hypoxia-inducible factor (HIF), cMyc and AMP-
activated protein kinase (AMPK)–liver kinase B1 (LKB1) pathways [82], amongst others 
(Figure 7). Initially, cMyc was described as an oncogene, but further acts as a global 
transcriptional regulator affecting metabolism, mitochondrial function and cell growth in 
physiological conditions [83]. Intracellular signaling differentiating between oncogene 
and physiological pathways is the topic of current research. Besides, it has been 
demonstrated that cMyc regulates many glycolytic genes involved in the Warburg effect 
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[84] and, moreover, cMyc overexpression has been shown to be linked with Ark5 (AMPK 
related kinase 5), an upstream regulator of AMPK, which is involved in maintaining 
energy homeostasis [85]. Additionally, HIF1α is overexpressed in many human tumors 
and moreover, loss of function mutations were found in tumor suppressor genes like VHL 
(von Hippel-Lindau tumor suppressor gene), suggesting an essential role in cancer 
progression and tumor growth [86]. In this context suppression of HIF1 decreased 
mitochondrial respiration and enhanced glycolysis by involving pyruvate dehydrogenase 
kinase 1 [87]. The exact relationship of intracellular signaling pathways leading to a 
metabolic shift towards glycolysis remains to be elucidated, but metabolic 
reprogramming might play a role in diseases related to oxidative stress by reducing 
mitochondrial ROS mediated damage. 
In the context of cellular energy supply, it was a major interest to elucidate the effects of 
Ze 450 on mitochondrial metabolism and molecular signaling, which might contribute to 
the previously observed metabolic changes in vitro, in vivo, and in patients [35,36,52]. 
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1.4. Caenorhabditis elegans 
 
Caenorhabditis elegans is a nematode, which is free-living [88] and inhabits in soil 
surrounded by microorganisms [89]. Before reaching adulthood, four larval stages (L1-
L4) have been passed, the termination of each stage is marked by a molt [88]. It is a self-
fertilizing hermaphroditic animal, with a length of 1 mm, which produces about 300 
progenies every 3.5 days [88]. Besides the hermaphrodites, there are a few males, which 
are smaller and behave differently [90,91]. There is an alternative larval stage, which is 
entered under certain stress conditions, like high population density or restricted food 
intake [92]. In this stage, the larvae are able to remain for months [92]. 
Caenorhabditis elegans is an emerging model system to study neuronal development, 
behavior, and longevity. The neuronal system of C. elegans is well-studied and less 
complex than the mammalian nervous system. The nervous system of C.elegans 
consists of 302 neurons classified into 118 different neuronal classes, which share 
neuronal morphology and connectivity but differ in their position [88]. Moreover, it is 
known that the genome of C. elegans and humans have many features in common since 
a lot of the genes have a counterpart between the species [93].  
In general, there are at least three classes of genes, which are involved in the regulation 
of lifespan: eat genes, clk genes and genes regulating dauer formation, for example daf 
[94,95]. For example, caloric restriction prolonged lifespan by affecting eat genes [95,96]. 
Moreover, it is known that mutations in clk-1-3 and gro-1 affect aging, but are further 
involved in plenty of other functions. Besides this, it was discovered that mitochondrial 
hydroxylase is encoded by clk-1, which is involved in the regulation of redox 
homeostasis; clk-2 encodes for a telomere length controlling protein and an enzyme that 
modifies tRNAs is encoded by gro-1 [97]. However, very little is known about the 
mechanisms leading to elongated lifespan [94]. The third group of genes is involved in 
the regulation of the larvae stage [94] and they merge in the same intracellular signaling 
pathway, involving DAF-2, which is an insulin receptor-like transmembrane tyrosine 
kinase [98], and DAF-16 that is a forkhead transcription factor and necessary for lifespan 
extension [99]. Further correlative data suggests that daf-2 mutants are more resilient to 
oxidative stress, thereby promoting the prolongation of lifespan [100].  
Besides this, it has been shown that many genes which are involved in thermoregulation 
further promoted the extension of lifespan [101]. Additionally, the response to heat stress 
is preserved across different species [102] making the heat shock test in C. elegans a 
valuable tool to analyze lifespan under stress conditions because it involves hsf-1 [102]. 
During the heat shock thermosensory neurons (AFDs) sense and guide, heat mediated 
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signaling leading among other things to protein miss folding [103]. Thereby, activating 
heat shock response via IGF/ILS signaling pathway and hsf-1 and daf-16 involvement 
[104], leading to transcription of target genes, like SOD and HSP, for cytoprotection. 
During heat shock this regulatory mechanism cannot compensate for cellular damage, 
leading to a shortening of lifespan [102,105,106]. 
Taking use of the reduced lifespan due to heat shock, i.e. at 37 degrees Celsius, effects 
on long term survival are accessible in C. elegans in shorter time periods (~15 hours) 
compared to the real-time setting (~30 days).  
Further, paraquat (PQ), a known herbicide, is used to induce oxidative stress, also in 
C elegans. It induces superoxides [107], which are mainly produced by mitochondria and 
lead, for example, to disruption of protein homeostasis and DNA damage [106,108]. This 
stress response might be detrimental for the nematode, depending on the dose, as low 
concentrations of PQ extended lifespan of C. elegans [109]. Paraquat-induced oxidative 
stress response is used to study protective mechanisms affecting mitochondria in 
C. elegans. 
Caenorhabditis elegans is fed on bacteria, therefore it is essential for them to differentiate 
between food and pathogens [89]. For this reason, they have an excellent olfactory 
sense [89], which implies specialized chemosensory neurons to detect a wide range of 
odorants, including, for example, aromatic compounds [110,111], and they respond in a 
regulated manner to sensory stimuli [88]. This characteristic feature of C. elegans is used 
to assess chemotactic behavior and thereby neuronal function.  
In this context, C. elegans is an excellent model system to gain new insights into the 
mechanism of longevity and aging and further studying mitochondrial involvement in the 
mentioned processes.  
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1.5. Petasites hybridus extract (Ze 339) 
 
Petasites hybridus has been used to treat a variety of diseases, including gastrointestinal 
disorders [112] and migraine [113,114]. Petasites hybridus is also known as common 
butterbur, it belongs to the sunflower family (Asteraceae) and is spread over the northern 
hemisphere [115]. Mostly the leaves and the rhizomes of Petasites hybridus are used for 
medicinal purposes [116]. Multitudes of effects are described, but extracts of the rhizome 
are known to act spasmolytic and analgetic, while extracts of the leaves were reported 
to be inflammatory and anti-allergic [116].  
Ze 339 is a standardized CO2 extract, which is used to treat seasonal allergic rhinitis with 
a dosage of 16-24 mg petasin per day [117,118]. Efficacy and safety were proven in a 
prospective, randomized, double-blind, placebo-controlled study with 168 patients [117]. 
Petasin, isopetasin and neopetasin are sesquiterpenes, which are considered to mediate 
anti-allergic effects due to inhibition of inflammatory signaling molecules [119]. Besides 
the petasines, there are a variety of different components described, including 
pyrrolizidine alkaloids (PA) [120]. For Ze 339 PA-reduced plant species were selectively 
grown and a purification procedure was performed to ensure minimal PA content 
[115,120]. Moreover, in a highly sensitive UPLC TOF MS method PA were not detectable 
in Ze 339 within 29 different batches [120]. Besides Ze 339, seasonal allergic rhinitis can 
be treated with antihistamines, corticosteroids, decongestants, cromones, and 
immunotherapy [121–123]. 
The pharmacological mode of action of Ze 339 is not fully understood. So far, it is known 
from in vitro experiments that leukotriene (LT) synthesis [124,125] and the binding to 
histamine 1 receptors are blocked [126]. Moreover, Ze 339 and petasin demonstrated 
inhibitory effects on PAF- and C5a-induced increases in intracellular calcium 
concentrations [124]. Recent findings revealed that Ze 339 was effective in acute viral 
rather than bacterial infections [119] in primary human nasal epithelial cells (HNECs 
cells). In the same cell type, it was shown that neutrophil chemotaxis was reduced and 
this effect was mechanistically linked to reduced cytokine-induced STAT (signal 
transducer and activator of transcription) signaling [119]. Upon cytokine (IL-4, IFN, IL-6) 
release and binding to cytokine receptor 1 or 2, janus kinases (JAK) initiate 
autophosphorylation and subsequent recruitment of STATs [127]. STAT transcription 
factors are phosphorylated by JAK and then enter the nucleus as homo- or heterodimers 
to interact with target gene promotors. In the case of allergic rhinitis, pro-inflammatory 
gene products, like chemokines are expressed [128].  
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Since Ze 339 is a CO2 extract it is mainly composed of lipophilic components, like 
terpenoids, lipids and glycolipids [129], which can interact with membranes and lower 
bioavailability. Further, the authors propose that the hydrophobic components interfere 
with the assembly of the JAK/STAT complex and thereby reducing pro-inflammatory 
responses [129].  
In patients, it was found that Ze 339 reduced local IL-8 and LTB-4 production leading to 
symptom relief of allergic rhinitis [130]. Furthermore, nasal obstruction was recovered 
faster in patients treated with Ze 339 compared to desloratadine [130]. Moreover, in 
another study, Ze 339 was used and compared to cetirizine in patients with seasonal 
allergic rhinitis and mediated comparable effects by avoiding sedative side-effects [131]. 
Immunological diseases, including allergic rhinitis, have been shown to be associated 
with ROS formation [132]. Besides this pathophysiological role, ROS generated by 
mitochondria and via NADPH oxidase mediate functions as signaling molecules [133] 
maintaining a proper immune response via IL-1β, TNFα and IFN [134]. The principle of 
hormesis describes a specific regulation depending on the concentration of a hazardous 
compound or exposure to stress, for example of ROS and also phytochemicals [135]. 
Mechanistically hormesis is defined as an adaptive metabolic regulation to modulate 
stress responses [134,136,137]. Additionally, it has been shown that especially mild 
mitochondrial ROS formation mediates beneficial health effects (Figure 8), which is 
called mitohormesis [138,139]. In the context of the treatment of seasonal allergic rhinitis 
hormetic modulation might contribute to symptom relief, as low levels of ROS restore a 
healthy immune system with adequate but not overshooting reactivity to an allergen 
[134]. 
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Figure 8. Scheme of mitohormesis 
Mild mitochondrial ROS formation is triggered by various factors for example caloric restriction, 
fasting, mild oxidative stress, and others, thereby, involving a multitude of cellular pathways like 
AMPK or mTOR mediated signaling. Hereby, mitochondrial ROS function as signaling molecules 
affecting downstream transcriptional regulators like FoxOs or NRF2 leading to adaptive gene 
expression and beneficial effects on health, lifespan and promoting stress and mitochondrial 
resilience.  
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2. Aims and Objectives  
 
The major aims of the study were to reveal novel insights into the mechanisms of action 
of Cimicifuga racemosa and Petasites hybridus extracts emphasizing new therapeutic 
concepts supported by a deeper understanding of their molecular targets.  
The first part of the study focuses on the effects of the Cimicifuga racemosa extract 
Ze 450 on mitochondria as a major target in different model systems (cultured neuronal 
and liver cells, isolated mitochondria, and C. elegans). Cimicifuga racemosa extracts are 
commonly used to treat menopausal symptoms, such as hot flushes and night sweating. 
More recently, in vitro and in vivo studies suggested metabolic effects of Cimicifuga 
racemosa extract Ze 450 on AMPK signaling and enhanced insulin sensitivity in ob/ob 
mice, respectively. In addition, a retrospective clinical study revealed beneficial effects 
of Cimicifuga racemosa extract on weight gain in postmenopausal women, overall 
suggesting metabolic regulation as a major underlying mechanism of Ze 450. In line with 
this, one major aim of this study was to elucidate molecular effects of Ze 450 with a 
particular focus on mitochondria, since disturbances in energy metabolism are closely 
linked to menopausal complaints and metabolic disorders. Thus, investigating the effects 
of Ze 450 on metabolic regulation in hippocampal, hypothalamic and cortical neurons, 
as well as in liver cells shall reveal novel insights into the mechanism of action of 
Cimicifuga racemosa extracts and provide evidence for a new mechanistic concept 
explaining the relief of menopausal symptoms. Moreover, liver cells were used to 
address the ongoing discussion about Cimicifuga racemosa extracts causing 
hepatotoxicity. In this regard, Ze 450 was exposed to HepG2 and H4IIE cells to 
investigate potential cytotoxic effects.  
Menopausal transition is a physiological phase, which is generally considered as a 
consequence of estrogen depletion. In addition to estrogen decline, age-related risk 
factors, such as accumulating reactive oxygen species (ROS), may contribute to 
menopausal alterations and associated diseases, such as diabetes mellitus type II or 
osteoporosis. In particular, accumulating oxidative stress may affect mitochondria and, 
thereby, energy homeostasis and metabolic changes, which occur during menopause 
and the mentioned associated diseases. In the present study, model systems of oxidative 
stress were applied to mimic processes of accelerated ROS formation contributing to 
climacteric complaints and age-related diseases and evaluate potential protective effects 
of Ze 450.  
Alterations of cellular (e.g. cell death, lipid-peroxidation) and mitochondrial parameters 
(mitochondrial ROS formation, mitochondrial membrane potential) were assessed in 
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neuronal and liver cells under basal conditions and after induction of oxidative stress. 
Further, effects of Ze 450 on mitochondrial respiration and the rate of glycolysis were 
investigated, since cellular energy metabolism was found to be altered in menopausal 
transition but also in metabolic disorders, like diabetes mellitus type II. 
In addition, functional analysis of isolated mitochondria addressed the question of 
whether Ze 450 directly impacts mitochondrial respiratory chain complexes. 
Furthermore, mechanistic regulations were assessed by analyzing protein and mRNA 
levels of key metabolic regulators, like mTOR and HIF1α. To gain further insights into 
Ze 450 mediated effects on energy metabolism, glucose uptake into cells was 
investigated for a comprehensive understanding of the effects of Ze 450 on glucose 
metabolism. 
Further, isolated components (actein, 23-epi-26-deoxyactein and cimiracemoside C) and 
specific sub-fractions (EtOAc-, BuOH- and Aq. fraction) were investigated to elucidate 
which components of the extract contributed to the major effects of Ze 450.  
Finally, the effects of Ze 450 were tested on a whole organism in Caenorhabditis 
elegans. In this model system, Ze 450 mediated effects on longevity and aging were 
studied in vivo. For that purpose, Ze 450 was tested in a lifespan analysis, a heat stress 
application and a real-time setup using C. elegans. Moreover, potential protective effects 
of Ze 450 in C. elegans were investigated upon mitochondrial impairment provoked by 
paraquat-induced oxidative stress.  
 
In the second part of the thesis Ze 339, a Petasites hybridus leaf extract was 
investigated. Ze 339 is used to treat seasonal allergic rhinitis but there is little known 
about the molecular mechanism of Petasites hybridus extracts. Mitochondrial ROS have 
been shown to contribute to the pathogenesis of immunological diseases, but in addition, 
depending on the concentration, ROS mediate beneficial effects by modulation of 
metabolic adaptation processes. In this regard, it was of major interest to gain new 
insights into the mechanism of action of Ze 339 with a particular focus on mitochondria, 
since they are the major source of ROS and play a crucial role in cellular energy 
homeostasis. Further, metabolic regulations of Ze 339 in a model system of erastin-
induced oxidative damage shall enable its potential protective effects in neuronal cells.  
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3. Materials and Methods 
 
3.1. Cell culture 
 
HT22 cells were generated from a glutamate sensitive sub-clone of HT-4 cells by David 
Schubert (Cellular Neurobiology Laboratory, Salk Institute for Biological Studies, La 
Jolla, California, USA). Originally, HT4 cells were derived from primary hippocampal 
neurons and immortalized with a temperature-sensitive SV40 T-antigen [140,141]. HT22 
and mHypo-CLU190 cells (Cedarlane®, Cellutions Biosystems Inc., Canada) were 
grown in Dulbecco’s modified Eagle medium (DMEM, Capricorn Scientific GmbH, 
Germany) supplemented with 10% heat-inactivated fetal calf serum (Merck KGaA, 
Germany), 100  units/mL penicillin (Merck KGaA, Germany), 100 μg/mL streptomycin 
(Merck KGaA, Germany), and 2 mM glutamine (Capricorn Scientific GmbH, Germany). 
To induce cell death, glutamate (Merck KGaA, Germany) or erastin (Calbiochem®, 
Germany) was added to the medium for the indicated amount of time (8-16 h). Neuronal 
cells were split twice a week in a ratio of 1:10 -1:20. HepG2 (ATCC®™ HB-8065™) cells 
were grown in Eagle´s minimum essential medium (EMEM, Merck KGaA, Germany) 
supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL penicillin, 
100 mg/mL streptomycin. 1S, 3R-RSL-3, which was kindly provided by Prof. Diederich 
(University of Marburg, Germany), was added to induce oxidative cell death in HepG2 
cells. H4IIE cells (ATCC®™ CRL-1548, batch: 59997514) were kindly provided by Max 
Zeller Söhne AG, Switzerland. H4IIE cells were grown in EMEM supplemented with 10% 
heat-inactivated fetal calf serum, 100 U/mL penicillin, 100 mg/mL streptomycin. Liver 
cells were split twice a week in a ratio of 1:5-1:10. Splitting of cells was performed as 
follows: growth medium was replaced by 1x PBS following replacement by 0.05%/0.02% 
trypsin/EDTA (Merck KGaA, Germany). After detachment of the cells growth medium 
(containing FCS) was used to stop trypsinization. Cells were centrifuged for 3 min at 
1000 x rpm and the cell pellet was re-suspended in fresh medium. The amount of cell 
suspension was adjusted to the size of the cultured flask. For determination of the cell 
number, a counting chamber was used (BLAUBRAND®, Brand GmbH, Germany). After 
dilution to the desired cell number, cells were seeded in appropriate plates. For standard 
cultivation, liver and neuronal cell lines were kept in 75 cm2 flasks (T75) in a standard 
unified incubator (HERAcell®, KOBE, Germany) at 37°C and 5% CO2. 
Cell culture plates for primary neurons were incubated with 5% PEI (polyethyleneimine) 
for 4 h at 37°C, subsequently washed with sterile water and dried for 30 min under UV 
light exposure. Primary cortical neurons were prepared from embryonic mouse brains 
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(E16-18 from wild type C57BL/6 mice, Charles River, Germany). Dissected cortices were 
kept in HBSS (Hank´s balanced salt solution) on ice and rapidly processed as follows: 
Isolated cortices were trypsinized in HBSS containing 1 mg/mL trypsin for 15 min at 
37°C. Next, DNase was added for 30 seconds and the cortices were washed with HBSS 
and then mixed with HBSS containing 2 mg/mL trypsin inhibitor (Merck KGaA, Germany) 
for 2 minutes at room temperature. Followed by a washing step with HBSS and trituration 
with a 1 mL pipet tip. The triturated cells were centrifuged at 2,000 rpm for 5 min at RT 
(room temperature) and the supernatant was removed. The neurons were cultured in 
neurobasal medium (NB, ThermoFisher Scientific, Germany) supplemented with 2 % 
(v/v) B-27 (Invitrogen, USA). Dissociated neurons were seeded with 50,000 cells per well 
onto PEI coated 96 well plates. Cultures were grown in NB medium supplemented with 
1.2 mM L-glutamine, 2% B-27 supplement, 100 U/mL penicillin and 100 mg/mL 
streptomycin. On day four in culture, 10% fresh medium was added and on day seven in 
culture half of the medium was replaced. Treatment with Ze 450 and glutamate (20 μM) 
was carried out on day nine to ten in culture. The NMDA receptor antagonist, MK-801 
(Merck KGaA, Germany) was added at a concentration of 10 μM. Compounds were 
diluted in EBSS and incubated for the indicated time.  
Primary cortical rat neurons (kindly provided by Prof. Schratt, BPC Marburg, Germany) 
were plated on PEI coated 96 well plates with 20,000 cells/well and handled as described 
for the primary mouse neurons. 
 
3.2. Materials, solutions, and chemicals  
 
3.2.1. Cimicifuga racemosa extract (Ze 450) 
 
The ethanolic (60% v/v) Cimicifuga racemosa dry extract Ze 450 was manufactured of 
dried roots and rhizomes and obtained from Max Zeller Söhne AG (Switzerland, batch: 
151033). The content of triterpene glycosides was 6.4%. Ze 450 was dissolved in 60% 
ethanol (v/v) (Carl Roth GmbH, Germany) and filtered with a 0.22 µm Whatman 
Puradisc™ sterile filter. Ze 450 conforms to the herbal preparation B, which was granted 
well-established use in the 2010 Community herbal monograph on Cimicifuga racemosa 
by the HMPC. For the characterization of the extract, the HPLC fingerprint of Ze 450 
(batch: 151033) was determined as reported previously [142]. 
Fractionation of Ze 450 was performed at Max Zeller Söhne AG in Switzerland by 
Samuel Hasler. Ze 450 (10.0 g) was re-suspended in 100 mL H2O and subsequently 
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extracted with ethyl acetate (EtOAc, 4 ×100 mL) and butanol (BuOH, 4 ×100 mL) as 
described previously [143]. The EtOAc-, BuOH-, and aqueous fractions were 
concentrated in vacuo to yield the EtOAc soluble fraction (1.94 g, 19.3% (m/m)), the 
BuOH soluble fraction (0.94 g, 9.39% (m/m)) as well as the remaining aqueous (Aq.) 
fraction (7.32 g, 72.9% (m/m)). 
The dried fractions were solubilized in 60% ethanol (v/v) and further diluted to equivalent 
potent Ze 450 concentrations. 70 µg/mL of the Aq. fraction, 10 µg/mL of the EtOAc 
fraction and 5 µg/mL of the BuOH fraction correspond to 100 µg/mL total Ze 450 extract. 
 
3.2.2. Petasites hybridus extract (Ze 339) 
 
The subcritical carbon dioxide (CO2) Petasites hybridus leaf extract (Ze 339, batch: 
140155) was provided by Max Zeller Söhne AG, Switzerland. Appropriate stock dilutions 
were made with DMSO in glass vials fresh on the day of the experiment. 
 
3.2.3. Materials  
 
Materials and equipment were used as listed in Table 1 
Table 1. Materials and equipment 
T75 flasks Greiner, Germany 
0.2, 0.5, 1.5 and 2 mL Eppendorf tubes Sarstedt, Germany 
0.22 µm Whatman Puradisc™ sterile filter Whatman, Germany 
1, 5, 10 mL syringes Braun, Germany 
15 and 50 mL tubes Greiner, Germany 
24-well plates Greiner, Germany 
4 mL glass vial  KOBE, Germany  
6-well plates  Greiner, Germany 
96-well plates Greiner, Germany 
96-well plates (white) for ATP Greiner, Germany 
96-well plates for BCA Roche, Applied Science, Germany 
Cell homogenizer  Isobiotec, Germany  
Cell scraper Sarstedt, Germany 
Cell Strainer 100 µm Nylon  Life Sciences, USA 
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ChemiDoc XRS system Bio-Rad Laboratories, USA 
Counting chamber BLAUBRAND®, Brand GmbH, Germany 
ELx808 Ultra Microplate Reader Bio-Tek, Germany 
FluoStar OPTIMA BMG Labtech, Germany 
Gas-tight glass syringe Sulpeco, Germany 
Guava Easy Cyte 6-2 L system  Merck Millipore, Germany 
Heraeus FRESCO17 ThermoFisher Scientific, Germany 
HERAcell® KOBE, Germany 
Leica DMI6000 Leica, Germany 
NanoPhotometer™ Implen, Germany 
Nalgene Rapid-Flow Bottle-Top Filter 0.2 µm filter ThermoFisher Scientific, Germany 
Neoject® Cannulae 20 G Dispomed® WITT oHG; Germany 
Omnifix®-FLuer Solo 1 mL Braun, Germany 
Pipette tips  Gilson, USA 
Greiner, Germany  
PVDF membrane Roche Diagnostics, Germany 
Rotilab sealing film Greiner Bio-One, Germany 
Seahorse XFe96 Flux Pak  Agilent Technologies, USA 
Sterican Cannulae 18 G Braun, Germany 
T175 flasks Greiner, Germany 
Whatman puradisc™ Sarstedt, Germany 
xCELLigence system Real-Time Cell Analyzer 
RTCA-MP 
ACEA Bioscience, Inc., USA  
E plate 96 ACEA Bioscience, Inc., USA 
XF Extracellular Flux Analyzer  Agilent Technologies, USA 
XF96-well microplates and cartridges Agilent Technologies, USA  
µ slide 8 well  Ibidi GmbH, Germany 
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3.2.4. Solutions 
 
Table 2. Phosphate buffered saline (PBS), pH 7.4 
NaCl 9 g 
Na2HPO4 0.527 g  
KH2PO4 0.144 g 
HCl (0.1 M) q.s. for pH 7.4 
Aqua demin. up to 1 L 
 
Table 3. Standard Trypsin/EDTA solution (TE) 
Trypsin 7,500 U/mg  100 mg  
Ethylene diamine-tetra-acetic acid (EDTA) 40 mg 
1x PBS up to 200 mL 
 
Table 4. Hank´s balanced salt solution (HBSS), pH 7.2 
10x HBSS 50 mL 
Pen/Strep 1%(v/v) 1.2 g 
KH2PO4 5 mL 
Aqua demin. up to 500 mL 
 
Table 5. Polyethylenimine 5% (PEI) 
Boric acid  3.1 g 
Borax 9.0 g 
PEI 5% 1 mL 
Aqua demin. up to 800 mL 
 
Table 6. 0.5 M Ethylenediaminetetraacetic acid (EDTA) pH 8.0 
EDTA (x 2 H2O)  242 mg 
NaOH 20 g 
Bidest. H2O  1000 mL 
 
  
Materials and Methods 
24 
 
3.2.5. Chemicals and Kits 
 
All standard chemical reagents commercially available were purchased from Merck 
KgaA (Germany) or Roth (Germany), in case otherwise stated. For the preparation of 
buffers and solution, ultrapure water (SG Ultra Clear UV plus pure water system, VWR, 
Germany) was used. Sterilization for aseptic preparation of solutions was achieved by 
using a steam autoclave (Systec V-40, Systec GmbH, Germany) or sterile filtration 
(0.22 µm Whatman Puradisc™ sterile filter, Sarstedt, Germany). 
The kits (Table 7) were used according to manufacturer´s protocol, unless otherwise 
stated. 
 
Table 7. Kits 
Annexin-V-FITC Detection Kit Promokine, Germany 
BODIPY (581/591 C11) Invitrogen, Germany 
GSH Assay Kit Cayman Chemical, USA 
InviTrap Spin Universal RNA Mini Kit Stratec Biomedical, Germany 
MitoPTTM TMRE Kit Immunochemistry Technologies, Germany 
MitoSOXTM Invitrogen, Germany 
Pierce BCA Kit ThermoFisher Scientific, Germany 
SuperScript III One-Step RT-PCR System 
with Platinum® Taq 
Invitrogen, Germany 
ViaLightTM ATP Plus-Kit Lonza, Switzerland 
 
Substances were purchased like listed in table 8.  
Table 8. Substances 
1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-
pyrazole (PPT)  
Merck KgaA, Germany  
17β-estradiol  Merck KgaA, Germany  
2,2-diphenyl-1-picrylhydrazyl (DPPH)  Cayman Chemical, USA 
23-epi-26-Deoxyactein (deoxyactein) PhytoLab GmbH & Co.KG, Germany  
4-Hydroxytamoxifen (4-OH-Tamoxifen) Merck KgaA, Germany  
6-(hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid) (Trolox) 
Merck KgaA, Germany 
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Actein  PhytoLab GmbH & Co.KG, Germany  
Agarose Merck KgaA, Germany 
Cimigenol-3-alpha-L-arabinosid 
(cimiracemoside C)  
PhytoLab GmbH & Co.KG, Germany  
Diarylpropionitrile (DPN) Merck KgaA, Germany  
Metformin hydrochloride (metformin) Cayman Chemical, USA 
Phalloidin555 Thermo Fisher Scientific, Germany 
Rhodamine 123 (R123) Thermo Fisher Scientific, Germany 
SYTOX™ green Life Technologies, Germany 
2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-
yl)amino]-D-glucose (2-NBDG) 
Cayman Chemical, USA 
 
3.3. Mitochondrial isolation 
 
Spraque Dawley rats were kept at the Institute of Psychology, Marburg (AG Schwarting/ 
Wöhr, MR20/35 Nr.19/2014) and then transferred to the Institute of Pharmacology and 
Clinical Pharmacy (Marburg, Germany). Mitochondria were isolated immediately after 
dissection of the prefrontal cortex and liver. The following isolation steps were all carried 
out on ice. For cortical tissue ~ 50 mg and for liver tissue ~ 20 mg was minced with a 
scalpel in 1 mL of isolation buffer (Table 9). Cortical tissue was homogenized via 10 
times trituration with a 20 G Neoject needle and strained through a 100 µm cell strainer 
(Life Science, USA). The cortical and liver suspension was filled in a gas-tight glass 
syringe (Supelco, Germany). Afterwards, a pump controlled cell homogenizer (Isobiotec, 
Germany) with a constant pump flow rate (700 µL/min) was used according to existing 
protocols with minor modifications [144,145]. The system was primed with 1 mL 
mitochondrial isolation buffer before usage. Using the cell homogenizer, the cortical 
suspension was pumped three times with a clearance of 10 µm and the liver suspension 
once through a clearance of 18 µm. Next, the system was rinsed with 1 mL isolation 
buffer to collect the total homogenate. Followed by centrifugation at 800 x g for 10 min 
at 4°C (Heraeus, FRESCO17, ThermoFisher Scientific, Germany). The supernatant was 
transferred to a new 1.5 mL tube and centrifuged at 9,000 g for 10 min at 4°C. The 
resulting pellet represents the crude mitochondrial fraction. After resuspension in ~1 mL 
of mitochondrial isolation buffer (MSHE, Table 10) a BCA assay for protein determination 
using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific, Germany) was 
performed. Protein concentration was calculated via linear regression with a BSA 
standard based on mitochondrial isolation buffer. 
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Table 9. Isolation buffer 
Sucrose  300 mM 
TES 5 mM 
EGTA  200 µM 
DTT 1 mM  
 
Table 10. Mitochondrial isolation buffer (MSHE, pH 7.2) 
Sucrose  70 mM 
Mannitol 210 mM 
HEPES 5 mM 
EGTA  1 mM 
BSA 0.5% 
 
3.4. MTT assay 
 
Metabolic activity as an indicator of cell viability was quantified using the MTT assay 
[59,146]. Viable and metabolically active cells convert 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Merck KGaA, 
Germany), which was added at a concentration of 2.5 mg/mL (cell lines) or 5 mg/mL 
(primary neurons) for 1 hour at 37°C to the culture medium, into purple formazan. Next, 
the supernatant was removed and the plate with the attached cells was frozen at -80°C 
for at least 1 h. Absorbance was measured at 570 nm versus 630 nm with a plate reader 
(FluoStar, BMG Labtech, Germany) after dissolving in 70 µL/well DMSO via shaking for 
1 h at 37°C (Carl Roth GmbH, Germany).  
 
3.5. ATP assay 
 
ATP levels were detected using the ViaLightTM plus Kit (Lonza, USA) according to the 
manufacturer’s protocol. Approximately, twenty-four hours post-seeding in 96-well 
plates, cells were exposed to the indicated treatment. At the indicated time points after 
treatment (8, 16, 24 h), cells were transferred into a white 96 well plate and ATP levels 
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were analyzed by luminescence detection with FluoStar OPTIMA (BMG Labtech, 
Germany). 
 
3.6. DPPH assay 
 
For determination of the radical scavenging activity via the DPPH assay samples were 
prepared in 75% ethanol. 90 µL of 150 µM DPPH and 10 µL of the sample were 
incubated for 30 min in a 96 well plate in the dark. Absorbance was measured at 517 nm 
with a plate reader (SPARK 20M, TECAN, Germany). Radical scavenging activity was 
calculated using the following formula: (A0-A1)/(A0) x 100 
 
3.7. FACS measurements 
 
The microcapillary Guava Easy Cyte 6-2 L system (Merck Millipore, Germany) was used 
for flow cytometry measurements. HT22, mHypo, HepG2, H4IIE cells were seeded in a 
24-well format and treated 24-32 hours post-seeding for the indicated treatment time. 
Data was collected from at least three replicates per treatment condition and 5,000 cells 
per sample. The GuavaSoft Software package was used for analysis. 
 
3.6.1. Cell death (Annexin V/PI)  
 
For seeding 24 well plates were used. Neuronal cell lines were seeded at a density of 
40,000 cells per well and liver cell lines were seeded at a density of 50,000 cells per well. 
Cell death of HT22, mHypo, HepG2 and H4IIE cells exposed to the indicated treatment 
and inducer of oxidative stress was detected using the Annexin-V-FITC/PI Detection Kit 
(PromoCell, Germany) followed by fluorescence-activated cell scanning (FACS, guava 
easyCyte, Merck KGaA, Germany). Annexin-V-FITC was excited at 488 nm and 
emission was detected through a 525 ± 30 nm bandpass filter. Propidium iodide was 
excited at 488 nm, fluorescence emission was detected using a 690 ± 50 nm bandpass 
filter. Data were collected from at least 5’000 cells with at least three replicates per 
condition. 
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3.6.2. Lipid-peroxidation (BODIPY™) 
 
For determination of lipid-peroxidation 24 well plates were used. Neuronal cell lines were 
seeded at a density of 50,000 cells per well and HepG2 cells were seeded at a density 
of 60,000 cells per well. After the indicated treatments, HT22, mHypo and HepG2 cells 
were stained with BODIPY™ 581/591 C11 (Invitrogen, USA) for 1 h (37°C, 4.5% CO2) 
and harvested for FACS analysis. Lipid-peroxidation was analyzed by recording green 
(excitation: 525nm/30) and red (emission: 690nm/50) fluorescence with 488 nm 
excitation wavelength of at least 5’000 cells of at least three replicates per condition. 
Upon oxidation of BODIPY, lipid-peroxidation was analyzed by recording a shift from red 
to green fluorescence.  
 
3.6.3. Mitochondrial ROS formation (MitoSOX™) 
 
For seeding 24 well plates were used. Neuronal cell lines were seeded at a density of 
40,000 cells per well and liver cell lines were seeded at a density of 50,000 cells per well. 
15 µg of mitochondrial protein was used per treatment condition for the experiments with 
isolated mitochondria. MitoSOX™ red (Invitrogen, USA) is selectively targeted to the 
mitochondria, where it is oxidized by superoxides exhibiting red fluorescence. For 
detection of mitochondrial ROS formation, MitoSOX™ red was applied for 30 min at 37°C 
and cells were harvested for FACS analysis. For analysis of isolated mitochondria 
MitoSOX™ red was added to 15 µg/ 500 µL mitochondrial suspension and incubated on 
ice for 30 min. Increasing red fluorescence correlates with the formation of mitochondrial 
ROS and was detected by FACS analysis (excitation 488 nm, emission 690/50 nm) as 
described previously [147]. Data were collected from at least 5’000 cells and three 
replicates per condition. 
 
3.6.4. Mitochondrial membrane potential (TMRE™) 
 
For seeding 24 well plates were used. Neuronal cell lines were seeded at a density of 
40,000 cells per well and HepG2 cells were seeded at a density of 50,000 cells per well. 
After the indicated treatment, cells were stained with TMRE™ (0.4 nM for 30 min at 37°C, 
MitoPT ΔΨm Kit, Immunochemistry Technologies, USA) and harvested for TMRE 
fluorescence measurement via FACS analysis. Upon loss of the mitochondrial 
membrane integrity and, thus, membrane potential, loss of TMRE fluorescence was 
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detected by FACS analysis (excitation 488 nm, emission 690/50 nm) [147]. Data were 
collected from at least 5’000 cells and three wells per condition. 
 
3.6.5. Glucose uptake (2-NBDG) 
 
2-NBDG (2-deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose) (Table 8) 
(excitation: 475 nm emission: 550 nm) was used to assess glucose uptake via flow 
cytometry according to published protocols with minor modifications [148]. In brief, HT22 
cells were treated with Ze 450 and metformin for 16 h and with insulin for 30 min. 
Afterwards, cells were washed three times with DMEM (D5030, Merck KgaA, Germany) 
without glucose and FCS. 10 µM 2-NBDG was added and incubated 1 h protected from 
light at 37°C and 5% CO2. After the incubation, cells were harvested via trypsinization 
and centrifugation including a washing step. Trypsinization was stopped using medium 
containing 10% FCS. Next, samples were collected in 1.5 mL tubes on ice, stained with 
propidium iodide for detection of dead cells and measured within 30 min by using 525 ± 
30 nm bandpass filter to detect 2-NBDG fluorescence intensity and a 690 ± 50 nm 
bandpass filter to detect dead cells. Data were collected from at least 5’000 cells with at 
least three replicates per condition. 
 
3.8. Impedance measurement  
 
Cell proliferation was analyzed in real-time by measuring electrical impedance via the 
xCELLigence system Real-Time Cell Analyzer [149]. First, the background of the 96-well 
E plate is determined with pure culture medium. Afterwards, cells were seeded at 6,000 
HT22 cells/well. Impedance is measured via gold electrodes on the bottom of the wells 
due to changes in electrical impedance and visualized as changes in cell index. After 
adding the treatment cell proliferation was monitored for 16- 24 h. Impedance is 
increasing by attached and proliferating cells, whereas the detachment of dying cells 
leads to a decrease in electrical impedance. Cell index was normalized to 1.0 before 
treatment was added for data analysis and comparability between treatment groups. 
Data are presented as mean ± SD.  
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3.9. Glutathione assay 
 
To determine GSH (glutathione) levels, HT22 cells seeded in 6-well plates (180,000 
cells/well). After treatment with Ze 450 and erastin for the indicated amount of time two 
to three wells per condition were harvested by scratching and rinsing with PBS on ice, 
followed by centrifugation at 1,000 rpm for three minutes. After a washing step with PBS 
and another centrifugation, the cell pellet was frozen and stored at -80°C. GSH 
measurements were performed using the Glutathione Assay Kit (Cayman Chemical 
Company, USA) following manufacturer's protocol. Therefore, the cells were thawed on 
ice, resuspended in 100 µL MES-buffer (Table 11), and homogenized by sonification. 
Insoluble fragments were removed by centrifugation at 10,000×g for 15 min at 4°C. 80 µL 
of metaphosphoric acid (MPA,1.25 M) was added to 80 µL of the supernatant. The 
remaining part of the supernatant was used for protein determination via BCA assay. 
After incubation for 5 min, the mixture was centrifuged at 17,000×g for 10 min at 4°C. To 
increase the pH, 100 µL of the supernatant was mixed with a 4 M solution of 
triethanolamine. After transferal of 50 µL of each sample and a GSH standard into a 96-
well plate, 150 µL of assay cocktail provided MES-buffer, co-factor mixture (NADP+ and 
glucose-6-phosphate), enzyme mixture (glutathione reductase and glucose-6-phosphate 
dehydrogenase) and Ellman's reagent (DTNB; (5,5-dithio-bis-(2-nitrobenzoic acid)) was 
added. Absorbance was measured at 405 nm after 30 min of incubation at RT using the 
ELx808 Ultra Microplate Reader (Bio-Tek, Germany). Total GSH amount was 
determined via standard curve calculation and normalized to protein content. Data are 
displayed as percent GSH of control. 
 
Table 11. MES buffer (pH 6.0) 
M 2-(N-mopholino)ethanesulphonic acid 
(MES) 
0.4 M 
Phosphate 0.1 M 
EDTA 2 mM 
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3.10. Microscopy 
 
3.9.1. Mitochondrial morphology 
 
MitoTracker® Deep Red FM (Invitrogen, Germany, 200 nM) was used to visualize 
changes in mitochondrial morphology. HT22 cells were seeded in 8-well ibidi slides (Ibidi 
GmbH, Germany) with 14,000 cells per well and treated with Ze 450 and erastin or 
glutamate. After 16 h of treatment 0.2 µM MitoTracker® Deep Red was added to cells 
and incubated for 30 min at 37°C. Cells were fixed with 4% formaldehyde for 20 min at 
RT. Mitochondrial morphology was analyzed by categorizing cells as previously 
described with minor modifications [63]. Category I mitochondria were organized in a 
tubular network, category II mitochondria were fragmented but equally distributed 
throughout the cytosol, whereas category III mitochondria were fully fragmented and 
surrounding the nucleus. At least 500 cells per condition were counted without 
knowledge of treatment history. Images were acquired using a Leica DMI6000 
(fluorescence microscope at 63x magnification, Leica Microsystems, Germany). 
 
3.9.2. Glucose uptake via confocal microscopy 
 
HT22 cells were seeded at 14,000 cells per well in 8-well ibidi slides (Ibidi GmbH, 
Germany) and grown for about 30-33 hours. Then, cells were treated with 100 µg/mL 
Ze 450 for 16 h. Afterwards, cells were washed three times with DMEM without glucose. 
10 µM 2-NBDG was added to half of the samples, the remaining wells were not stained 
and used later on for background measurements. After incubation for 1 h protected from 
light at 37°C and 5% CO2 cells were washed two times with cold PBS and fixed with 4% 
formaldehyde for 20 min at RT. Samples were stained with 4',6-diamidino-2-phenylindol 
(DAPI,1:1000 in PBS) and phalloidin555 (Thermo Fisher Scientific, Germany; 1:400) for 
10 min at RT. Images were obtained using an LSM 700 confocal microscope with a 63x, 
1.4 NA oil objective (Zeiss, Germany). Sections of approximately 200 µm in width and 
length were chosen with an average number of 20 cells per section. Fluorescent 
microscopy pictures of the cells were captured with the following laser settings: 405 nm 
for DAPI, 488 nm for 2-NBDG and 555 nm for phalloidin-Alexa555. Two out of six Z-
stacks (center planes; best DAPI fluorescence) were processed to maximum intensity 
projections using FIJI (National Institute of Health, USA). For quantification, brightness 
and contrast of each channel were adjusted to equal histogram settings. Phalloidin555 
signal was used to select ROIs surrounding the cell groups (to avoid background errors) 
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and 2-NBDG fluorescence intensity was measured for corresponding areas. Values were 
normalized to corresponding background values within the individual experiments.  
 
3.11. Seahorse 
 
3.10.1. Cellular analysis of mitochondrial respiration and glycolysis 
 
To assess oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) 
as measures of mitochondrial respiration and glycolysis, respectively, simultaneous real-
time measurements were performed using the XF Extracellular Flux Analyzer (Agilent 
Technologies, USA) as previously described [59]. Briefly, HT22 and HepG2 cells were 
plated in XF96-well microplates (6’000/10,000 cells per well, Seahorse Bioscience) 
without seeding into the corner wells (background determination) and treated with the 
indicated compounds or extracts. After 16 h of treatment, the growth medium was 
replaced by ~180 μl of assay medium (containing 143 mM NaCl, 4.5 g/l glucose, 2 mM 
glutamine, 1 mM pyruvate, pH 7.35) and cells were incubated at 37°C for 60 min. Three 
to six baseline measurements were recorded before adding the compounds. Oligomycin 
(ATP synthase inhibitor) (Merck KGaA, Germany) was injected into port A (20 µL) at a 
final concentration of 3 µM (HT22 cells) or 2 µM (HepG2 cells), FCCP (uncoupling agent) 
(22.5 µL into port B) (Merck KGaA, Germany) at a concentration of 0.5 µM (HT22 cells) 
or 0.8 µM (HepG2 cells), rotenone/antimycin A (complex I/III inhibitors) (25 µL into port 
C) (Merck KGaA, Germany) at a concentration of 100 nM and 1 µM (HT22 and HepG2 
cells) and 2-deoxyglucose (Carl Roth GmbH, Germany) (glycolysis inhibitor) at a 
concentration of 50 mM (HT22 and HepG2 cells) (27.5 µL into port D), respectively. 
Three measurements were performed after the addition of each compound (4 min mixing 
followed by 3 min detection). Data analysis was performed using XFe Wave software 
and visualized using GraphPad Prism software. 
 
3.10.2. Analysis of mitochondrial respiration of isolated mitochondria 
 
Electron flow assay  
Electron flow assay was used to analyze the activity of mitochondrial complex I 
measuring the OCR with a Seahorse XFe96 Analyzer. To this end, mitochondrial 
isolation was performed as described before (Chapter 3.3.). 10 µg of cortical or liver 
mitochondrial protein per well were resuspended in 25 µL/well of mitochondrial assay 
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solution (Table 12, MAS) supplemented with pyruvate (10 mM) and malate (2 mM). 
Subsequently, the plate was centrifuged at 2,000 x g for 20 min at 4°C (Heraeus 
Megafuge 40R, ThermoFisher Scientific, Germany) to ensure adherence of the 
mitochondria to the bottom. Afterwards, 155 µL/well MAS with 4 µM FCCP was added 
to the final volume of 180 µL/well. Rotenone, succinate and antimycin A were diluted in 
MAS without sucrose and mannitol, while ascorbate and TMPD was diluted in MAS 
containing sucrose and mannitol, and serially injected as follows: 2 µM rotenone (port 
A), 10 mM succinate (port B), 4 μM antimycin A (port C), 10 mM/100 μM ascorbate and 
TMPD (N1,N1,N1,N1-tetramethyl-1,4-phenylene diamine) (port D). For investigating 
complex IV driven respiration, 1.0 M ascorbate in H2O (pH 7.2) and 10 mM TMPD in H2O 
(pH 7.2) was mixed with an equimolar concentration (10 mM) ascorbate to ensure TMPD 
remains reduced. Up to three baseline measurements were recorded and up to three 
measurements were performed after each injection (3 min mixing followed by 3 min 
detection). Data analysis and visualization were performed using XFe Wave software 
and GraphPad Prism software displayed as point-to-point oxygen consumption rates. 
 
Table 12. Mitochondrial assay solution (MAS, pH 7.2) 
Sucrose 70 mM  
Mannitol  220 mM  
KH2PO4 10 mM  
MgCl2 5 mM 
HEPES 2 mM  
EGTA 1 mM 
Fatty acid free BSA 0.2 % (w/v) 
 
Coupling assay  
The coupling assay was used to measure the activity of mitochondrial complex II and III 
recording the OCR with a Seahorse XFe96 Analyzer. The coupling assay was realized 
as previously described with minor modifications [150]. In brief, mitochondria were 
isolated like described before (Chapter 3.3.). 10 µg of cortical and 12 µg of liver 
mitochondrial protein per well were re-suspended in MAS (Table 12) with the addition of 
the complex II substrate succinate (10 mM) and the complex I inhibitor rotenone (2 μM). 
Subsequently, the plate was centrifuged at 2,000 xg for 20 minutes at 4°C (Heraeus 
Megafuge 40R, ThermoFisher Scientific, Germany) to ensure adherence of the 
mitochondria to the bottom of the well. Afterwards, 155 µL/well MAS was added to the 
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final volume of 180 µL/well. Modulators of the respiratory chain were diluted in MAS 
without sucrose and mannitol and serially injected as follows: 4 mM ADP (port A), 
2.5 μg/mL oligomycin (port B), 4 μM FCCP (port C), 4 μM antimycin A (port D). Up to 
three baseline measurements were recorded and up to three measurements were 
performed after each injection (3 min mixing followed by 3 min detection). Data analysis 
and visualization was performed using XFe Wave software and GraphPad Prism 
software and displayed as point-to-point oxygen consumption rates. 
 
3.12. Rhodamine measurement  
 
Rhodamine measurement was used to assess mitochondrial membrane potential 
integrity. Therefore fluorescence quenching of rhodamine 123 (ThermoFisher Scientific, 
Darmstadt, Germany) was measured over 40 min as described previously [151]. 
Mitochondria were plated in a black 96-well plate with 75 µg mitochondrial protein per 
well and therefore diluted in a buffer containing 200 mM sucrose, 10 mM MOPS-Tris, 
5 mM succinate, 1 mM Pi(H3PO4), 10 µM EGTA, and 2 µM rotenone (pH 7.3). Loss of 
mitochondrial membrane potential was induced by FCCP (500 nM), which was injected 
at the end of the measurement. Fluorescence (excitation: 485/12 nm, 
emission: 530/10 nm) was measured with FLUOstar OPTIMA plate reader. 
 
3.13. Protein analysis  
 
HT22 cells were seeded in 6-well plates at a density of 200,000 cells per well. After 24-
32 h cells were treated for the indicated amount of time and harvested by scratching in 
lysis buffer (Table 13) at 4 °C. Liquid nitrogen was used to disrupt cell membranes; 
afterwards, the lysate was stored at -80 °C or thawed on ice and centrifuged for 15 min 
at 10,000 rpm at 4 °C. Protein lysate was used from the resulting supernatant and a BCA 
was performed according to the manufacturer’s protocol for the determination of protein 
content. Therefore, 2.5 μL of the respective protein sample was mixed with 97.5 μL of 
BCA mix (1:50 reagent A: reagent B) and shaken at 60°C for 30 min. Absorbance was 
measured at 560 nm (FLUOstar OPTIMA, BMG Labtech, Germany) and the respective 
protein amount was calculated using a protein standard curve of bovine serum albumin 
(BSA). 
40-80 µg protein in loading buffer (Table 22) was loaded on a 7.5-12.5% polyacrylamide 
gel (Table 19-21) and a 3.5% stacking gel was used (Table 18). Spectra Multicolor High 
Materials and Methods 
35 
 
Range Protein Ladder or PageRuler Prestained Protein Ladder (ThermoFisher Scientific, 
Germany) were used as molecular weight (MW) marker and gel electrophoresis was 
performed at 60 V for ~30 min, and then switched to 110 V until separation in running 
buffer (Table 23). After electrophoresis, the proteins were transferred from the gel onto 
a PVDF membrane (Roche Diagnostics, Germany), which was previously activated by 
incubation in methanol for 2 min and then transferred in 1x transfer buffer (Table 24). 
Blotting was performed in a Mini-Trans-Blot Cell tank (Bio-Rad, Germany) for 105-
150 min at 350 mA in ice-cold 1x transfer buffer. Afterwards, the membrane was 
transferred shortly into TBS (Table 25) followed by at least 1 hour incubation in blocking 
solution (5 % BSA in TBST or 5% milk in TBST, Table 26-28). Next, the primary antibody 
(Table 29) was incubated at 4°C overnight. Followed by 1 h incubation at room 
temperature and incubation with the corresponding peroxidase-labeled secondary 
antibodies (Table 30). Before and after the secondary antibody incubation three x 10 
minutes washing steps with TBST (Table 26) were performed. The membrane was 
incubated with luminol based HRP-Juice Plus (PJK GmbH, Germany) for 2 minutes for 
protein detection. Visualization was realized with a ChemiDoc XRS system (Bio-Rad, 
Germany). For densitometric protein analysis, the Bio Rad Image Lab Software was 
used. For loading control, a housekeeping protein (Actin, GAPDH, Vinculin) was 
detected in the same way. 
 
Table 13. Lysis buffer for protein analysis 
D-Mannitol  0.25 M 
Tris 0.05 M 
EDTA 1 mM 
EGTA 1 mM 
100 mM DTT 1:100 
Triton® X-100 1:100 
PhosSTOP 1 tablet  
Complete MiniProtease Inhibitor Cocktail 1 tablet  
Bidest. H2O Ad 10 mL 
 
Table 14. 1.5 M Tris pH 8.8 
Tris-HCl  23.6 g 
HCl  q.s. 
Bidest. H2O ad 100 mL 
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Table 15. 0.5 M Tris pH 6.8 
Tris-HCl  7.88 g 
HCl  q.s. 
Bidest. H2O ad 100 mL 
 
Table 16. 10% sodium dodecyl sulfate (SDS) 
SDS  1 g 
Bidest. H2O ad 10 mL 
 
Table 17. 10% ammonium persulfate (APS) 
APS  1 g 
Bidest. H2O ad 10 mL 
 
Table 18. 3.5 % stacking gel  
Acrylamide/bisacrylamide (37.5:1) 0.58 mL 
10% SDS 0.05 mL 
0.5 M Tris-HCl pH 6.8 1.2 mL 
10% APS 0.03 mL 
Tetramethylethylenediamine (TEMED) 0.008 mL 
Bidest. H2O ad 5 mL 
 
Table 19. 6% running gel  
Acrylamide/bisacrylamide (37.5:1) 30% 2 mL 
10% SDS 0.1 mL 
1.5 M Tris-HCl pH 8.8 2.5 mL 
10% APS 0.0625 mL 
Tetramethylethylenediamine (TEMED) 0.0125 mL 
Bidest. H2O ad 10 mL 
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Table 20. 10% running gel  
Acrylamide/bisacrylamide (37.5:1) 30% 3.34 mL 
10% SDS 0.1 mL 
1.5 M Tris-HCl pH 8.8 2.5 mL 
10% APS 0.0625 mL 
Tetramethylethylenediamine (TEMED) 0.0125 mL 
Bidest. H2O ad 10 mL 
 
Table 21. 12.5% running gel 
Acrylamide/bisacrylamide (37.5:1) 30% 4.17 mL 
10% SDS 0.1 mL 
1.5 M Tris-HCl pH 8.8 2.5 mL 
10% APS 0.0625 mL 
Tetramethylethylenediamine (TEMED) 0.0125 mL 
Bidest. H2O ad 10 mL 
 
Table 22. Loading buffer for protein analysis (5x SDS sample buffer) 
1.5 M Tris-HCl pH 6.8  2 mL 
Glycerol 5 mL 
SDS 1 g 
β-Mercaptoethanol 2.5 mL 
1% Bromophenol blue 0.5 mL 
 
Table 23. 10x running buffer for SDS PAGE (dilution 1:10 with H2O) 
Tris base 30 g  
SDS 10 g 
Glycine 144 g 
Bidest. H2O ad 1000 mL 
 
  
Materials and Methods 
38 
 
Table 24. 10x transfer buffer for blotting (dilution 1:10 with H2O and 20% methanol) 
Tris base 30 g  
Glycine 144 g 
HCl q.s. (pH 8.3) 
Bidest. H2O ad 1000 mL 
 
Table 25. 10x TBS pH 7.5 (dilution 1:10 with H2O) 
NaCl 292 g  
Tris base 24.2 g 
HCl q.s. (pH 7.5) 
Bidest. H2O ad 1000 mL 
 
Table 26. 1x TBST 
10x TBS 100 mL 
Tween® 20 0.05 mL 
Bidest. H2O ad 1000 mL 
 
Table 27. 5% Blocking milk 
Skim milk powder 5 g 
TBST ad 100 mL 
 
Table 28. 5% BSA 
BSA 5 g 
TBST ad 100 mL 
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Antibodies were used as listed: Table 29. Primary antibodies 
Primary Antibody Company  Host  Dilution  
Akt  Cell signaling, USA Rabbit 1:1000 in 5% milk 
Catalase Santa Cruz, USA Mouse 1:1000 in 5% milk 
cmyc Cell signaling, USA Rabbit 1:1000 in 5% milk  
CuZnSOD Santa Cruz, USA Mouse 1:1000 in 5% milk 
HIF1α Cell signaling, USA Rabbit 1:1000 in 5% milk  
HXKII Cell signaling, USA Rabbit 1:1000 in 5% milk  
LDHA Cell signaling, USA Rabbit 1:1000 in 5% milk  
mitoProfile® 
OXPHOS 
Abcam, USA Mouse 1: 250 in 5% milk 
MnSOD Sigma Aldrich, USA Rabbit 1:500 in 5% milk 
mTOR Cell signaling, USA Rabbit 1:500 in 5% BSA 
pAkt  Cell signaling, USA Rabbit 1:1000 in 5% milk 
PDK1 Enzo Life Science, 
USA 
Rabbit 1:1000 in 5% milk  
pmTOR Cell signaling, USA Rabbit 1:1000 in 5% milk  
Actin Novus Biologicals, 
USA 
Mouse 1:2000 in 5% milk  
GAPDH Cell signaling, USA Rabbit 1:50,000 in 5% milk 
Vinculin  Sigma-Aldrich, 
Germany 
Mouse 1:10,000 in 5% milk 
 
Table 30. Secondary antibodies 
Secondary 
Antibody 
Company  Host  Dilution  
HRP-anti-mouse Vector 
Laboratories, Inc., 
USA 
Mouse 1:2000 in 5% milk 
HRP-anti-rabbit Vector 
Laboratories, Inc., 
USA 
Mouse 1.3000 in 5% milk 
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3.14. RNA analysis 
 
Reverse transcription PCR was performed after isolation of mRNA. To this end, HT22 
cells were plated into 6 well plates with 200,000 cells per well. After treatment, cells were 
harvested and RNA was isolated using the InviTrap Spin Universal RNA Mini Kit (Stratec 
Biomedical, Germany). RNA isolation was performed according to the manufacturer’s 
protocol. Eluted RNA was placed on ice and directly used or stored at - 80°C until the 
day of analysis. RNA content was determined using the NanoPhotometerTM (Implen, 
Germany) an absorbance ratio (260/280 nm) of ~2.0 was accepted as pure RNA. 
Reverse transcription PCR (RT PCR)was performed (Table 33) using SuperScript III 
One-Step RT-PCR system with platinum Taq DNA polymerase (Thermo Fisher 
Scientific, Germany) and the following primer (Table 34). 
 
Table 31. 10x Loading dye for agarose gel 
Tris base  60.57 mg 
40% Glycerol 20 mL 
EDTA 186.2 mg 
0.25% Orange G 125 mg 
Bidest. H2O ad 50 mL  
 
Table 32. 50x TAE 
Tris base  242 mg 
Acetic acid 57.1 mL 
0.5 M EDTA pH 8.0  10 mL 
 
Table 33. RT PCR 
2x reaction buffer 12.5 µL 
RNA sample 500 ng 
Primer fwd. 0.5 µL 
Primer rev. 0.5 µL 
Superscript III enzyme 0.5 µL 
Nuclease free water ad 25 µL 
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Table 34. Primer 
Primer Sequence (5´to 3´)  Amplicon size  
cmyc fwd. 
cmyc rev.  
GCTCGCCCAAATCCTGTACCTCGTCCGAT 
GAGATGAGCCCGACTCCGACCTCTT 
237 bp 
Glut1 fwd.  
Glut1 rev.  
CAGTTCGGCTATAACACTGGTG 
GCCCCCGACAGAGAAGATG 
156 bp 
Glut4 fwd. 
Glut4 rev. 
GGACCGGATTCCATCCCAC 
TCCCAACCATTGAGAAATGATGC 
120 bp 
Raptor fwd. 
Raptor rev.  
TCAAATTCCATCCCTTTACACC 
TCAGCAAAATTCTTCCAGACC 
217 bp 
GAPDH fwd. 
GAPDH rev.  
CGTCTTCACCACCATGGAGAAGGC 
AAGGCCATGCCAGTGAGCTTCCC 
399 bp 
 
mRNA was transcribed into DNA and then amplified using the following programs: 
Table 35. cmyc  
cmyc cycles 
55°C 30 min  
95°C 2 min  
95°C 45 sec 30 
61°C 45 sec 
70°C 1 min 
70°C 5 min   
4°C ∞  
 
Table 36. Glut1 
Glut1 cycles 
55°C 30 min  
95°C 2 min  
95°C 30 sec 30 
60°C 30 sec 
70°C 1 min 
70°C 10 min   
4°C ∞  
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Table 37. Glut4 
Glut4 cycles 
55°C 30 min  
95°C 2 min  
95°C 30 sec 35 
58°C 30 sec 
70°C 1 min 
70°C 10 min   
4°C ∞  
 
Table 38. Raptor 
Raptor cycles 
55°C 30 min  
95°C 2 min  
95°C 45 sec 27 
50.5°C 45 sec 
70°C 1 min 
70°C 10 min   
4°C ∞  
 
Table 39. GAPDH 
GAPDH cycles 
55°C 30 min  
95°C 2 min  
95°C 30 sec 27 
60°C 30 sec 
70°C 1 min 
70°C 10 min   
4°C ∞  
 
After amplification, the samples were loaded mixed with a 10x loading dye (Table 31) on 
a 1.5% agarose gel (Biozym Scientific GmbH, Germany) stained with ethidium bromide. 
Electrophoresis was performed at 80 V for 20-35 min in TAE buffer (Table 32). 
GeneRuler 100 bp Plus DNA Ladder (ThermoFisher Scientific, Germany) was used as 
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a size standard. For visualization of the resulting DNA bands, UV light of the ChemiDoc 
XRS system (Bio-Rad, Germany) was used.  
 
3.15. Caenorhabditis elegans  
 
The experimental procedures including C. elegans were conducted in collaboration with 
the group of Gunter Eckert at the Institute of Nutritional Sciences, Justus-Liebig 
University Giessen (Giessen, Germany). Benjamin Dilberger performed the cultivation 
and the experimental procedures with C. elegans. 
 
3.15.1. Nematode and bacterial strain 
 
C. elegans wild-type strain N2 was obtained from the Caenorhabditis elegans Genetics 
Center (University of Minnesota, MN, US). Nematodes were maintained on nematode 
growth medium (NGM) agar plates seeded with E. coli OP50 at 20°C according to 
standard protocols [152]. For all experiments, synchronous populations were generated 
through a standard bleaching protocol [153]  
 
Preparation of NGM agar plates  
3 g NaCl, 2.5 g Bactopeptone (Difco) and 17 g Bacto-agar (Difco) were dissolved in 
975 mL distilled water. After autoclaving, 1 mL cholesterol in ethanol (5 mg/mL), 1 mL 
1 M CaCl2, 1 mL 1 M MgSO4, and 25 mL 1 M potassium phosphate buffer (pH 6.0) 
(108.3 g KH2PO4, 35.6 g K2HPO4, H2O to 1 L) are added in order. 
 
3.15.2. Cultivation and treatment  
 
Synchronous larvae were washed twice in M9 buffer (6 g Na2HPO4, 3 g KH2PO4, 5 g 
NaCl and 0.2 g MgSO4 x 7 H2O per L), counted and adjusted to 10 larvae per 10 µL. 
Nematodes were cultivated in cell culture flasks (Sarstedt, Germany) or OP50 spread 
NGM plates. OP50-NGM was added as a standardized food source with a volume 4.4-
fold of the larvae containing M9 solution used. L1 larvae were maintained under shaking 
at 20°C reaching adulthood within 3 days. 
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After reaching young adulthood, 48 h prior to the experiment, nematodes were treated 
with Ze 450 dissolved in EtOH 1% and metformin or paraquat (5 mM) dissolved in M9. 
Standard OP50, M9, and EtOH 1% served as controls. 
 
3.15.3. Lifespan assay 
 
To determine the lifespan of the nematodes at 20°C a modified protocol from Amrit et. 
al. was applied [154] and synchronized larvae, obtained from egg preparation as stated 
above, were raised on NGM agar plates spread with standard OP50 E. coli culture. After 
completing the L4 larval stage 40 healthy animals per group were transferred to fresh 
NGM E. coli containing plates with a sterilized platinum wire. Effectors were incorporated 
into the OP50 culture with the concentration as needed. Nematodes were transferred to 
new plates every two days to distinguish between offspring until egg-laying stopped. In 
line with the separation from eggs and larvae, nematodes were checked for vital signs 
using a hot platinum wire held next to the animal´s heads. Worms showing no reaction 
to the heat stimulus were considered dead. The lifespan curves were statistically 
compared using the log-rank test. 
 
3.15.4.  Heat-shock survival assay 
 
Approximately 10 nematodes were raised per well in a 96-well microplate as mentioned 
above. After 48 h of incubation with effectors, time till death was determined using a 
microplate thermo-tolerance assay [155]. In brief, nematodes were washed off the wells 
with M9-buffer into 15 mL tubes followed by three additional washing steps. Each well of 
a black 384-well low-volume microtiter plate (Greiner Bio-One, Germany) was prefilled 
with 6.5 μL M9-buffer/Tween® 20 (1% v/v). Subsequently, one nematode was immersed 
in 1 μL M9 buffer under a stereomicroscope (Breukhoven Microscope Systems, 
Netherlands). A volume of 7.5 μL SYTOX™ green (final concentration 1 μM; Life 
Technologies, Germany), which penetrates only into cells with compromised plasma 
membrane and gets fluorescent after binding to DNA, was added for fluorescent 
detection. To prevent water evaporation, the plates were sealed with a Rotilab sealing 
film (Greiner Bio-One, Germany). Heat shock (37°C) was applied and fluorescence 
measured with a ClarioStar plate reader (BMG, Germany) every 30 min over the course 
of 17 hours. The excitation wavelength was set at 485 nm and the emission was detected 
at 538 nm. 
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3.15.5. Chemotaxis assay 
 
Chemotaxis was assessed using a previously published method [156]. Briefly, agar 
plates were divided into four quadrants. Sodium azide (0.5 M) was mixed in same parts 
with ethanol (95%) as control, or diacetyl (0.5%) as attractant. 2 µL of either control or 
attractant solution was added to the center of two opposite quadrants with the same 
distance to the middle of the plate. Nematodes were washed and separated from larvae 
as stated above and a number of approximately 150 animals placed in the center of the 
plates. After 1 h each quadrant was counted and a chemotaxis index calculated 
((number of attractant –  number of control) / number total). 
 
Figure 9. Chemotaxis assay 
Principle of the chemotaxis assay  
 
3.16. Statistical analysis  
 
For statistical analysis of two treatment groups, the unpaired t-test was used. Statistical 
comparison between more than two treatment groups was performed by analysis of 
variance (two-way ANOVA) followed by Scheffé’s post hoc test and a p-value < 0.05 was 
considered to be statistically significant. Calculations were executed with Winstat 
standard statistical software (R. Fitch Software, Germany) and data visualization was 
performed using GraphPad Prism software (GraphPad Software, USA). 
For statistical analysis of the survival curves, the log-rank test (Mantel-Cox test) was 
employed compared to the corresponding control. A p-value lower than 0.05 was 
considered to be a significant difference between two survival curves (***p<0.001; 
**p<0.01; *p<0.05). 
For statistical analysis of the chemotaxis assay, one-way ANOVA with post hoc Turkey 
HSD test was used. A p-value lower than 0.05 was considered to be a significant 
difference between two survival curves (***p<0.001; **p<0.01; *p<0.05). 
  
Results 
46 
 
4. Results 
 
4.1. Effects of Ze 450 on neuronal cells 
 
4.1.1. Ze 450 prevents neuronal cell death in model systems of oxidative 
stress 
 
In order to study the impact of Ze 450 on neuronal cells, metabolic activity and cell death 
were investigated. The HT22 cells were treated with Ze 450 (1-200 µg/mL) for 16 h and 
oxidative stress was induced via co-treatment with erastin. Ze 450 reduced metabolic 
activity in a concentration-dependent manner under control conditions to ~60% at 
concentrations of 100-200 µg/mL but also significantly prevented erastin-mediated 
decrease of metabolic activity at these concentrations (Figure 10A). Analyzing cell death 
via Annexin V and PI staining revealed that Ze 450 did not affect cell viability under 
control conditions, but significantly protected erastin-induced cellular damage at 
concentrations of 50-200 µg/mL (Figure 10B). In neuronal mHypo cells, metabolic activity 
was not affected in the controls (Figure 10C), but similar protective effects of Ze 450 
were observed in the co-treatment with erastin resulting in a protection of metabolic 
activity as well as cell death (Figure 10C, D).  
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Figure 10. Effects of Ze 450 on cell viability in neuronal HT22 and mHypo cells 
A: MTT assay was performed after 16 h of treatment with Ze 450 and erastin in HT22 cells. Eight 
replicate wells per condition are displayed as mean + SD. The absorbance under control 
conditions is set as 100%. B: Cell death was assessed by flow cytometry using Annexin V and PI 
staining after 16 h of treatment in HT22 cells. The bar graph shows one representative experiment 
with three replicates per sample (mean + SD; 5,000 cells per replicate). C: Metabolic activity was 
evaluated in erastin-challenged mHypo cells by measuring MTT formazan absorbance (1 µM, 
16 h). Eight replicate wells per condition are displayed as mean + SD. The absorbance under 
control conditions is set as 100%. D: Annexin V and PI measurement of mHypo cells treated with 
Ze 450 and erastin for 16 h. The bar graph shows one representative experiment with three 
replicates per sample (mean + SD; 5,000 cells per replicate). A-D: ***p<0.001; **p<0.01, *p<0.05 
compared to erastin-treated control; ###p<0.001, ##p<0.01, #p<0.05 compared to untreated 
control (ANOVA, Scheffé’s test). 
 
Further, Ze 450 was analyzed in paradigms of oxytosis in HT22 cells. Consistently, the 
same effects were observed after 16 h of treatment with Ze 450 and glutamate 
investigating metabolic activity and cell death (Figure 11A, B).  
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Figure 11. Effects of Ze 450 in paradigms of oxytosis 
A: Metabolic activity was evaluated in glutamate-challenged HT22 cells by measuring MTT 
formazan absorbance (10 mM, 16 h). Eight replicate wells per condition are displayed as mean + 
SD. The absorbance under control conditions is set as 100%. B: Cell death was assessed by flow 
cytometry using Annexin V and PI after 16 h of treatment in HT22 cells. The bar graph shows one 
representative experiment with three replicates per sample (mean + SD; 5,000 cells per replicate). 
A, B: ***p<0.001 compared to glutamate-treated control; ###p<0.001, ##p<0.01, #p<0.05 
compared to untreated control (ANOVA, Scheffé’s test). 
 
Besides the concentration-dependent protection against oxidative stress, Ze 450 was 
also effective in post-treatment paradigms. The cells were incubated with either erastin 
or glutamate and Ze 450 was added afterwards at the indicated time points. Ze 450 
provided protection even when added up to 6 hours after onset of erastin or glutamate 
challenge (Figure 12A, B). Interestingly, 100 µg/mL of Ze 450 was protective even 10 h 
after glutamate exposure (Figure 12B)  
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Figure 12. Ze 450 post-treatment 
A+B: Metabolic activity was evaluated in erastin or glutamate-challenged HT22 cells by 
measuring MTT formazan absorbance (1 µM/10 mM, total incubation of 16 h, pre-treatment with 
erastin or glutamate 4-12 h). Eight replicate wells per condition are displayed as mean + SD. The 
absorbance under control conditions is set as 100% (***p<0.001; **p<0.01; *p<0.05 compared to 
erastin/glutamate-treated control; ANOVA, Scheffé’s test). 
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In addition, the effects of Ze 450 on glutamate-mediated excitotoxicity were assessed in 
primary cortical rat and mouse neurons via MTT assay. Ze 450 protected against 
excitotoxicity in primary cortical rat and mouse neurons after early and late time points 
(Figure 13A-D). 50 µg/mL Ze 450 was able to protect against glutamate-mediated 
(20 μM, 8 h, 24 h, 48 h) reduction of metabolic activity in primary cortical neurons. 
Besides, ATP levels were investigated in primary cortical mouse neurons. Glutamate-
mediated ATP depletion was prevented by 50 µg/mL of Ze 450, while basal ATP levels 
were not affected by Ze 450 (Figure 13E). 
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Figure 13. Effects of Ze 450 on primary cortical neurons 
A-D: Metabolic activity was evaluated in glutamate-challenged primary cortical cells (A+B: rat, 
C+D: mouse) by measuring MTT formazan absorbance (20 µM, timepoint as indicated). Six-eight 
replicate wells per condition are displayed as mean + SD. The absorbance under control 
conditions is set as 100%. E: ATP levels were assessed using a luciferase-based assay in 
glutamate-exposed (20 µM) primary cortical mouse neurons. Values from eight replicate wells per 
condition are displayed as mean + SD. The luminescence under control conditions is set as 100%. 
A-E: ##p<0.01, ###p<0.001 compared to untreated control; *p<0.05, **p<0.01, ***p<0.001 
compared to glutamate treated primary cortical cells; ANOVA Scheffé׳s test (rctx: rat cortical 
neurons; mctx: mouse cortical neurons). 
 
Results 
51 
 
Further, real-time impedance measurements showed that proliferation of HT22 cells was 
reduced at Ze 450 concentrations greater than 100 μg/mL compared to the control 
condition (Figure 14A). These real-time measurements revealed that 10 and 50 μg/mL 
of Ze 450 conducted to a transient protection against erastin-toxicity, while at 
concentrations higher than 100 μg/mL, Ze 450 mediated a permanent protective effect 
(Figure 14B). These results were confirmed in mHypo cells (Figure 14C, D) and in 
paradigms of oxytosis in HT22 cells (Figure 14E). The impairment of proliferation was 
reversible after the withdrawal of Ze 450 (Figure 14F). 
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Figure 14. Influence of Ze 450 on proliferation in HT22 and mHypo cells 
xCELLigence measurements were conducted after the indicated treatment was added. A, B, E, 
F: HT22 cells. C, D: mHypo cells. Data are displayed as mean ± SD (n=5-8/treatment condition). 
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Moreover, the mammalian target of rapamycin (mTOR) was investigated at protein and 
mRNA levels, as it is a crucial regulator of cell growth [157]. 100 µg/mL Ze 450 reduced 
mTOR protein level in HT22 cells after 16 h of treatment (Figure 15A, B). The 
phosphorylation level of mTOR was not affected by Ze 450 (Figure 15C, D). 
Consequently, reduced mTOR protein levels might contribute to the decreased 
proliferation of Ze 450 treated cells. 
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Figure 15. mTOR and pmTOR Western Blot 
A: The representative Western Blot shows a decrease of mTOR protein levels after 16 h of Ze 450 
treatment (100 µg/mL) in HT22 cells. B: Quantification of Western Blot as optical density 
compared to vinculin as loading control (n=12-14 per treatment condition; ***p<0.001 compared 
to control, unpaired t-test). C: The representative Western Blot shows comparable protein levels 
of pmTOR in Ze 450 treated (100 µg/mL, 16 h) and control HT22 cells. D: Quantification of 
Western Blot as optical density compared to vinculin as loading control (n=6/treatment condition). 
 
Raptor is the regulatory subunit of mTORC1 complex, which is necessary for mTOR 
activation and downstream signaling [158]. The mRNA analysis of Raptor revealed that 
Raptor mRNA levels of HT22 cells treated with Ze 450 were not altered (Figure 16A, B). 
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Figure 16. Raptor mRNA level upon 16 h of Ze 450 treatment 
A: Raptor mRNA levels were analyzed after 16 h of treatment with 100 µg/mL Ze 450. B: 
Quantification of Raptor mRNA levels normalized to GAPDH (n=3/treatment condition, unpaired 
t-test). 
 
4.1.2. Ze 450 preserves glutathione level and protects against mitochondrial 
fragmentation 
 
Oxidative stress-mediated cell death, including oxytosis and ferroptosis, has been linked 
to depleted glutathione levels, leading to cellular and mitochondrial ROS formation and 
finally cell death. Ze 450 did not affect glutathione levels and did not rescue erastin-
mediated glutathione depletion in HT22 cells (Figure 17A). 
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Figure 17. Effects of Ze 450 on glutathione level in HT22 cells 
A: Measurement of cellular glutathione levels depicts a rapid decrease of GSH after 4 h of erastin 
exposure, which was not restored by Ze 450 (n=5-7/treatment condition). Data are shown as 
mean + SD (***p<0.001 compared to untreated control; ANOVA, Scheffé׳s test).  
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Further, mitochondrial morphology was analyzed. Mitochondrial shape was evaluated by 
classifying mitochondria as previously described [64]. Oxidative stress-induced neuronal 
cell death is accompanied by mitochondrial fragmentation, whereas under standard 
culture conditions mitochondria build a tubular network throughout the cytosol [64]. 
Cytotoxicity induced by erastin and glutamate was associated with massive 
fragmentation of mitochondria and accumulation of the organelles around the nucleus 
(Figure 18). There was no difference observed between category I-III mitochondria of 
control and Ze 450 treated cells. In line with this, Ze 450 did not cause mitochondrial 
fragmentation under standard culture conditions, and the cells showed similar 
mitochondrial morphology as the control cells (Figure 18). Furthermore, concentrations 
greater than 50 µg/ml of Ze 450 prevented mitochondrial fragmentation despite erastin 
or glutamate treatment (Figure18). 
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Figure 18. Mitochondrial morphology  
A+B: Quantification of mitochondrial morphology in HT22 cells exposed to Ze 450 and erastin 
(0.8 μM, 16 h) or glutamate (3 mM, 16 h). Mean values were pooled from three independent 
experiments, where mitochondrial morphology was determined from at least 500 cells per 
condition without knowledge of treatment history. All data are given as mean + SD. There were 
no changes within category II mitochondria in any of the treatment conditions. A: Glutamate 
exposure led to an increase in category III mitochondria, which was prevented upon 100 µg/mL 
of Ze 450 (p<0.001 compared to glutamate control, ANOVA Scheffé´s test). B: Erastin exposure 
led to an increase in category III mitochondria, which was prevented by concentrations greater 
than 50 μg/mL of Ze 450 (p<0.001 compared to erastin control, ANOVA Scheffé´s test). C: 
Representative epifluorescence images were acquired with a fluorescence microscope 
(DMI6000, Leica, Germany; using 63×1.4 NA oil immersion objective; scale bar 20 μm).  
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4.2. Metabolic effects of Ze 450 
 
4.2.1. Ze 450 protects mitochondria from oxidative damage  
 
As demonstrated in the previous chapter, Ze 450 affected metabolic activity and 
proliferation (4.2.), leading to the question of whether mitochondria are involved in the 
mechanism of action and if Ze 450 is capable to reduce oxidative damage induced by 
erastin or glutamate at the level of mitochondria. Therefore, lipid-peroxidation was 
investigated, since this is an early event in the model system of glutamate- and erastin-
induced oxidative cell death. Cellular ROS formation, through increased activity of 12/15 
lipoxygenases was investigated using C11-BODIPY FACS analysis at 8 h and 16 h of 
treatment in HT22 and mHypo cells (Figure 19). Ze 450 did not increase cellular ROS 
formation but abolished erastin-mediated increase in lipid-peroxidation at concentrations 
higher than 50 µg/mL as detected at both time points in HT22 cells (Figure 19A, B). The 
same effect was observed in HT22 cells challenged with glutamate (Figure 19C). 
Consistently, these results were confirmed in mHypo cells (Figure 19D). 
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Figure 19. Effects of Ze 450 on lipid-peroxidation 
Lipid-peroxidation was assessed by flow cytometry using BODIPY™ after the indicated times of 
treatment. Each bar graph diagram shows one representative experiment with three replicates 
per sample (mean + SD; 5,000 cells per replicate; ***p<0.001 compared to glutamate- or erastin-
treated control; ANOVA, Scheffé’s test). A-C: HT22 cells; D: mHypo cells 
 
The influence of Ze 450 on ATP levels was further analyzed to gain insights into 
mitochondrial involvement in the neuroprotective effects of Ze 450 (Figure 20). In mHypo 
and HT22 cells, Ze 450 reduced cellular ATP levels to ∼70% upon concentrations 
greater than 150 µg/mL under standard culture conditions (Figure 20). After erastin-
exposure, ATP depletion was partly prevented by concentrations greater than 100 µg/mL 
in HT22 cells and by 50-150 µg/mL of Ze 450 in mHypo cells (Figure 20A, C). This was 
confirmed in HT22 cells challenged with glutamate (Figure 20B). 
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Figure 20. Effects of Ze 450 on ATP levels 
ATP levels were determined using a luciferase-based assay after 16 h of treatment. Values from 
five-eight replicate wells per condition are displayed as mean + SD. The luminescence under 
control conditions is set as 100% (***p<0.001; **p<0.01; *p<0.05 compared to glutamate-/erastin-
treated control, ###p<0.001; ##p<0.01; #p<0.05 compared to untreated control; ANOVA, 
Scheffé’s test). A+B: HT22 cells, C: mHypo cells 
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Mitochondrial ROS are important mediators of cellular stress, and mitochondrial 
dysfunction is associated with increased mitochondrial ROS formation and associated 
pathways of oxidative cell death. Mitochondrial ROS formation was investigated using 
MitoSOX™ red staining and FACS analysis in HT22 and mHypo cells 16 hours after 
treatment. In both neuronal cell lines, Ze 450 did not affect mitochondrial ROS 
accumulation at basal conditions (Figure 21A-C). In contrast, erastin- and glutamate-
induced increase in mitochondrial ROS formation was prevented by concentrations 
greater than 50 µg/mL of Ze 450 (Figure 21A-C). This effect was also observed in a post-
treatment paradigm when Ze 450 was applied 1 h after onset of erastin or glutamate 
exposure (Figure 21D, E). 
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Figure 21. Effects of Ze 450 on mitochondrial ROS formation 
Mitochondrial ROS formation was assessed by flow cytometry using MitoSOX™ after 16 h of 
treatment. The bar graph shows one representative experiment with three replicates per sample 
(mean + SD; 5,000 cells per replicate, ***p<0.001; **p<0.01; *p<0.05 compared to erastin or 
glutamate treated control; ANOVA, Scheffé’s test). A, B, D, E: HT22 cells; C: mHypo cells; D, E: 
HT22 cells were stressed with either erastin or glutamate 1 h before Ze 450 co-treatment.  
 
Next, mitochondrial membrane potential was analyzed after 16 h of treatment in HT22 
and mHypo cells using TMRE™. Mitochondrial membrane potential was not affected by 
Ze 450 in both neuronal cell lines under standard culture conditions (Figure 22A-C), but 
loss of mitochondrial membrane potential due to erastin or glutamate exposure was 
prevented by concentrations greater than 50 µg/mL of Ze 450 (Figure 22A-C).  
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Figure 22. Effects of Ze 450 on mitochondrial membrane potential  
Mitochondrial membrane potential was assessed via flow cytometry analysis with TMRE™ 
staining after 16 h of erastin or glutamate treatment. Each bar chart depicts one representative 
experiment with three replicates per sample (mean + SD; 5,000 cells per replicate, ***p<0.001 
compared to erastin- or glutamate- treated control; ANOVA, Scheffé’s test). A-B: HT22 cells; C: 
mHypo cells 
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Overall, Ze 450 demonstrated strong protective effects at the level of mitochondria in the 
applied model systems of erastin- and glutamate-induced oxidative stress in both 
neuronal cell lines. Further, Ze 450 prevented glutamate-mediated excitotoxicity in 
primary cortical neurons.  
 
4.2.2. Ze 450 provokes a glycolytic shift under oxidative stress conditions 
 
Mitochondria are crucial organelles responsible for the energy metabolism and energy 
supply for the whole cell and play a decisive role in regulated oxidative cell death, 
especially in neurons as described before in chapter 1.3. To gain further insights into 
potential metabolic effects such as alterations of mitochondrial respiration and metabolic 
status of cells exposed to Ze 450, oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR) were investigated using the Agilent Seahorse XF96 system for 
detection of oxidative phosphorylation and glycolysis, respectively. These functional 
metabolic parameters are essential for further elucidating the mechanism of action of 
Ze 450 at the level of mitochondria. Figure 23A shows that Ze 450 reduced the OCR 
compared to control cells in a concentration-dependent manner; especially the basal and 
maximal respiration after FCCP injection were affected. Intriguingly, oxidative stress-
mediated reduction of mitochondrial respiration after erastin exposure was not rescued 
by Ze 450 (Figure 23B). While cells performed less mitochondrial respiration, an 
enhanced glycolysis rate compared to control cells was detected. Furthermore, 
100 µg/mL of Ze 450 increased the ECAR compared to control cells (Figure 23C). 
Consistently, Ze 450 compensated the erastin-mediated reduction of ECAR in a 
concentration-dependent manner (Figure 23D), thereby preserving the energy 
production of the cell. Interestingly, the response after oligomycin injection (port A) was 
much steeper in control cells compared to cells treated with 100 µg/mL Ze 450 and 
erastin (Figure 23D). Oligomycin inhibits the ATP synthase of the respiratory chain, and 
consequently, leading to an increase of the ECAR. Ze 450 induced a shift towards 
glycolysis and following the increase in glycolysis stimulated by oligomycin was not as 
prominent as in corresponding control conditions.  
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Figure 23. Effects of Ze 450 on energy metabolism 
Data of one representative experiment is depicted showing OCR and ECAR under basal and 
oxidative stress conditions. A, B: After 16 h of treatment with Ze 450 (A) and challenged with 
0.5 µM erastin (B), the oxygen consumption rate (OCR) of HT22 was analyzed with a Seahorse 
XFe96 Analyzer. Data of 5-12 replicate wells per condition are given as mean ± SD. C, D: After 
16 h of treatment with Ze 450 (C) and challenged with 0.5 µM erastin (D) the extracellular 
acidification rate (ECAR) was determined with a Seahorse XFe96 Analyzer. Data of 4-12 replicate 
wells per condition are given as mean ± SD (port A: oligomycin; port B: FCCP; port C: rotenone 
and antimycin A; port D: 2-deoxyglucose). 
 
Overall, Ze 450 reduced OCR in a concentration-dependent manner under basal 
conditions (Figure 24A), and attenuated erastin-mediated reduction of the ECAR (Figure 
24B), thereby preventing mitochondrial ROS formation, deletion of mitochondrial 
membrane potential and preserving ATP levels. 
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Figure 24. Energetic phenotype 
The cell energy phenotype is depicted as the OCR blotted against the ECAR under basal (A) and 
oxidative stress conditions (B). Baseline phenotype after 16 h of treatment is depicted with an 
open square representing the OCR and ECAR of HT22 cells at starting conditions. Stressed 
phenotype is depicted with a filled square representing the energy phenotype demand under 
FCCP treatment (induced energy demand, uncoupling agent), (Cim. 100: 100 µg/mL Ze 450; 
Cim.  200: 200 µg/mL Ze 450). 
 
Furthermore, protein levels of the mitochondrial respiratory chain complexes were 
assessed to reveal insights into translational regulation by Ze 450 (Figure 25A). While 
mitochondrial respiratory chain function is reduced upon Ze 450 treatment, there was no 
impact on the level of protein of all five mitochondrial respiratory chain complexes 
detectable (Figure 25B-F). 
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Figure 25. Protein levels of the five electron transport chain complexes  
Relative protein levels of the five electron transport chain complexes (CI-CV) were assessed in 
HT22 cells treated with 100 µg/mL Ze 450 for 16 h compared to untreated control (- control, + 
Ze 450). Rat cortical mitochondria served as a positive control (+ ctrl). Figure A depicts a 
representative immunoblot. Figures B-F show the densitometric quantification of the individual 
complexes (CI-CV). The values are normalized to vinculin as a housekeeping protein. Data is 
presented as percent of control (mean ± SD, n=6).  
 
Ze 450 exerted potent effects at the level of mitochondria indicating a strong influence 
on metabolism. However, the question remained, whether this metabolic shift is 
important for protection against oxidative damage. Therefore, Ze 450 was combined with 
the glycolysis inhibitor 2-deoxyglucose and erastin and investigated via Annexin V and 
PI flow cytometry analysis (Figure 26A). Erastin-induced cell death was prevented by 
Ze 450, but the addition of 2-DG led to a loss of the protective effect. To further analyze 
the mechanism of action, Ze 450 was compared to the known antioxidant Trolox. While 
the metabolic shift is a prerequisite for Ze 450 mediated protection against oxidative 
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damage, in contrast, the antioxidant Trolox still mediated protection against erastin-
induced toxicity in the presence of 2-DG (Figure 26A). Moreover, Cimicifuga racemosa 
plant extracts, such as Ze 450 contain many components including antioxidants, for 
example, ferulic acid. However, the content of ferulic acid is less than 0.2% in this batch 
of Ze 450, and therefore, most likely not the major component contributing to the 
observed protective effects. In order to study the antioxidant properties of Ze 450, the 
radical scavenging activity of Ze 450 was analyzed using the DPPH assay (Figure 26B). 
Indeed, Ze 450 showed only moderate antioxidant properties compared to Trolox but as 
demonstrated in figure 26A this antioxidant capacity was unlikely contributing to the 
observed protective effects of Ze 450. 
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Figure 26. Ze 450 mediated effects in comparison to Trolox  
A: Cell death was assessed by flow cytometry using Annexin V and PI after 16 h of treatment in 
HT22 cells. The bar graph shows one representative experiment with three replicates per sample 
(mean + SD; 5,000 cells per replicate; ***p<0.001 compared to erastin treated control; ANOVA 
Scheffé´s test). B: DPPH radical scavenging activity was determined at 517 nm (***p<0.001, 
**p<0.01 compared to control; ANOVA Scheffé´s test). 
 
Additionally, the protein level of key antioxidant enzymes (Catalase, MnSOD and 
CuZnSOD) were analyzed (Figure 27A-F). None of the mentioned proteins of the cellular 
antioxidant defense were upregulated upon 16 h of Ze 450 treatment (Figure 27A-F). 
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Figure 27. Protein levels of antioxidant enzymes  
A, B: Representative Immunoblots showed no changes in protein levels after 16 h of Ze 450 
treatment (100 µg/mL) in HT22 cells. C-E: Quantification of Western Blot as optical density 
compared to actin as loading control (n=3-4/treatment condition). 
 
4.2.3. Ze 450 influences the functionality of mitochondrial respiratory chain 
complexes 
 
Isolated mitochondria were used to elucidate, whether Ze 450 directly targeted 
mitochondria. For that purpose, mitochondrial respiration was investigated using the 
coupling assay, with rotenone as an inhibitor for complex I and succinate as substrate 
for complex II driven respiration. Rat cortical mitochondria were incubated with Ze 450 
on ice for 30-60 minutes (Figure 28A, B). After 30 min, the respiration profile under 
control conditions and in Ze 450 treated mitochondria did not differ (Figure 28A), 
whereas, after 60 min incubation, Ze 450 mediated a concentration-dependent reduction 
of oxygen consumption rate (after injection of ADP) and complex II functionality upon 
FCCP stimuli (Injection C, Figure 28B). Rhodamine 123 measurement was performed 
as a quality control of isolated mitochondria to test the integrity of the mitochondrial 
membrane. Control mitochondria and Ze 450 treated mitochondria showed similar 
quenching of the Rhodamine 123 fluorescence (Figure 28C). 
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Figure 28. Ze 450 affects mitochondrial complex II and III functionality  
A, B: OCR was analyzed after 30 and 60 min of incubation with Ze 450 (50 and 100 µg/mL). ADP 
(port A), oligomycin (port B), FCCP (port C) and antimycin A (port D) were injected, successively. 
Rotenone was initially present and hence respiration is being driven by complex II-IV activity. C: 
Rhodamine 123 is positively charged and accumulated within the mitochondria. Fluorescence 
quenching was monitored until FCCP was injected. 
 
In order to sequentially study the electron flow through different complexes of the 
electron transport chain, the coupling assay was used. Basal respiration served as an 
indicator for complex I activity as pyruvate and malate were initially present to deliver 
NADH as a substrate for mitochondrial complex I. Ze 450 affected pyruvate and malate 
driven respiration in a time-dependent manner (Figure 29A), but did not completely 
inhibited complex I activity, since the injection of rotenone (port A, Figure 29A) further 
reduced mitochondrial respiration. Injection of FCCP (port B, Figure 26A) led to an 
increase in OCR, showing that the electron transport chain is function properly.  
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Figure 29. Ze 450 affects mitochondrial complex I functionality  
A: OCR was analyzed after 30 and 60 min of incubation with Ze 450 (50 and 100 µg/mL). 
Rotenone (port A), FCCP (port B), antimycin A (port C) and ascorbate with TMPD (port D) were 
injected successively. Pyruvate and malate were initially present and hence respiration is being 
driven by complex I.  
 
Taken together, the findings of the coupling and electron transport chain assay 
demonstrated that Ze 450 affected mitochondrial respiration by mild inhibition of complex 
I-III activities. 
Mitochondrial ROS produced by the electron transport chain are majorly contributing to 
oxidative damage and further function as signaling molecules [134]. Thus, investigating 
mitochondrial ROS formation of isolated mitochondria treated with Ze 450, allowed for 
the conclusion that Ze 450 did not induce superoxide formation (Figure 30A, B) after an 
acute incubation time of 60 minutes, whereas antimycin A served as a positive control.  
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Figure 30. Ze 450 did not induce mitochondrial ROS formation  
A-B: Mitochondrial ROS formation of cortical mitochondria was assessed with MitoSOX™ red 
staining and flow cytometry. Mitochondrial superoxide levels were not altered upon Ze 450 
treatment (60 minutes). 10 µM antimycin A (AA) was incubated for 30 min and served as a 
positive control. A: Representative data is shown as mean +SD of three replicates per treatment 
condition (5,000 events per condition, ***p<0.001 compared to untreated control mitochondria; 
ANOVA, Scheffé´s test). B: Representative flow cytometry histograms.  
 
Overall, the experiments on ETC functionality and mitochondrial ROS formation with 
isolated cortical mitochondria confirmed that Ze 450 modulates oxidative 
phosphorylation by weakly inhibiting mitochondrial respiration complexes and thereby 
lower oxidative damage most likely by reducing mitochondrial ROS formation. 
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4.2.4. Metabolic regulation upon Ze 450 treatment in neurons 
 
Hypoxia-inducible factor α (HIF1α) is a transcriptional regulator, known to be majorly 
involved as a key regulator in response to hypoxia [159]. The alpha subunit of HIF is 
responsive to low oxygen concentrations and then activates genes involved in 
angiogenesis [160], glucose metabolism, proliferation, and many more [161].  
In order to study the involvement of HIF1α in the metabolic changes upon Ze 450 
treatment, Western Blot analysis was performed (Figure 31A). Ze 450 regulated HIF1α 
protein levels in a time-dependent manner.  
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Figure 31. Time-dependent Western Blot analysis of HIF1α protein level 
A: The depicted Western Blot shows an initial increase of HIF1α protein levels and subsequent 
decrease after 16 h of Ze 450 treatment (100 µg/mL) in HT22 cells.  
 
The initially increased HIF1α protein levels were further studied within 3 hours of 
treatment with 100 µg/mL Ze 450 (Figure 32A, B). Indeed, the HIF1α upregulation was 
confirmed as depicted in the representative immunoblot (Figure 32A) and the 
quantification (Figure 32B). In contrast, HIF1α protein level was decreased after 16 h of 
Ze 450 treatment (Figures 31A and 32C). 
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Figure 32. Western Blot analysis of HIF1α protein level after 3 and 16 h of Ze 450 treatment  
A: Representative Western Blot showed an initial increase of HIF1α protein level after 3 h of 
Ze 450 treatment (100 µg/mL) in HT22 cells. B: Quantification of Western Blot as optical density 
compared to vinculin as loading control (n=4-5/treatment condition; ***p<0.001; unpaired t-test). 
C: Quantification of Western Blot revealed decreased HIF1α protein level after 16 h of Ze 450 
treatment (100 µg/mL) in HT22 cells, depicted as optical density compared to GAPDH as loading 
control (n=7-8/treatment condition; ***p<0.001; unpaired t-test). 
 
Besides HIF1α, cMyc is known to be involved in promoting and regulating glycolysis. It 
was initially described as an oncogene involved in tumor progression and invasiveness, 
but it also promotes important physiological functions, including energy metabolism [83]. 
In this study, it was of great interest to analyze, whether cMyc contributed to the observed 
metabolic shift towards glycolysis induced by Ze 450 [162]. 
Therefore, cMyc protein levels were investigated after 3 and 16 h upon Ze 450 treatment 
(Figure 33). Initially, there was no change detected, but after 16 h of Ze 450 treatment, 
cMyc protein levels were significantly upregulated (Figure 33).  
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Figure 33. Western Blot analysis of cMyc upon Ze 450 treatment  
A: Representative Western Blot of cMyc protein levels after 3 h of Ze 450 treatment (100 µg/mL) 
in HT22 cells. B: Quantification of Western Blot as optical density compared to vinculin as loading 
control (n=4-5/treatment condition, unpaired t-test). C: Representative Western Blot of cMyc 
protein levels after 16 h of Ze 450 treatment (100 µg/mL) in HT22 cells. D: Quantification of 
Western Blot revealed decreased cMyc protein levels after 16 h of Ze 450 treatment (100 µg/mL) 
in HT22 cells, depicted as optical density compared to vinculin as loading control (n=3/treatment 
condition; *p<0.05; unpaired t-test).  
 
In contrast to the regulation of cMyc at the protein level, there was no change detected 
after 16 h of Ze 450 incubation at the mRNA level (Figure 34A, B). 
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Figure 34. Analysis of cMYC mRNA levels after 16 h of treatment with Ze 450  
A: cMyc mRNA level was analyzed after 16 h of treatment with 100 µg/mL Ze 450. 
B: Quantification of cMyc mRNA levels normalized to GAPDH (n=3/treatment condition, unpaired 
t-test). 
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Since both, HIF1α and cMyc are known to activate key enzymes involved in energy 
metabolism [83,87], protein levels of hexokinase II (HXKII), pyruvate dehydrogenase 
kinase 1 (PDK1) and lactate dehydrogenase A (LDHA) were investigated after 16 h of 
treatment with Ze 450 (Figure 35). While the protein levels of HXKII and PDK1 were 
upregulated, there was no change detectable for LDHA (Figure 35). 
Ctrl Ze 450 
0
50
100
150
200
PDK1
P
D
K
1
/V
in
cu
lin
 [
%
]
✱✱✱
Ctrl Ze 450 
0
50
100
150
LDHA
L
D
H
A
/V
in
cu
lin
 [
%
]
n.s.
Ctrl Ze 450 
0
100
200
300
400
HXKII
H
X
K
II
/V
in
cu
lin
 [
%
]
**
Vinculin
PDK1
120 kDa
48 kDa
-  Ze 450
LDHA 37 kDa
HXKII 102 kDa
A B
C D
 
Figure 35. Western Blot analysis of HXKII, PDK1, and LDHA after Ze 450 treatment  
A: Representative Western Blot of LDHA, PDK1, and HXKII protein levels after 16 h of Ze 450 
treatment (100 µg/mL) in HT22 cells. B-D: Quantification of Western Blot as optical density 
compared to vinculin as loading control (n=8/treatment condition, ***p<0.001; **p<0.01, unpaired 
t-test).  
 
4.2.5. Ze 450 enhances glucose uptake 
 
Generally, there are two types of glucose transporters; sodium-independent (GLUTs) 
and sodium-dependent ones (for example SGLTs) [163]. They further differ in their 
regulation: GLUT 1-3 are constitutively expressed at the cell membrane, while GLUT 4 
is translocated to the membrane upon specific stimuli (e.g. insulin). These are important 
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glucose transporting proteins, controlling the glycolytic flux. Here, glucose uptake into 
cells was measured using a fluorescent-labeled analog of glucose, 2- NBDG [148]. 2-
NBDG can not be fully used in glycolysis and thus accumulates intracellularly after 
uptake into the cell. Glucose and 2-NBDG enter the cell via glucose transporters 
according to the Michalis-Menten-kinetics [164]. Compared to glucose, 2-NBDG 
transport is slower and less sufficient. The effects of Ze 450 on glucose uptake were 
studied using flow cytometry (Figure 36) and confocal microscopy (Figure 37). Compared 
to control conditions, Ze 450 mediated enhanced glucose uptake (Figure 36A, B), and 
this effect was not affected by any auto-fluorescence (Figure 36 B). Notably, neither 
metformin nor insulin led to a detectable increase in glucose uptake. For Ze 450, it was 
demonstrated that there is a mild initial increase after 2-6 hours of treatment (Figure 
36C), which further increased after 14 h of treatment (Figure 36D). 
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Figure 36. Glucose uptake measured with 2-NBDG via flow cytometry analysis 
A-D: Flow cytometry analysis with 2-NBDG of HT22 cells treated with Ze 450. A: The negative 
control without 2-NBDG staining did not show an increase in fluorescence intensity. B: Auto-
fluorescence of Ze 450 was excluded. Acute treatment without 2-NBDG staining did not show 
enhanced fluorescence intensity. C-D: Time-dependent effects of Ze 450 on glucose uptake were 
analyzed (n=3/treatment condition; ***p<0.001, **p<0.01, *p<0.05 compared to untreated control; 
ANOVA, Scheffé´s test). 
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Furthermore, glucose uptake was investigated using confocal microscopy (Figure 37). 
After 16 h of treatment with Ze 450 enhanced glucose uptake was confirmed by an 
increase in fluorescence intensity of 2-NBDG (Figure 37D).  
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Figure 37. Ze 450 led to an increase of glucose uptake in HT22 cells  
A+B: Confocal images of 2-NBDG staining A: 2-NBDG control cells, scale bar 10 µm. B: 
100 µg/mL Ze 450 for 16 h and 2-NBDG staining. C: Representative confocal background image, 
100 µg/mL Ze 450 for 16 h without 2-NBDG staining. D: Quantification depicts data of four 
independent experiments with n=20 per treatment condition (***p<0.001, unpaired t-test).  
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Moreover, mRNA expression of glucose transporter 1 and 4 (SLC2A1 and 4) were 
analyzed to confirm expression in HT22 cells (Figure 38).  
Besides this 100 µg/mL of Ze 450 increased SLC2A4 expression levels compared to 
control, while the expression of SLC2A1 was not affected.  
Consequently, it can be concluded that Ze 450 promoted the increase of SLC2A4 
expression levels, thereby supporting glucose uptake and glycolysis. In contrast to 
SLC2A1, the regulation of SLC2A4 is inducible, which indicated a specific effect of 
Ze 450 on the glucose transport system.  
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Figure 38. mRNA analysis of SLC2A1 and 4  
A: SLC2A4 mRNA levels were analyzed after 16 h of treatment with 100 µg/mL Ze 450 and 
10 mM metformin in HT22 cells. Insulin was exposed for 30 min. Ze 450, metformin and insulin 
increased optical density compared to GAPDH control. B: Quantification of SLC2A4 mRNA levels 
normalized to GAPDH (n=3/treatment condition, unpaired t-test). C: SLC2A1 mRNA levels were 
analyzed after the indicated time of treatment with 100 µg/mL Ze 450 compared to GAPDH.  
 
SLC2A4 is known to be induced upon insulin stimulus leading to the transfer of vesicular 
GLUT4 to the plasma membrane enhancing glucose uptake. To gain insights into insulin 
signaling and compare this to Ze 450-mediated effects, Akt protein levels and according 
phosphorylation states were investigated. Figure 39A demonstrates that insulin 
increased phospho Akt levels, while basal Akt protein levels were not altered (Figure 
39A). These results suggested proper insulin signaling in HT22 cells. Consequently, the 
question remained, why insulin did not increase 2-NBDG uptake. In comparison to 
insulin, Ze 450 rather decreased phospho Akt protein levels, while Akt level remained 
stable. These effects led to the conclusion, that Ze 450 mediated signaling affected 
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glucose uptake in an insulin-independent manner, while effects of insulin were restricted 
to Akt phosphorylation, while GLUT4-mediated glucose uptake was not stimulated by 
insulin in HT22 cells. 
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Figure 39. Western Blot analysis of phospho Akt and Akt protein levels  
A: Representative Western Blots of pAkt and Akt protein levels after 30 min of 1 µM insulin (INS) 
treatment in HT22 cells. B: Representative Western Blots of pAkt and Akt protein level after 16 h 
of treatment with 100 µg/mL Ze 450 in HT22 cells. 
 
4.2.6. Effects of isolated components and sub-fractions of Ze 450 on cell 
metabolism  
 
Ze 450 is a plant extract consisting of many different components. In the literature 
triterpene glycosides, for example, actein, 23-epi-26-deoxyactein and cimiracemoside C 
have been described as active ingredients [5]; besides this group, Ze 450 further 
contains flavonoids [11] and multiple phenolic acids. In order to study the effects of the 
isolated components (actein, 23-epi-26-deoxyactein and cimiracemoside C) HT22 cells 
were co-treated with glutamate and the triterpene glycosides (Figure 40A-C). Routine 
analysis of this batch of Ze 450 (performed at Max Zeller Söhne AG, Switzerland) 
revealed that total amount of triterpene glycosides was 6.4%, thereof 1.08% actein, 
0.94% deoxyactein and 0.52% cimiracemoside C. Hence, 1,6 µM actein, 1.42 µM 
deoxyactein and 0.848 µM cimiracemoside C correspond to 100 µg/mL Ze 450. Notably, 
none of these concentrations did show comparable effects to Ze 450. Actein reduced 
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metabolic activity upon concentrations greater than 20 µM but protected glutamate-
mediated reduction of metabolic activity in a concentration range that is not reached in 
corresponding amounts of Ze 450 (Figure 40A). Similar effects on metabolic activity were 
obtained from deoxyactein (Figure 40B) and cimiracemoside C (Figure 40C).  
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Figure 40. Effects of actein, 23-epi-26-deoxyactein and cimiracemoside C on metabolic 
activity  
A-C: Metabolic activity was evaluated in glutamate-challenged HT22 cells by measuring MTT 
formazan absorbance (3-10 mM, 16 h). Eight replicate wells per condition are displayed as mean 
+ SD. The absorbance under control conditions is set as 100% (***p<0.001, **p<0.01, *p<0.05 
compared to glutamate-treated control; ###p<0.001, ##p<0.01, #p<0.05 compared to untreated 
control; ANOVA, Scheffé’s test). 
The isolated components did not exert comparable effects like Ze 450, and this may be 
attributed to two reasons: one is the need for a combination of the different triterpene 
glycosides, or second only insufficient concentrations of the individual components were 
reached intracellularly. To answer the first assumption the triterpene glycosides were 
combined and metabolic activity was investigated (Figure 41A). The combination of 6 µM 
of each triterpene-glycoside mediated comparable effects like 100 µg/mL of Ze 450. 
Notably, equivalent concentrations corresponding to 100 µg/mL of Ze 450 were 
exceeded by the use of 6 µM triterpene-glycosides by a multiple.  
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Figure 41. Metabolic activity of combined triterpene glycosides  
A: Metabolic activity was evaluated in glutamate-challenged HT22 cells by measuring MTT 
formazan absorbance (2 mM, 16 h). Eight replicate wells per condition are displayed as mean + 
SD. The absorbance under control conditions is set as 100% (***p<0.001; compared to glutamate-
treated control; ###p<0.001 compared to untreated control; ANOVA, Scheffé’s test). Different 
concentrations of the triterpene glycosides were tested in combination: ADC 100: 1.6 µM actein, 
1.42 µM deoxyactein and 0.838 µM cimiracemoside C (corresponds to 100 µg/mL Ze 450); 6 µM 
ADC: 6 µM of each; 8 µM ADC: 8 µM of each  
 
To gain further insights into which components are relevant for the mechanism of 
protection and metabolic regulation of Ze 450 different solvents were used to obtain sub-
fractions of Ze 450. Three sub-fractions resulted: ethyl acetate fraction (EtOAc), 
buthanolic fraction (BuOH) and water fraction (Aq.). 
10 µg/mL EtOAc, 5 µg/mL BuOH and 70 µg/mL Aq. fraction were present in 100 µg/mL 
of total Ze 450. 
Metabolic activity was reduced at concentrations greater than 20 µg/mL of the EtOAc 
fraction (Figure 42A). Erastin-mediated reduction in metabolic activity was prevented by 
high concentrations of EtOAc and BuOH fraction, but not by the Aq. fraction (Figure 42A).  
Besides Ze 450, the EtOAc fraction mediated protection against erastin-induced 
oxidative cell death (Figure 42B). Regarding cell proliferation 20 µg/mL of the EtOAc 
fraction showed similar effects compared to 100 µg/mL Ze 450 (Figure 42C, D). 
Moreover, this fraction remained to be the most promising compared to Ze 450, since 
erastin-mediated lipid-peroxidation and mitochondrial ROS were partly prevented 
(Figure 42E, F). 
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Figure 42. Cellular and mitochondrial effects of sub-fractions of Ze 450 on HT22 cells  
A: Metabolic activity was evaluated in erastin-challenged HT22 cells by measuring MTT formazan 
absorbance (1 µM, 16 h). Eight replicate wells per condition are displayed as mean + SD. The 
absorbance under control conditions is set as 100%. B: Cell death was assessed by flow 
cytometry using Annexin V and PI after 16 h of treatment in HT22 cells. C: Lipid-peroxidation was 
assessed by flow cytometry using BODIPY™ after 16 h of treatment. D: Mitochondrial ROS 
formation was investigated by flow cytometry using MitoSOX™ after 16 h of treatment. A-D: The 
bar graph shows one representative experiment with three replicates per sample (mean + SD; 
5,000 cells per replicate; ***p<0.001, **p<0.01, *p<0.05 compared to erastin-treated control; 
###p<0.001 compared to untreated control; ANOVA, Scheffé’s test). 
 
Ze 450 demonstrated strong effects on mitochondrial respiration. Similar effects on OCR 
were observed with 20 µg/mL of EtOAc fraction, while 70 µg/mL of the Aq. fraction 
enhanced mitochondrial respiration after FCCP injection (Figure 43A). None of the tested 
fractions rescued erastin-mediated reduction of OCR (Figure 43B). Under basal 
conditions, EtOAc and BuOH fraction had comparable rates of glycolysis, but their 
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oligomycin response was more pronounced than it was the case for Ze 450 treated cells 
and further erastin-mediated reduction of ECAR was not rescued by any sub-fraction, 
but by Ze 450 (Figure 43C, D).  
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Figure 43. Effects of sub-fractions on OCR and ECAR of HT22 cells  
A-D: Data of a representative experiment is depicted, showing OCR and ECAR under basal and 
oxidative stress conditions. A, B: After 16 h of treatment (A) and challenged with 0.8 µM erastin 
(B), the oxygen consumption rate (OCR) of HT22 was analyzed with a Seahorse XFe96 Analyzer. 
Data of 4-6 replicate wells per condition are given as mean ± SD. C, D: After 16 h of treatment 
(C) and challenged with 0.8 µM erastin (D) the extracellular acidification rate (ECAR) was 
determined with a Seahorse XFe96 Analyzer. Data of 4-6 replicate wells per condition are given 
as mean ± SD (Injections: port A: oligomycin; port B: FCCP; port C: rotenone and antimycin A; 
port D: 2-deoxyglucose). 
 
Taken together, EtOAc was identified as the most promising fraction with similar effects 
comparable to Ze 450, but none of the tested fractions was capable to be as effective as 
Ze 450. As triterpene glycosides were enriched in EtOAc fraction they most likely 
contribute to the mechanism of action of Ze 450, but not exclusively. Since, Ze 450 is a 
plant extract with a variety of components the complex and robust metabolic effects 
might be caused by an interplay of the compounds, thus making it difficult to highlight 
just one group or even one component as the leading active ingredient.  
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4.3. Effects of Ze 450 on neuronal cells in comparison to metformin 
 
Metformin is considered as the state of the art in the treatment of patients with diabetes 
mellitus type II [165]. In a recent study, Ze 450 was compared to metformin in an ob/ob 
mouse model [35]. It was found, that Ze 450 exerted anti-diabetic effects, as it led to a 
reduction in body weight and further improved insulin sensitivity and glucose tolerance 
in male, diabetic mice. In the present study, metformin was compared to Ze 450 in 
neuronal cells to elucidate similarities or differences in their mechanism of action and 
response to oxidative stress.  
Millimolar concentrations of metformin did not influence metabolic activity (Figure 44A). 
Erastin-meditated reduction of metabolic activity was prevented by 50 mM metformin in 
a similar fashion like 100 µg/mL of Ze 450 (Figure 44A). In addition, metformin-mediated 
protection against erastin-induced oxidative cell death in a concentration-dependent 
manner (Figure 44B). 
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Figure 44. Metformin protects HT22 cells against oxidative damage  
A: Metabolic activity was evaluated in erastin-challenged HT22 cells by measuring MTT formazan 
absorbance (0.3 µM, 16 h). Eight replicate wells per condition are displayed as mean + SD. The 
absorbance under control conditions is set as 100%. B: Cell death was assessed by flow 
cytometry using Annexin V and PI after 16 h of treatment in HT22 cells. The bar graph shows one 
representative experiment with three replicates per sample (mean + SD; 5,000 cells per replicate). 
A, B: ***p<0.001, **p<0.01 compared to erastin treated control (ANOVA, Scheffé´s test). 
 
Whether metformin has similar effects as Ze 450 on cell proliferation was assessed using 
the xCELLigence system (Figure 45A, B). Metformin affected proliferation at a 
concentration of 50 mM in a comparable manner as 100 µg/mL of Ze 450 (Figure 45A), 
and erastin-mediated reduction in proliferation was partly prevented by 50 mM metformin 
(Figure 45B). 
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Figure 45. Effects of metformin on proliferation 
xCELLigence measurements were conducted after the indicated treatment was added. A: HT22 
cells were treated with Ze 450 or metformin. B: HT22 cells were co-treated with either Ze 450 or 
metformin and 0.3 µM erastin (n=5-8/treatment condition). Data are displayed as mean ± SD. 
 
Next, lipid-peroxidation and mitochondrial parameters (mitochondrial ROS formation, 
mitochondrial membrane potential, and ATP levels) were investigated. Most prominently 
was the complete rescue of erastin-mediated lipid-peroxidation by Ze 450 (Figure 46A). 
After 8 hours of treatment, this effect was less pronounced with metformin (Figure 46A). 
In addition, mitochondrial ROS formation was assessed and erastin-induced 
superoxides were reduced upon concentrations greater than 2 mM metformin (Figure 
46B). Moreover, metformin prevented erastin-mediated loss of mitochondrial membrane 
potential in a concentration-dependent manner (Figure 46C). Interestingly, metformin led 
to ATP depletion, while 100 µg/mL of Ze 450 did not affect ATP levels (Figure 46D). 
Erastin-induced drop of ATP levels were completely prevented by 100 µg/mL Ze 450, 
whereas metformin merely preserved ATP levels under these conditions of cellular stress 
(Figure 46D). 
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Figure 46. Effects of metformin on lipid-peroxidation and mitochondrial parameters  
A: Lipid-peroxidation was assessed by flow cytometry using BODIPY™ after 8 h. The bar graph 
shows one representative experiment with three replicates per sample. B: Mitochondrial ROS 
formation was measured by flow cytometry using MitoSOX™ after 16 h of treatment. The bar 
graph shows one representative experiment with three replicates per treatment. C: Mitochondrial 
membrane potential was assessed via flow cytometric analysis with TMRE™ staining after 16 h 
of erastin treatment. Each bar chart depicts one representative experiment with three replicates 
per sample D: ATP levels were determined using a luciferase-based assay after 16 h of treatment. 
Values from five-eight replicate wells per condition are displayed as mean + SD. The 
luminescence under control conditions is set as 100%. A-D: ***p<0.001, **p<0.01, *p<0.05 
compared to erastin-treated control; ###p<0.001, ##p<0.01, #p<0.05 compared to untreated 
control (ANOVA, Scheffé’s test). 
 
In order to evaluate the effects of metformin on the energy supply of HT22 neuronal cells, 
mitochondrial respiration and the rate of glycolysis were assessed using the Seahorse 
system (Figure 47A-D). Metformin reduced OCR in a concentration-dependent manner 
comparable to Ze 450 (Figure 47A) and erastin-mediated reduction of mitochondrial 
respiration was neither rescued by metformin nor Ze 450 (Figure 47B). Focusing on the 
ECAR, metformin showed an enhanced basal rate of glycolysis, which was more 
pronounced than the effect obtained with Ze 450 (Figure 47C), but however, 
metformin-mediated rescue of the ECAR was less pronounced compared to Ze 450 
(Figure 47D). This might explain that Ze 450 was capable to fully rescue erastin-
mediated ATP depletion and metformin did not, because ATP production was less 
compensated by glycolysis in the metformin-treated cells compared to Ze 450 treatment. 
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Figure 47. Metformin mediated effects on OCR and ECAR 
Data of a representative experiment is depicted, showing OCR and ECAR under basal and 
oxidative stress conditions. A, B: After 16 h of treatment with Ze 450 and metformin (A) and 
challenged with 0.5 µM erastin (B), the oxygen consumption rate (OCR) of HT22 was analyzed 
with a Seahorse XFe96 Analyzer. Data of 5-8 replicate wells per condition are given as mean ± 
SD. C, D: After 16 h of treatment with Ze 450 and metformin (C) and challenged with 0.5 µM 
erastin (D) the extracellular acidification rate (ECAR) was determined with a Seahorse XFe96 
Analyzer. Data of 5-8 replicate wells per condition are given as mean ± SD (port A: oligomycin; 
port B: FCCP; port C: rotenone and antimycin A; port D: 2-deoxyglucose).  
 
Overall, metformin and Ze 450 mediated similar effects on HT22 cells, but in this study, 
some main differences were identified. Surprisingly, Ze 450 mediated effects on 
glycolysis, ATP levels and according cytoprotection were more pronounced and potent 
compared to metformin in the model system of erastin-mediated oxidative stress.  
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4.4. Effects of Ze 450 in comparison to estrogen receptor signaling 
 
In previous years, the mechanism of action of Cimicifuga racemosa rhizoma extracts had 
been attributed to an estrogen-like effect, but more recently, this was rebutted [46,166–
168]. Moreover, researchers found out, that Cimicifuga racemosa extracts were rather 
anti-estrogenic than exerting hormone-like effects [166,169,170]. Nevertheless, in this 
study, Ze 450 was compared to 17β-estradiol, estrogen receptor agonists (DPN, PPT), 
and a selective estrogen receptor modulator (4-OH-Tamoxifen) to gain new insights in 
this previously proposed mechanism of action. 
In order to evaluate the effects of 17β-estradiol on HT22 neuronal cells, metabolic activity 
was determined. A wide concentration range was tested. Notably, just nanomolar or low 
micromolar concentrations were considered to mediate hormonal effects, whereas 
higher micromolar concentrations of 17β-estradiol were described to exhibit anti-oxidant 
effects [171–173].  
At concentrations greater than 100 µM, 17β-estradiol reduced metabolic activity (Figure 
48A). Erastin-mediated reduction of metabolic activity was prevented upon 50 µM 17β-
estradiol (Figure 48A). Moreover, protection against erastin-induced cytotoxicity was 
analyzed using the Annexin V/PI assay; here, 17β-estradiol preserved cell viability at 
50 µM (Figure 48B, C), while nanomolar concentrations did not demonstrate any 
protective effect (Figure 48B). At the level of lipid-peroxidation, the results were largely 
confirmed (Figure 48D). These experiments suggested that protective effects by 17β-
estradiol were mediated through its antioxidant effects at high concentration, thereby 
also supporting the conclusion that estrogen-like effects were not involved in the 
mechanism of action of Ze 450.  
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Figure 48. Effects of 17β-estradiol on HT22 cells  
A: Metabolic activity was evaluated in erastin-challenged HT22 cells by measuring MTT formazan 
absorbance (0.5 µM, 16 h). Eight replicate wells per condition are displayed as mean + SD. The 
absorbance under control conditions is set as 100%. B, C: Cell death was assessed by flow 
cytometry using Annexin V and PI staining after 16 h of treatment in HT22 cells. The bar graph 
shows one representative experiment with three replicates per sample (mean + SD; 5,000 cells 
per replicate). D: Lipid-peroxidation was assessed by flow cytometry using BODIPY™ after 8 h. 
The bar graph shows one representative experiment with three replicates per sample (***p<0.001, 
**p<0.01 compared to erastin-treated control; ###p<0.001 compared to untreated control; 
ANOVA, Scheffé´s test). 
 
In particularly, mitochondrial function was analyzed with special regard on the energy 
phenotype of cells treated with 17β-estradiol in comparison to Ze 450 treatment (Figure 
49A-D). Opposite to Ze 450, 1 µM of 17β-estradiol led to an increase in mitochondrial 
respiration (Figure 49A). 50 µM of 17β-estradiol acted in a similar fashion like Ze 450 as 
it decreased OCR (Figure 49A). In contrast to Ze 450, erastin-mediated reduction of 
OCR was partly prevented by 50 µM 17β-estradiol (Figure 49B). Regarding the basal 
rate of glycolysis, there was no difference observed between 17β-estradiol-treated and 
control conditions (Figure 49C). The reduction of the ECAR mediated by erastin was 
partly prevented by 50 µM 17β-estradiol and Ze 450 (Figure 49D). 
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Figure 49. Effects of 17β-estradiol on energy metabolism  
Data of a representative experiment is depicted, showing OCR and ECAR under basal and 
oxidative stress conditions. A, B: After 16 h of treatment with Ze 450 and 17β-estradiol (A) and 
challenged with 0.5 µM erastin (B), the oxygen consumption rate (OCR) of HT22 was analyzed 
with a Seahorse XFe96 Analyzer. Data of 5-8 replicate wells per condition are given as mean ± 
SD. C, D: After 16 h of treatment with Ze 450 and 17β-estradiol (C) and challenged with 0.5 µM 
erastin (D) the extracellular acidification rate (ECAR) was determined with a Seahorse XFe96 
Analyzer. Data of 5-8 replicate wells per condition are given as mean ± SD (port A: oligomycin; 
port B: FCCP; port C: rotenone and antimycin A; port D: 2-deoxyglucose).  
 
Moreover, the estrogen receptor agonists (DPN and PPT) were used to investigate 
selective estrogen-mediated signaling in comparison to Ze 450. Estrogen binds to two 
different isoforms of the estrogen receptor (ER) alpha and beta. ERα can be found, for 
example, in the mammary gland, male reproductive organs, bone and brain, and ERβ is 
localized in pulmonary epithelial cells, uterus and also in the brain. DPN preferentially 
binds to ERβ and PPT is binding to ERα. 
Both agonists did not affect metabolic activity and did not prevent erastin-mediated 
oxidative damage, which was assessed via the MTT assay (Figure 50A, B). 
Furthermore, combined treatment of the ER agonists together with 100 µg/mL of Ze 450 
did not exceed Ze 450-mediated effects (Figure 50C). 
In addition, 4-OH-Tamoxifen, the active metabolite of tamoxifen and a selective estrogen 
receptor modulator with tissue-specific agonistic and antagonistic effects, was tested. 
Tamoxifen is a known antagonist of ER in breast tissue and therefore used to treat breast 
cancer [174].  
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Here, the effects of 4-OH-Tamoxifen were compared to Ze 450 in neuronal cells exposed 
to oxidative stress. 50 µM 4-OH-Tamoxifen strongly reduced metabolic activity (Figure 
50D), and in the erastin model of ferroptosis in HT22 cells, 10 µM 4-OH-Tamoxifen 
mediated protection against oxidative damage (Figure 50D). To further analyze 
synergistic or additive effects of Ze 450 with 4-OH-Tamoxifen, sub-protective 
concentrations of 4-OH-Tamoxifen (0.5 and 1 µM) were used (Figure 50E). In this study, 
no additional effects of 4-OH-Tamoxifen were detected on metabolic activity compared 
to Ze 450 alone (Figure 50E).  
The MTT assay, however, does not differentiate between metabolic effects and 
cytotoxicity. Therefore, propidium iodide staining with subsequent flow cytometry 
analysis was used to investigate cell death (Figure 50F). In accordance with the previous 
findings, Ze 450 protected against erastin-mediated cytotoxicity, while there was no 
additive or synergistic effect observed, neither for ER agonists (DPN, PPT) nor for 
4-OH-Tamoxifen (Figure 50F).  
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Figure 50. Effects of ER agonists and 4-OH-Tamoxifen on HT22 neuronal cells in 
comparison to Ze 450 
A+B: Metabolic activity was evaluated in erastin-challenged HT22 cells by measuring MTT 
formazan absorbance (0.3-0.5 µM, 16 h). Eight replicate wells per condition of four independent 
experiments are displayed as mean + SD. The absorbance under control conditions is set as 
100%. C-E: Metabolic activity was evaluated in erastin-challenged HT22 cells by measuring MTT 
formazan absorbance (0.3-0.5 µM, 16 h). Eight replicate wells per condition of one representative 
experiment are displayed as mean + SD. The absorbance under control conditions is set as 100%. 
A: DPN; B: PPT, C: DPN, PPT combined with 100  µg/mL Ze 450; D: 4-OH-Tamoxifen; E: 4-OH-
Tamoxifen combined with 100  µg/mL Ze 450. F: Cell death was assessed by flow cytometry 
using PI staining after 16 h of treatment (DPN, PPT, 4-OH-Tamoxifen, Ze 450) in HT22 cells. The 
bar graph shows one representative experiment with three replicates per sample (mean + SD; 
5,000 cells per replicate). A-F: ***p<0.001 compared to erastin treated control, ###p<0.001 
compared to untreated control (ANOVA, Scheffé´s test). 
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Overall, the mode of action of Ze 450 is most likely independent of estrogen-receptor-
mediated signaling, since 17β-estradiol only provided protection at concentrations 
mediating antioxidant effects. In contrast, appropriate concentrations of 17β-estradiol 
and the ER agonists, as well as 4-OH Tamoxifen, did not exceed Ze 450 mediated 
effects on metabolic activity. Furthermore, no additive or synergistic effects of the tested 
ER-binding compounds were detected in HT22 neuronal cells.  
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4.5. Effects of Ze 450 on longevity  
 
Caenorhabditis elegans has been widely used as a model organism to investigate the 
effects of pharmacological compounds, genetic approaches, and nutritional or other 
environmental factors on lifespan and is a suitable model organism to study behavior. In 
addition, heat shock is an established method to assess lifespan after a stress insult 
[102], which impedes transcriptional and translational processes of most proteins [105]. 
In this study, heat shock conditions were used as a screening tool to elucidate an optimal 
concentration range of Ze 450 for a long-term lifespan assay in the C. elegans model. It 
was found that Ze 450 affected the survival of C. elegans in a concentration-dependent 
manner under heat shock conditions (Figure 51A). From these initial results, 100 µg/mL 
of Ze 450 was considered as an appropriate concentration for an experiment 
investigating paraquat (PQ)-induced stress (Figure 51B). Paraquat led to a reduction of 
median survival from 11 h (vehicle) to 8 h. Ze 450 was capable to improve overall 
survival and improved median survival compared to PQ treated conditions in the heat 
shock assay (9.5 h; Figure 51B).  
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Figure 51. Effects of Ze 450 on C. elegans under heat shock and paraquat (PQ) treatment   
A: Effects of different concentrations of Ze 450 in a heat stress model system in C. elegans. 50- 
250 µg/mL Ze 450 did not affect lifespan, while worms treated with 750 or 1500 µg/mL showed a 
decrease in lifespan (*p<0.05, n= 85-115). B: Effects of 100 µg/mL Ze 450 in a model system of 
paraquat (PQ) induced oxidative stress in C. elegans (n=65-113, ***p<0.001 PQ compared to 
vehicle, *p<0.05 Ze 450 + PQ compared to PQ). 
 
As metformin is known to prolong lifespan [175,176] and as it acts in a similar fashion on 
mitochondrial metabolism like Ze 450 in HT22 cells it was used as a control substance. 
In line with previous investigations for effects of Ze 450, the heat stress survival assay 
was used to test for an effective concentration range of metformin (Figure 52A). The 
results showed that 50 and 100 mM metformin decreased survival of C. elegans, while 
25 mM led to an increase in survival compared to vehicle control (Figure 52A). In the 
paraquat-induced stress model system, 25 mM metformin demonstrated an 
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improvement of survival in paraquat challenged nematodes compared to PQ treated 
control condition (Figure 52B).  
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Figure 52. Effects of metformin on C. elegans under heat shock and PQ treatment  
A: Effects of metformin (25-100 mM) in a heat stress model system in C. elegans. 25 mM 
metformin improved lifespan (*p<0.05 compared to M9 vehicle control), while treatment with 
≥50 mM metformin did not affect lifespan (n=75-97). B: Effects of 25 mM metformin in a model 
system of paraquat (PQ) induced oxidative stress in C. elegans (n=76-97, ***p<0.001 PQ 
compared to M9 vehicle, *p<0.05 25 mM metformin +PQ compared to PQ).  
Next, a real-time assay without further stress conditions was performed to elucidate the 
influence of Ze 450 and metformin on the life cycle of worms. There was no difference 
observed regarding overall and median survival between the control conditions (Figure 
53A), therefore, OP50 was used as a standard feeding control; M9 was the vehicle for 
metformin and 1% ethanol for Ze 450. In contrast to the heat shock survival assay, 
100 µg/mL Ze 450 prolonged the overall survival in the real-time setting (Figure 53B). 
The Ze 450 extract improved the median survival (24 days) compared to vehicle control 
(20 days) (Figure 53B). Metformin (25 mM) improved the overall survival rate compared 
to the vehicle control (Figure 53C), but not the median survival rate (22 days for both, 
M9 and 25 mM metformin). In conclusion, Ze 450 was more effective on both parameters 
overall survival and median survival rates than the approved drug metformin in this 
setting.  
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Figure 53. Lifespan analysis 
A-C: Lifespan was analyzed using 40 healthy animals for each group. Control conditions (OP50, 
M9 and EtOH) showed comparable lifespan, while 100 µg/mL Ze 450 (***p<0.001) and 25 mM 
metformin (**p<0.01) improved lifespan compared to vehicle control (1% EtOH, M9). 
 
C. elegans have a pronounced sensory and olfactory system since this is essential for 
their survival. It has been shown that C. elegans respond in a regulated manner to certain 
sensory stimuli [88], thus making the nematodes suitable to study for chemotactic 
behavior in response to olfactory sensing as an indicator for neuronal function [156]. The 
chemotactic index was improved in both, Ze 450 (100 µg/mL) and metformin (25 mM) 
treated conditions (Figure 54A). 
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Figure 54. Chemotactic behavior of C. elegans treated with Ze 450 and metformin  
A: Chemotaxis was assessed using four replicates of each condition using 100-200 worms per 
plate. Chemotaxis index was calculated as followed: ((number of attractant – number of 
control) / number total).  
 
Taken together, the findings in C. elegans demonstrated that Ze 450 improved lifespan 
and chemotactic behavior, i.e. neuronal functions suggesting that Ze 450 mediates 
beneficial effects on the level of a whole organism. 
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4.6. Effects of Ze 450 on liver cells  
 
In the context of drug metabolism research focuses on the liver since this organ is 
responsible for the majority of metabolic processes. For this purpose, Ze 450 was 
exposed to liver cells and metabolic parameters including cellular energy supply were 
analyzed. Moreover, the human hepatoma cell line HepG2 was used as it is a common 
system for toxicological studies to address the ongoing discussion about plant extracts 
causing hepatotoxicity [177]. In this study, aspects of cytotoxicity and mitochondrial 
involvement in response to oxidative stress were investigated. Since erastin treatment 
only exerted minor toxicity in the hepatoma cells, the GPX4 inhibitor, RSL-3, was applied 
in this liver cell line to directly induce ferroptotic oxidative stress. RSL-3 [178] acts 
downstream of the cysteine/glutamate antiporter and directly blocks the GPX4 
independent of glutathione depletion, thereby leading to lipid-peroxidation and to 
ferroptosis-associated comparable cell death signaling pathway such as erastin 
treatment (Figure 3). Figure 55A shows that Ze 450 did not induce cell death at 
concentrations up to 200 µg/mL. The toxic effects were exerted at very high 
concentrations above the therapeutic range relevant for the treatment of 
postmenopausal complaints (Figure 55A). Moreover, at concentrations higher than 
50 µg/mL Ze 450 protected against RSL-3-mediated cytotoxicity (Figure 55B).  
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Figure 55. Effects of Ze 450 on cell viability in HepG2 cells 
A: Cell death was assessed by flow cytometry using Annexin V and PI after 16 h of treatment in 
HepG2 cells. The bar graph shows a representative experiment with three replicates per sample 
(mean + SD; 5,000 cells per replicate, ***p<0.001 compared to untreated control; ANOVA, 
Scheffé´s test). B: Cell death was assessed by flow cytometry using Annexin V and PI after 16 h 
of treatment in HepG2 cells. The bar graph shows consolidated data from three independent 
experiments with each three replicates per sample (mean + SD; 5,000 cells per replicate, 
***p<0.001 compared to RSL-3 treated control; ANOVA, Scheffé´s test). 
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As detected previously in the neuronal cell lines, Ze 450 affected mitochondrial function 
by inducing a bioenergetic shift from mitochondrial respiration towards glycolysis that 
mediated protection of mitochondrial integrity and reduced mitochondrial ROS formation. 
Therefore, investigating the effects of Ze 450 on mitochondrial parameters on human 
HepG2 cells was of major interest. Analyzing lipid ROS levels using C11-BODIPY 
staining and FACS analysis revealed that Ze 450 did not affect lipid-peroxidation after 
8 h and 16 h under basal conditions (Figure 56A). In contrast, RSL-3-induced lipid-
peroxidation was abolished by concentrations greater than 1 µg/mL of Ze 450 after 8 
hours of treatment. At the later time point (16 h) 100 µg/mL of Ze 450 prevented oxidative 
stress-mediated increase in lipid-peroxidation. In the model system of HepG2 cells, 
Ze 450 attenuated RSL-3-mediated mitochondrial ROS formation, while Ze 450 alone 
did not induce an increase in mitochondrial ROS levels (Figure 56C). Moreover, 
mitochondrial membrane potential was not affected by Ze 450, while the RSL-3-induced 
loss of mitochondrial membrane potential was prevented by concentrations of Ze 450 
greater than 10 µg/mL (Figure 56D). ATP levels remained unaltered by Ze 450 at 
concentrations up to 200 µg/mL, while RSL-3-mediated ATP depletion was rescued by 
Ze 450 at concentrations higher than 100 µg/mL (Figure 56E).  
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Figure 56. Effects of Ze 450 on lipid-peroxidation and mitochondrial parameters in HepG2 
cells  
A, B: Lipid-peroxidation was assessed by flow cytometry using BODIPY™ after 8 and 16 h. The 
bar graph shows one representative experiment with three replicates per sample. C: 
Mitochondrial ROS formation was measured by flow cytometry using MitoSOX™ after 16 h of 
treatment. The bar graph shows one representative experiment with three replicates per 
treatment. D: Mitochondrial membrane potential was assessed via flow cytometric analysis with 
TMRE™ staining after 16 h of RSL-3 treatment. Each bar chart depicts one representative 
experiment with three replicates per sample E: ATP levels were determined using a luciferase-
based assay after 16 h of treatment. Values from five-eight replicate wells per condition are 
displayed as mean + SD. The luminescence under control conditions is set as 100%. A-E: 
***p<0.001, **p<0.01, *p<0.05 compared to erastin-treated control, ###p<0.001, ##p<0.01, 
#p<0.05 compared to untreated control (ANOVA, Scheffé’s test). 
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For detailed analysis of mitochondrial respiration and glycolysis, OCR and ECAR were 
assessed using the Seahorse system. Consistent with the previous results obtained in 
models of erastin and glutamate-induced oxidative stress in neuronal cells, Ze 450 
reduced OCR in a concentration-dependent manner in the liver cells (Figure 57A) and 
did not affect the reduction of mitochondrial respiration mediated by RSL-3 (Figure 57B). 
At the level of glycolysis, Ze 450 acted in a comparable manner like control cells (Figure 
57C). Nevertheless, Ze 450 prevented RSL-3-mediated reduction of ECAR (Figure 57D).  
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Figure 57. Ze 450 mediated effects on OCR and ECAR in HepG2 liver cells  
Data of a representative experiment is depicted, showing OCR and ECAR under basal and 
oxidative stress conditions. A, B: After 16 h of treatment with Ze 450 (A) and challenged with 
4 µM RSL-3 (B), the oxygen consumption rate (OCR) of HepG2 cells was analyzed with a 
Seahorse XFe96 Analyzer. Data of 5-8 replicate wells per condition are given as mean ± SD. 
C, D: After 16 h of treatment with Ze 450 (C) and challenged with 4 µM RSL-3 (D) the extracellular 
acidification rate (ECAR) was determined with a Seahorse XFe96 Analyzer. Data of 5-8 replicate 
wells per condition are given as mean ± SD (port A: oligomycin; port B: FCCP; port C: rotenone 
and antimycin A; port D: 2-deoxyglucose).  
HepG2 cells were derived from human heptoma, but they do not express all cytochrome 
P enzymes, which are important for drug metabolism. Because of this lack of metabolic 
activity in the HepG2 cells, H4IIE cells were used, in addition. H4IIE cells are derived 
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from rat hepatoma and an established model system for studies of cytochrome P450 
enzyme activity and induction [179,180].  
Consistent with the previous results (Chapter 4.1.), the H4IIE cells demonstrated in 
response to Ze 450 a slight reduction of metabolic activity in response to Ze 450 in the 
MTT assay (Figure 58A). In contrast to HepG2 cells, erastin treatment led to sufficient 
oxidative damage and was used for the experiments in H4IIE cells as oxidative stressor. 
Erastin-mediated reduction of metabolic activity was prevented at concentrations of 
Ze 450 higher than 50 µg/mL (Figure 58A). Under basal conditions, Ze 450 alone did not 
exert any cytotoxic effect in the tested concentration range (Figure 58B). The 
AnnexinV/PI assay confirmed that erastin-induced cytotoxicity was prevented by 
concentrations higher than 50 µg/mL of Ze 450 (Figure 58B). Moreover, mitochondrial 
ROS formation was investigated (Figure 58C), also confirming the protective effects of 
Ze 450 obtained in HepG2 cells and neuronal cell lines. Overall, these results showed 
that Ze 450 did not exert toxic effects on the liver cells but rather protected these from 
the oxidative challenge, indicating that Ze 450 mediates protective effects in a variety of 
different cell types.  
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Figure 58. Effects of Ze 450 an H4IIE cells 
A: Metabolic activity was evaluated in erastin-challenged H4IIE cells by measuring MTT formazan 
absorbance (4 µM, 16 h). Eight replicate wells per condition are displayed as mean + SD. The 
absorbance under control conditions is set as 100%. B: Cell death was assessed by flow 
cytometry using Annexin V and PI after 16 h of treatment in H4IIE cells. The bar graph shows one 
representative experiment with three replicates per sample (mean + SD; 5,000 cells per replicate). 
C: Mitochondrial ROS formation was measured by flow cytometry using MitoSOX™ after 16 h of 
treatment. The bar graph shows a representative experiment with three replicates per treatment. 
A-C: ***p<0.001 compared to erastin-treated control, ###p<0.001 compared to untreated control 
(ANOVA, Scheffé’s test). 
 
To further analyze direct effects on liver mitochondria, the organelles were isolated from 
rat liver for functional investigations using the coupling and the electron flow assay.  
Isolated liver mitochondria were exposed to 100 µg/mL Ze 450 in the presence of 
rotenone and succinate. Notably, initial OCR of control and treated mitochondria was 
low, in turn, there was no statistical difference observed between the different 
pretreatment paradigms (Figure 59A). After injection of FCCP (port C) Ze 450 treatment 
demonstrated a less pronounced increase in OCR compared to control mitochondria.  
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Figure 59. Effects of Ze 450 on isolated liver mitochondria (coupling assay)  
A: OCR was analyzed after 30 and 60 min of incubation with Ze 450 (100 µg/mL). ADP, 
oligomycin, FCCP and antimycin A were injected successively. Rotenone was initially present 
and hence respiration is being driven by complex II-IV activity.  
 
Moreover, complex I functionality of liver mitochondria treated with Ze 450 was analyzed. 
While 50 µg/mL of Ze 450 did not impact electron flow, 100 µg/mL of Ze 450 slightly 
reduced OCR after FCCP injection, but the effect was not statistically significant (Figure 
60A). 
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Figure 60. Ze 450 affects mitochondrial complex I functionality  
A, B: OCR was analyzed after 60 min of incubation with Ze 450 (100 µg/mL). Rotenone, FCCP, 
antimycin A and ascorbate with TMPD were injected successively. Pyruvate and malate were 
initially present and hence respiration is being driven by complex I.  
 
Taken together, the results in liver cells and isolated liver mitochondria supported the 
previous findings in neurons, suggesting that Ze 450 impaired mitochondrial respiration 
in a direct manner, thereby reducing mitochondrial ROS formation and mediating 
protection against oxidative damage.   
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4.7. Effects of Ze 339 on neuronal cells 
 
4.7.1. Effects of Ze 339 on cell viability and proliferation 
 
In order to study the influence of Ze 339 on neuronal cells, cell death was analyzed to 
determine a non-toxic concentration range of Ze 339 (Figure 61A). Ze 339 induced cell 
death at concentrations of 100 µg/mL (Figure 61A), consequently, 50 µg/mL of Ze 339 
was set as the highest concentration tested in the following experiments. Furthermore, 
erastin-mediated cell death was prevented by 10 and 50 µg/mL Ze 339 detected with 
Annexin V and propidium iodide (Figure 61A). Metabolic activity was reduced by 1 µg/mL 
of Ze 339 compared to the controls (Figure 61B), and in the same concentration range, 
metabolic activity was preserved after erastin exposure (Figure 61B). Reduced metabolic 
activity upon Ze 339 suggested an influence of the extract on cell metabolism, these 
finding was supported by impaired proliferation measured with the xCELLigence system. 
Ze 339 reduced proliferation in a concentration-dependent manner (Figure 61C). 
Interestingly, erastin-mediated reduction in cell index was not compensated by Ze 339 
(Figure 61C). 
Ze 339 [µg/mL]
m
e
ta
b
o
lic
 a
ct
iv
ity
(%
 o
f 
co
n
tr
o
l)
-
0.
01 0.
1 1 10 50
-
0.
01 0.
1 1 10 50
0
50
100
150
***
***
*
#
# ##
0.3 µM erastin
Time of treatment (hours)
N
o
rm
a
liz
e
d
 c
e
ll 
in
d
e
x
0 5 10 15 20
0
1
2
3
4 Ctrl  0.1 µg/ml Ze 339
1 µg/mL Ze 339 10 µg/mL Ze 339
50 µg/mL Ze 339 100 µg/mL Ze 339
1µM erastin
Time of treatment (hours)
N
o
rm
a
liz
e
d
 c
e
ll 
in
d
e
x
0 5 10 15 20
0
1
2
3
4 Ctrl 1 µM erastin
0.1 µg/mL Ze 339 + era. 1 µg/mL Ze 339 + era.
10 µg/mL Ze 339 + era. 50 µg/mL Ze 339 + era.
100 µg/mL Ze 339 + era.
Ze 339 [µg/mL]
A
V
/P
I 
p
o
si
tiv
e
 c
e
lls
(%
 o
f 
 g
a
te
d
 c
e
lls
)
-
10
 
50 10
0 -
10
 
50 10
0
0
50
100 0.5 µM erastin###
*** ***
A B
C D
 
  
Results 
103 
 
Figure 61. Effects of Ze 339 on cell viability and proliferation 
A: Cell death was assessed by flow cytometry using Annexin V and PI staining after 16 h of 
treatment in HT22 cells. The bar graph shows one representative experiment with three replicates 
per sample (mean + SD; 5,000 cells per replicate). B: MTT assay was performed after 16 h of 
treatment with Ze 339 and erastin in HT22 cells. Eight replicate wells per condition are displayed 
as mean + SD. The absorbance under control conditions is set as 100 %. A-B: ***p<0.001, 
*p<0.05 compared to erastin-treated control; ##p<0.01, #p<0.05 compared to untreated control 
(ANOVA, Scheffé’s test) C-D: xCELLigence measurements were conducted after the indicated 
treatment was added (n=4-6/treatment condition). Data are displayed as mean ± SD. 
 
4.7.2. Effects of Ze 339 on mitochondrial function and bioenergetics 
 
Next, lipid-peroxidation was assessed to analyze soluble ROS formation. After 8 h of 
exposure Ze 339 induced an increase in green fluorescence detecting oxidized lipids 
(Figure 62B), which was statistically significant at 50 µg/mL Ze 339 (Figure 62A). 
Nevertheless, the even more pronounced erastin-mediated lipid-peroxidation was 
attenuated with 1-50 µg/mL of Ze 339 at this time point of incubation (Figure 62C, D). 
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Figure 62. Impact of Ze 339 on lipid-peroxidation   
Lipid-peroxidation was assessed by flow cytometry using BODIPY™ after the indicated time of 
treatment. The bar graph shows one representative experiment with three replicates per sample 
(mean + SD; 5,000 cells per replicate; **p<0.01 compared to erastin-treated control; #p<0.05 
compared to untreated control; ANOVA, Scheffé’s test). A, C: Quantification B, D: representative 
flow cytometry histograms 
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To gain insights, whether Ze 339 induced superoxide generation by mitochondria, 
mitochondrial ROS formation was investigated after 8 h of treatment. At concentrations 
greater than 10 µg/mL of Ze 339 an increase in red fluorescence detected under basal 
incubation conditions (Figure 63A, B). However, the erastin-mediated mitochondrial ROS 
formation was partly prevented with 1 µg/mL of Ze 339 at this time point. Notably, 10 and 
50 µg/mL of Ze 339 were not effective against oxidative stress-mediated damage after 
8 h of treatment.  
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Figure 63. Effects of Ze 339 on mitochondrial ROS formation after 8 h of treatment 
Mitochondrial ROS formation was assessed by flow cytometry using MitoSOX™ after 8 h of 
treatment. The bar graph shows one representative experiment with three replicates per sample 
(mean + SD; 5,000 cells per replicate, *p<0.05 compared to erastin treated control; ###p<0.001 
compared to untreated control; ANOVA, Scheffé’s test). A, C: Quantification B, D: representative 
flow cytometry histograms, two different gates were used to differentiate between smaller (B) and 
greater changes (D). 
 
The basal effect of Ze 339 on mitochondrial ROS formation was at a similar level after 
16 h of incubation (Figure 64A, B), while erastin-mediated induction of superoxides was 
more pronounced after 16 h compared to the 8 h treatment. In turn, also 10 and 50 µg/mL 
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of Ze 339 protected against erastin-induced mitochondrial ROS formation at 16 hours of 
incubation (Figure 64C, D).  
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Figure 64. Effects of Ze 339 on mitochondrial ROS formation after 16 h of treatment  
Mitochondrial ROS formation was assessed by flow cytometry using MitoSOX™ after 16 h of 
treatment. The bar graph shows a representative experiment with three replicates per sample 
(mean + SD; 5,000 cells per replicate, ***p<0.001 compared to erastin treated control; 
###p<0.001, ##p<0.01 compared to untreated control; ANOVA, Scheffé’s test). A, C: 
Quantification B, D: representative flow cytometry histograms, two different gates were used to 
differentiate between smaller (B) and greater changes (D). 
 
Furthermore, ATP levels were investigated to analyze energy supply. Ze 339 led to a 
decrease of basal ATP levels, while further erastin-mediated ATP depletion was 
attenuated in a concentration-dependent manner (Figure 65A). In addition, the integrity 
of the mitochondrial membrane potential was assessed (Figure 65B). While erastin- 
mediated loss of mitochondrial membrane potential was protected at concentrations of 
Ze 339 greater than 10 µg/mL, there was no effect of Ze 339 on mitochondrial membrane 
potential under basal conditions (Figure 65B).  
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Figure 65. Effects of Ze 339 on ATP levels and on mitochondrial membrane potential   
A: ATP levels were determined using a luciferase-based assay after 16 h of treatment. Values 
from five-eight replicate wells per condition are displayed as mean + SD. The luminescence under 
control conditions is set as 100%. B: Mitochondrial membrane potential was assessed via flow 
cytometric analysis with TMRE™ staining after 16 h of erastin treatment. Each bar chart depicts 
one representative experiment with three replicates per sample. A-B: mean + SD; 5,000 cells per 
replicate, ***p<0.001 compared to erastin- treated control (ANOVA, Scheffé’s test). 
 
In line with the previous findings, Ze 339 reduced mitochondrial respiration in a 
concentration-dependent manner as detected in OCR measurements using the 
Seahorse system (Figure 66A). In addition, erastin-mediated reduction of OCR was not 
prevented by Ze 339 (Figure 66B). HT22 cells treated with Ze 339 led to an increase in 
ECAR, which was the most pronounced with 10 µg/mL Ze 339 (Figure 66C). Erastin-
mediated reduction of ECAR was less distinct, but 10 and 20 µg/mL Ze 339 preserved 
ECAR under oxidative challenge (Figure 66D). Moreover, upon oligomycin injection, the 
increase in ECAR in Ze 339 treated samples was not as steep as in the control condition, 
suggesting that the pre-incubation of the cells with Ze 339 already stimulated glycolysis.  
Taken together, Ze 339 demonstrated strong effects on metabolism in neuronal HT22 
cells and further protected against oxidative damage mediated by erastin, while ROS 
formation was promoted, suggesting that ROS contribute to Ze 339 mediated molecular 
signaling. 
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Figure 66. The impact of Ze 339 on mitochondrial respiration and the rate of glycolysis   
Data of a representative experiment is depicted, showing OCR and ECAR under basal and 
oxidative stress conditions. A, B: After 16 h of treatment with Ze 339 (A) and challenged with 
0.8 µM erastin (B), the oxygen consumption rate (OCR) of HT22 was analyzed with a Seahorse 
XFe96 Analyzer. Data of 5-12 replicate wells per condition are given as mean ± SD. C, D: After 
16 h of treatment with Ze 339 (C) and challenged with 0.8 µM erastin (D) the extracellular 
acidification rate (ECAR) was determined with a Seahorse XFe96 Analyzer. Data of 4-12 replicate 
wells per condition are given as mean ± SD (port A: oligomycin; port B: FCCP; port C: rotenone 
and antimycin A; port D: 2-deoxyglucose). 
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5. Discussion  
 
5.1. Impact of Ze 450 on metabolism 
 
Cimicifuga racemosa extracts are well established in the treatment of menopausal 
symptoms, such as hot flushes and night sweating, but the exact mechanism of action 
is still elusive. Menopausal transition is considered as a physiological process, which 
ends one year after the final menstruation. Besides estrogen depletion, age-related 
metabolic changes (for example the increase in body weight) occur during this phase, 
leading to the accumulation of risk factors for metabolic diseases, like diabetes mellitus 
type II or osteoporosis. Recent studies demonstrated that Ze 450 promoted 
advantageous metabolic changes including a reduction in body weight and improved 
glucose metabolism in a mouse model of diabetes [35] and attenuated weight gain in 
menopausal women [52]. Based on these results, it was hypothesized that Ze 450 
mediated its therapeutic effects through alterations of metabolic regulation and 
independent of estrogen receptor stimulation. In this context, a novel concept of 
menopausal transition emerged, suggesting that climacteric complaints and weight gain 
in menopause are largely caused by metabolic changes. Therefore, it was of great 
interest to investigate basal effects of Ze 450 on metabolism in neuronal cells and its 
impact on cellular resilience under conditions of oxidative stress as a model of age-
related alterations. In fact, it was found that Ze 450 modulated cellular energy supply, 
thereby protecting from oxidative damage.  
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5.1.1. Ze 450 induces metabolic changes by mild mitochondrial inhibition  
 
Mitochondria are the powerhouses of the cell. In this context, respiratory chain activity 
and oxidative phosphorylation are important in meeting the cellular energy demand, as 
they are responsible for the majority of energy supply, while, anaerobic glycolysis plays 
a minor role in ATP production under physiological conditions [75]. Ze 450 demonstrated 
strong effects on energy supply at the level of mitochondria. Surprisingly, Ze 450 
mediated a concentration-dependent reduction of the OCR, which corresponds to 
mitochondrial respiration, but in contrast, only concentrations greater than 150 µg/mL 
reduced ATP levels in HT22 cells (Figure 20). Further, Ze 450 did not rescue the erastin-
mediated decrease of OCR (Figures 23A, B and 24A), while erastin-mediated ATP 
depletion was prevented by Ze 450 (Figure 20). Concomitantly, cells treated with 
100 μg/mL of Ze 450 showed an increase in ECAR suggesting that the energy supply 
was switched from oxidative phosphorylation to anaerobic glycolysis in cells exposed to 
Ze 450 (Figures 23C, B and 24B). Notably, the response to oligomycin in Ze 450-treated 
cells was not as pronounced as in control conditions assuming that Ze 450 treatment 
provoked maximal glycolytic flux (Figure 23C). Besides this, erastin-mediated reduction 
of glycolysis was prevented by Ze 450 (Figures 23D and 24B). From these results, it was 
concluded that mitochondrial protection and cell survival after oxidative stress was 
attributed to the metabolic switch from mitochondrial respiration to glycolysis. In fact, 
inhibition of glycolysis by 2-DG abolished the protection against oxidative stress (Figure 
26A) supporting, the proposed link between the bioenergetic shift induced by Ze 450 and 
the observed protective effects. In order to specify the mode of action of Ze 450 on the 
ETC complexes, isolated mitochondria were used to investigate mitochondrial complex 
functionality. It was observed, that Ze 450 decreased the activity of CI-III in a time and 
concentration-dependent manner (Figures 28 and 29). These findings support the 
hypothesis that Ze 450 modulates mitochondrial respiration by inhibiting respiratory 
chain complexes and thereby reducing mitochondrial ROS formation, which is regarded 
as the underlying protective mechanism. 
ROS production as a side product of OXPHOS can occur in forward and reverse direction 
of the electron flow. Through normal electron flow, CI and CII mainly produced 
mitochondrial ROS, but if the Coenzyme Q pool is over-reduced, reversed electron flow 
is promoted, leading to an increased ROS production by CI. The exact mechanisms 
leading to reverse electron flow are still not known, but it has been proposed that it occurs 
when CV is inactive [138,181]. To maintain a high mitochondrial membrane potential, 
CV transfers protons in the opposite direction into the IMS by consuming ATP, leading 
to enhanced ROS production by CI. Moreover, it has been shown that blockage of CI by 
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rotenone at low concentrations prevents reversed electron flow to CI and following ROS 
production [182,183], thereby mediating beneficial effects. On the other hand, at high 
concentrations, rotenone potentiates ROS production by interfering with the flavin-
binding site of CI [183,184]. Besides this, slightly enhanced ROS production by reverse 
electron flow was suggested to contribute to mitohormesis and thereby leading, for 
example, to lifespan extension in C. elegans [138]. The reduction of OCR by Ze 450 in 
neuronal cells and in isolated mitochondria found in this study suggests an inhibitory 
effect of Ze 450 on mitochondrial respiration, which is most likely involved in beneficial 
cellular effects, such as protection against oxidative damage. For example, it was 
detected here that Ze 450 directly inhibited mitochondrial respiratory chain activity 
(Figures 28 and 29), but in contrast to rotenone [184], Ze 450 neither induced 
mitochondrial ROS formation in neuronal nor liver cells, nor in isolated mitochondria 
(Figures 21, 56 and 30). Consequently, it is assumed that Ze 450 interferes with the 
ubiquinone-binding site but not with the flavin-binding site of CI, since rotenone exposure 
on isolated mitochondria led to a further decrease of mitochondrial respiration (29) and 
increased mitochondrial ROS formation [184]. Most intriguingly, the protective effects of 
Ze 450 at the level of mitochondria and on cell viability were attributed to a bioenergetic 
shift from oxidative phosphorylation to anaerobic glycolysis, in particular under 
conditions of oxidative stress. 
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5.1.2. Ze 450 promotes metabolic reprogramming  
 
Moreover, other mechanisms are known for enhancing the rate of anaerobic glycolysis, 
like activation of AMPK [35], which is a master regulator of cellular energy homeostasis. 
In addition, a previous study demonstrated that AMPK is activated by Ze 450 in HepaRG 
cells [35]. Therefore, AMPK might be one target of Ze 450, which provides a potential 
mechanistic link between mitochondrial parameters and cellular responses to oxidative 
stress.  
Furthermore, AMPK has been identified as a key player in promoting aerobic glycolysis 
[75]. In this regard, the major proteins involved in the Warburg effect (Figure 7) were 
analyzed to gain further insights into the mechanism of action of Ze 450 (Figure 67).  
In particular, HIF1α and cMyc have been identified as crucial regulators of key glycolytic 
enzymes, like HXKII. In HT22 cells, Ze 450 mediated time-dependent effects on HIF1α 
protein level. Initially, an increase in HIF1α was detected (Figure 32) promoting glycolytic 
gene expression [185], which was confirmed by an increase in HXK II protein level 
(Figure 35A, D). Interestingly, HIF1α protein levels dropped after 16 h of Ze 450 
treatment, while a concomitant increase in cMyc protein levels was observed at these 
late time points (Figure 33C, D).  
One main difference between HIF and cMyc signaling on metabolic regulation is that HIF 
blocks the entry of pyruvate into the TCA cycle by enhanced activity of PDK1, which 
inhibits PDH mediated transformation of pyruvate to acetyl-CoA, and, as a consequence, 
mitochondrial respiration is decreased (Figure 67) [186,187]. In line with this, the PDK1 
protein levels were increased (Figure 35C) and the OCR decreased (Figure 23A) upon 
Ze 450 treatment in the current study. HIF has been demonstrated to alter COX4 
subunits in response to hypoxia in mammalian cells and thereby reducing toxic levels of 
ROS production by restoring the electron transfer to O2 resulting in H2O formation [188] 
and thereby reducing superoxide formation by CI and CIII [188]. In this context, the 
limitation of ROS formation is an essential HIF-mediated metabolic adaption [188,189], 
which might contribute to the observed protective effect by Ze 450.  
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Figure 67. Metabolic reprogramming mediated by Ze 450 
Ze 450 increased HIF1α and cMyc protein levels, and following glycolytic gene expression (for 
example HXKII) was upregulated. Moreover, protein levels of pyruvate dehydrogenase kinase 1 
(PDK1) were increased upon Ze 450 treatment, leading to decreased oxygen consumption rate 
(OXPHOS). Moreover Ze 450 promoted the expression of glucose transporter 4 (GLUT) and 
increased glucose uptake. Ze 450 mediated these metabolic changes supporting the enhanced 
glycolytic energy supply.  
 
Besides the enhanced expression of key glycolytic enzymes, cMyc is further involved in 
growth regulation. For this purpose mitochondrial respiration and the production of 
biosynthetic substrates are crucial to support cMyc-mediated increases in proliferation 
[189]. In the present study, this is not the case since mitochondrial respiration and mTOR 
protein levels are reduced by Ze 450 (Figure 23A and 15A, B), suggesting that the initial 
enhancement of glycolytic energy metabolism was largely mediated by HIF1α. 
In this context, the increase in cMyc protein levels after 16 hours may support the 
glycolytic shift rather than promoting cMyc-mediated oncogene signaling (enhanced 
proliferation), suggesting a predominant metabolic regulation by cMyc that is 
independent of the regulation of enhanced cell proliferation. In line with this, Ze 450 
reduced proliferation in different cell lines (Chapter 4.1.1.), highlighting major differences 
to cMyc-driven tumorigenesis, which relays on mTORC1 activation promoting oncogene 
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signaling [190]. These findings distinguish Ze 450 mediated adaptive regulations on cell 
metabolism from cMyc-dependent signaling in proliferating cancer cells.  
In this regard, the effects of Ze 450 on cellular metabolism were of particular interest in 
this study. Indeed, it was demonstrated that Ze 450 mediated concentration-dependent 
effects on metabolic activity in neuronal and liver cells, but did not induce cell death 
(Chapter 4.1. and 4.6.), suggesting a significant influence of the extract on metabolism. 
Furthermore, Ze 450 reduced proliferation in a time- and concentration-dependent 
manner (Figure 14), but this effect on cell growth was reversible after withdrawal of 
Ze 450 (Figure 14F). Thus, assuming regulatory effects at the protein level, the 
mammalian target of rapamycin (mTOR) was of major interest in further investigations 
on the mechanism of action. So far, two protein complexes have been identified with 
mTOR as a main component, mTORC1 and mTORC2 [191], which are involved in many 
essential processes of the cell, for example, cell growth, proliferation, energy 
metabolism, and protein synthesis [192]. Inhibition of mTOR is well known to initiate 
autophagy by ULK1 activation leading to beneficial health effects, for example, lifespan 
extension [193]. Whether Ze 450 modulates autophagy or the autophagic flux is a matter 
of current research. However, the exact downstream signaling involved in mTOR-
mediated cell proliferation is still elusive [191]. Ze 450 reduced total mTOR protein levels; 
while the expression levels of Raptor (regulatory subunit of mTORC1) was not affected. 
These findings led to the conclusion, that Ze 450 affected mTORC2-mediated signaling, 
leading to a reduced proliferation rate upon Ze 450 treatment (Figure 14A). It is known 
that upon growth factor stimulus mTORC2 is activated via Akt signaling leading to the 
activation of mTORC1 and, thereby, enhanced proliferation [191] In contrast, in this study 
phospho Akt protein levels were not increased upon Ze 450 treatment suggesting Akt-
independent signaling of Ze 450. Moreover, recent findings revealed that both mTOR 
complexes were involved in the regulation of cell proliferation by regulating FoxO3 gene 
expression [191]. Whether Ze 450 enhances FoxO3 gene expression and thereby 
reduced proliferation was not addressed in this study but might have an impact on Ze 450 
mediated metabolic effects.  
Besides the impact on proliferation, it was demonstrated that upregulation of mTOR 
contributes to obesity and associated metabolic diseases. Overnutrition enhanced 
mTOR signaling, which led to alterations in energy metabolism and insulin resistance, 
and therefore, contributed to metabolic diseases, such as diabetes mellitus type II [194]. 
In a recent study, it was demonstrated that Ze 450 mediated anti-diabetic effects in an 
ob/ob mouse model, which was accompanied by enhanced AMPK activation, an 
upstream regulator of mTOR [35]. The present findings, in cultured neuronal cells 
supported this link suggesting that the observed metabolic effects of Ze 450 were 
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mediated via impaired mTOR signaling, thereby might involve modulation of autophagy 
and regulation via enhanced FoxO3 gene expression.  
Besides the proposed metabolic regulation by Ze 450 via modulated mTOR signaling, 
enhanced expression of cMyc, HIF1α, HXKII, and PDK1 contributed in a time-dependent 
manner to an enhanced glycolytic energy supply upon Ze 450 exposure (Figure 67). 
Thus, leads to the hypothesis that Ze 450 modulates different molecular pathways, in 
which reduced proliferation lowers the energy demand of the cells and the above-
mentioned proteins support glycolytic energy supply contributing to the described 
protective effect against oxidative damage (Chapter 4.2.1. and 5.1.4.). Since glycolytic 
energy supply is less sufficient than oxidative phosphorylation, the cells’ demand for 
glucose is expanded. In this regard, functional analysis of glucose uptake via flow 
cytometry and confocal microscopy upon Ze 450 treatment was investigated (Figures 36 
and 37). In fact, Ze 450 stimulated glucose uptake in a concentration- and time-
dependent manner supporting the observed metabolic reprogramming with the supply of 
sufficient glucose to maintain cellular energy homeostasis (Figures 36 and 37). In this 
context, an increase of glucose uptake mediated by insulin was not observed (Figure 
36A). However, functional insulin signaling was proven by an increase of pAkt protein 
level (Figure 39A), which was not detectable upon Ze 450 treatment, suggesting a 
metabolic regulation independent of insulin-mediated signaling.  
In conclusion, it was demonstrated that Ze 450 mediated important metabolic changes 
at the level of mitochondria and affected important regulators of cellular energy supply, 
thus offering promising therapeutic potential in diseases related to impaired energy 
metabolism, like diabetes mellitus type II. Moreover, increased ROS formation is largely 
contributing to typical climacteric complaints, such as hot flushes, supporting the 
hypothesis that menopausal transition is a phase of accumulation of age-related risk 
factors and not exclusively relying on estrogen depletion. In this context, the direct effects 
of Ze 450 on mitochondrial respiration provide a novel mechanistic explanation for the 
relief of menopausal symptoms, like weight gain and hot flushes.  
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5.1.3. Effects of Ze 450 on hypothalamic neurons in the context of 
thermoregulation 
 
As Cimicifuga racemosa extracts were used to treat menopausal complaints, like hot 
flushes and night sweating it was a major interest to gain insights into the effects of 
Ze 450 on neuronal cells from the hypothalamus, as this is the superordinate endocrine 
control center of metabolism and thermoregulation [22,195]. In this context, it was 
previously hypothesized that Ze 450 acts as a serotonergic agent and thereby reducing 
hot flushes [40–42]. Moreover, the hypothalamus has been discussed as a central 
regulator of mediating menopausal symptoms, such as hot flushes and associated 
metabolic impairments [196]. ARC neurons of the hypothalamus consist of “neurons of 
first-order”, which are the first neurons in contact with peripheral signals [197,198]. In this 
regard, metabolic changes occurring during menopause may directly affect energy 
homeostasis of the hypothalamus, since it was demonstrated that arcuate neurons are 
responsive to many peripheral signals, such as hormones like leptin [197]. The 
importance of the hypothalamus in metabolic regulation was demonstrated, for example, 
by lesions in this brain region, which induced obesity [199].  
mHypo cells are hypothalamic neurons and a suitable in vitro system to study the impact 
of Ze 450 under oxidative stress conditions. Since the development of menopausal 
symptoms, like hot flushes and night sweating, is associated with an increase in reactive 
oxygen species, which contribute to the mentioned symptoms (Figure 2) [20,38,39]. 
Increased ROS formation dependent and independent of estrogen depletion has shown 
to trigger climacteric complaints [20] (Figure 2). 
Ze 450 demonstrated protective effects on the level of mitochondria and cell death in a 
model system of erastin-induced oxidative damage (Chapter 4.1. and 4.2.1). Erastin-
mediated mitochondrial ROS formation, lipid-peroxidation and loss of mitochondrial 
membrane potential was attenuated upon concentrations greater than 50 µg/mL of 
Ze 450 demonstrating that Ze 450 is capable to reduce ROS mediated signaling, thereby 
preventing oxidative damage. Hence, this provides a mechanistic link, for the beneficial 
effects of Ze 450 on menopausal symptoms [4], like night sweating and hot flushes, 
which are triggered by an imbalance in redox homeostasis especially in neuronal cells 
(Chapter 4.2.1 and Figure 2).  
In conclusion, the experimental approaches in hypothalamic neurons demonstrated that 
Ze 450 is capable to reduce oxidative damage, especially mitochondrial ROS formation 
thus suggesting a mechanistic link for the reduction of hot flushes and night sweating. 
Implications of the energy metabolism in mHypo cells by Ze 450 were not assessed, but 
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might explain the metabolic regulation, by promoting glycolysis and thereby protecting 
from oxidative damage, as it was demonstrated in hippocampal HT22 cells. 
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5.1.4. Ze 450 protects against oxidative damage  
 
Maintaining redox homeostasis is essential for crucial cell functions, as reactive oxygen 
species are important second messengers [134,200]. Besides this, many age-related 
neurodegenerative pathologies including Alzheimer´s and Parkinson´s disease, but also 
metabolic illnesses, like diabetes mellitus type II, hypertension and cancer share 
common pathomechanisms, involving enhanced ROS production and imbalanced redox 
homeostasis [54,182,201,202]. More specifically, enhanced free radical formation has 
been described as massively damaging to cells and organs, thereby significantly 
contributing to the mentioned diseases. Moreover, it was demonstrated that climacteric 
complaints, like hot flushes, were associated with an increase in reactive oxygen 
species, which contributed to the mentioned symptoms (Figure 2) [20,38,39]. Further, 
metabolic disturbances in redox homeostasis provide evidence that menopausal 
transition is rather an impairment involving energy metabolism than exclusively caused 
by estrogen depletion [20]. Thus, it was a major aim to evaluate the effects of Ze 450 
under oxidative stress conditions with a particular focus on mitochondrial integrity and 
function, since they are the major source of reactive oxygen species and crucial for 
maintaining cellular energy homeostasis.  
HT22 neuronal cells were established as a suitable model system to study oxidative 
stress. In these cells, oxidative cell death such as oxytosis or ferroptosis can be induced 
by glutamate or erastin, respectively (Figure 3) [59,203]. Ze 450 exerted protective 
effects in various cells in model systems of oxidative stress (Chapter 4.1.1) as 
summarized in Figure 68.  
Oxidative stress-mediated lipid-peroxidation was abolished by concentrations higher 
than 50 µg/mL of Ze 450, while Ze 450 alone did not induce enhanced lipoxygenase 
12/15 activity. Notably, this pronounced protective effect was present after 8 h, but also 
after 16 h of the oxidative challenge. This finding indicated that even the secondary ROS 
burst initiated through mitochondrial impairment was prevented by Ze 450. In turn, 
Ze 450 protected mitochondria from oxidative damage. Mitochondria are the 
powerhouses of the cell and they are key regulators in maintaining energy homeostasis. 
One major hallmark in neuronal cell death is massive mitochondrial impairment due to 
enhanced cellular and following mitochondrial ROS formation [55,202,204]. In fact, 
Ze 450 prevented oxidative stress-mediated mitochondrial ROS formation. Besides this, 
loss of mitochondrial membrane potential, ATP depletion and enhanced mitochondrial 
fragmentation mark mitochondrial damage and the so-called “point of no return” (Figure 
3) [65]. 
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Figure 68. Scheme of Ze 450 mediated effects under oxidative challenge 
Disruption of redox homeostasis by erastin, glutamate or RSL-3 led to mitochondrial impairment 
and subsequently cell death. Ze 450 mediated protection against erastin/glutamate or RSL-3 
induced lipid-peroxidation, mitochondrial ROS formation, ATP depletion, and cell death by 
decreasing mitochondrial respiration and enhancing glycolysis to compensate energy supply of 
the cells.  
 
Upon mitochondrial impairment, AIF is released and mediates neuronal cell death [67]. 
Thus, protecting mitochondria is an important strategy to prevent neuronal damage, 
since oxidative stress is closely linked to many neurodegenerative diseases, like stroke 
or Parkinson’s disease and further metabolic diseases including diabetes mellitus type II 
and the development of menopausal symptoms [205]. The results of this study show that 
Ze 450 mediated a shift in energy metabolism towards glycolysis, as described before in 
chapter 4.2 and discussed in chapter 5.1.2. and 5.1.3., thereby protecting against 
erastin- and glutamate-mediated mitochondrial damage (Chapter 4.1.2 and 4.2). 
Consequently, cell viability was persevered by Ze 450 under oxidative stress conditions, 
which might provide new therapeutic options for other metabolic diseases, which are 
related to increased ROS formation and a disbalance in energy homeostasis.  
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5.1.5. Ze 450 and metformin share protective effects against oxidative 
damage in neuronal cells  
 
Besides the effective treatment of menopausal complaints, it was suggested that Ze 450 
has further therapeutic potential. Since Ze 450 mediated antidiabetic effects in an ob/ob 
mouse model which were comparable to metformin [35], this study provided evidence 
for Ze 450 as a potential treatment option for metabolic diseases, like diabetes mellitus 
type II. Therefore, in the present study, it was a major interest to compare the mode of 
action of Ze 450 to metformin. Metformin is currently used to treat type II diabetes 
mellitus, but so far, the molecular mechanism of action is not fully understood. It is known 
that metformin lowers blood glucose levels and fasting insulin levels by reducing 
gastrointestinal and increasing peripheral glucose uptake [165,206]. At the cellular level, 
metformin acts as an ETC inhibitor and an AMPK activator [207], thereby it is interfering 
with several important cellular pathways involved in energy metabolism [208]. It has been 
demonstrated that activation of AMPK contributed to neuroprotective effects of 
metformin in H2O2-treated PC12 neuronal cells [209]. In this context, metformin is 
currently discussed as a potential anticancer, antiaging, neuroprotective and 
cardioprotective agent [165,206].  
In this study, metformin and Ze 450 both protected against erastin-mediated cytotoxicity, 
mitochondrial ROS formation and loss of mitochondrial membrane potential (Chapter 
4.3). However, metformin did not decrease metabolic activity in the tested concentration 
range in the MTT assay and was not as effective as Ze 450 in protecting against erastin-
mediated lipid-peroxidation. Notably, proliferation was reduced in a similar manner, 
assuming an impairment in mTOR signaling, which was shown in this study for Ze 450 
(Chapter 4.1) and was demonstrated for metformin earlier [165,210–212]. Furthermore, 
it is known, that metformin inhibits mitochondrial CI, thereby reducing ROS production 
by mitochondria [78,208]. In line with this, metformin reduced OCR in a concentration-
dependent manner in the current study (Figure 47). Moreover, metabolic reprogramming 
by an energetic shift towards glycolysis was less pronounced in metformin treatment 
conditions compared to Ze 450 (Figure 47C). In accordance with this Ze 450 was more 
effective in the rescue of erastin-mediated ATP depletion compared to metformin, most 
likely because the promoted shift towards glycolysis was more pronounced under 
oxidative stress conditions (Figure 46D). 
In this study, it was demonstrated that Ze 450 exerted metabolic effects in a similar 
fashion as metformin, but the Ze 450 mediated effects were more pronounced and the 
protective effects against oxidative damage were more potent. Therefore, it is of great 
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interest to further characterize the complex mechanism of action of Ze 450 and to 
evaluate its potential use as a treatment against diseases related to oxidative damage 
and metabolic impairments, like diabetes mellitus type II. 
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5.1.6. Ze 450 mediated effects are distinct from estrogen receptor-mediated 
signaling  
 
Hormonal replacement therapy is an effective treatment option against menopausal 
complaints, like hot flushes or mood disorders [18,19]. However, the indication of HRT 
is limited by adverse side effects and contraindications, like coronary heart disease, 
stroke, and personal history of thromboembolic disease. In this context, the need for 
alternative treatment options was highly warranted. Cimicifuga racemosa extracts are 
hormone-free compositions and well-established for the treatment of climacteric 
complaints. Nevertheless, Cimicifuga racemosa extracts have been initially linked to 
mediate estrogenic effects, but this classification of the extracts as “phyto-estrogens” 
was revised. In fact, it was demonstrated that Cimicifuga racemosa extracts rather 
mediate anti-estrogenic than hormone-like effects [47]. Further, Cimicifuga racemosa 
extracts can be used in menopausal women with, for example, hormone-sensitive 
endometrial cancer [33]. In the current study, Ze 450 mediated effects were compared 
to estrogen-driven effects in neuronal cells in order to further evaluate a distinct or similar 
mode of action of the extract compared to estrogen receptor-mediated signaling 
activated by estrogens. 17β-estradiol is known to mediate hormonal and anti-oxidant 
effects in a concentration-dependent manner [173,213]. The results depicted in 
chapter 4.4 demonstrate that17β-estradiol protected against erastin-mediated damage, 
but this effect is most likely linked to its antioxidant activities as described before 
[171,172,213]. More intriguingly, mitochondrial respiration was slightly increased by 
1 µM of 17β-estradiol compared to control conditions (Figure 49A), in contrast to Ze 450, 
which decreased OCR. In line with current research [20,214], the increase in OXPHOS 
by 17β-estradiol has shown beneficial effects on disturbed energy metabolism in the 
brain of menopausal women. The findings of this study clearly indicate a distinct 
mechanism of action of Ze 450, since OXPHOS was decreased by the extract as 
summarized in figure 69.  
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Figure 69. Effects of estradiol and Ze 450 on altered energy metabolism in postmenopause 
17-β estradiol and Ze 450 mediate beneficial effects on brain energy metabolism during 
menopause by distinct mechanisms. Compensation of energy deficit during postmenopause is 
compensated by 17-β estradiol by an increase in mitochondrial respiration, while Ze 450 led to a 
metabolic reprogramming towards glycolysis (OXPHOS: oxidative phosphorylation, mROS: 
mitochondrial ROS). 
 
Besides this, both ER agonists (PPT and DPN) did not affect HT22 cells under basal and 
oxidative stress conditions (Figure 50A, B), supporting the hypothesis that Ze 450 rather 
mediates a metabolic than an estrogen-like effect. Furthermore, the comparison to 4-
OH-Tamoxifen did not show a synergistic or additive effect in combination with Ze 450. 
Tamoxifen has been studied in model systems of oxidative stress previously, and the 
reported neuroprotective effects were independent of estrogen receptor inhibition [215]. 
In line with this, in the present study 10 µM of 4-OH-Tamoxifen mediated protective 
effects against erastin-induced oxidative damage (Chapter 4.4). 
Taken together, the results obtained in the present study confirmed that Ze 450 
promoted effects were distinct from estrogen receptor-mediated signaling, underlining 
the importance of Cimicifuga racemosa extracts as hormone-free alternatives to HRT in 
the treatment of climacteric complaints.   
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5.1.7. Total Ze 450 is more effective than isolated components and sub-
fractions 
 
Cimicifuga racemosa extract contains many components, including antioxidants, like 
ferulic acid. In line with this, it was demonstrated earlier that the main antioxidant 
properties of Cimicifuga racemosa extracts from rhizomes were attributed to phenolic 
acids, for example, caffeic acid, ferulic acid and isoferulic acid [12]. The content of ferulic 
acid, however, is less than 0.2 % in this batch of Ze 450 and, therefore, most likely not 
responsible for the observed protective effects. Further, Ze 450 demonstrated a strong 
influence on energy metabolism, and this metabolic regulation is important for the 
protection against oxidative damage (Chapter 4.2.1.). 
In fact, the protective effect of Ze 450 against erastin-mediated toxicity was abolished by 
the glycolysis inhibitor 2-DG. In contrast, the antioxidant Trolox still mediated protection 
against erastin-induced toxicity in the presence of 2-DG (Figure 26A). These results 
demonstrated that the protective effects of antioxidants cannot be inhibited through 
interference with glycolysis, suggesting that protection by Ze 450 was mediated by 
metabolic mechanisms beyond the inherent antioxidant properties. In order to evaluate 
the upregulation of the key antioxidant enzymes, the protein levels of MnSOD, 
CuZnSOD, and Catalase were analyzed, since it is known that some antioxidants 
accelerate their direct radical scavenging potential through an increased expression of 
the mentioned enzymes for ROS detoxification [216,217]. Notably, the protein levels of 
the mentioned antioxidant enzymes were unaltered after incubation with the extract 
(Figure 27), supporting the conclusion that the antioxidant properties of Ze 450 were not 
substantially contributing to the observed protective effects in HT22 cells. 
Ze 450 is a plant extract; therefore, there are besides the above-mentioned antioxidants 
many other components. So far, it is not possible to attribute all of the therapeutic effects 
of Cimicifuga racemosa extracts to either a single constituent or a class of components. 
Nevertheless, much research was done and triterpene glycosides [5–7] for example, 
actein, 23-epi-26-deoxyactein and cimiracemoside C [8,9]; phenolic acids, 
predominantly derivatives of hydroxycinnamic acid [10], including caffeic, ferulic and 
cimicfugic acid [7] and flavonoids [11] were represented in extracts of the rhizome. For 
example, a fraction containing triterpene glycosides [5] inhibited the growth of MCF7 
human breast cancer cells and induced cell cycle arrest at the G1 phase. In line with this, 
it is known that the EtOAc fraction consists of major triterpene glycosides and this fraction 
showed reduced proliferation in HT22 neuronal cells, which was comparable to total 
Ze 450 (Figure 42C), in a reproducible and reliable way. In addition, 20 µg/mL of EtOAc 
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fraction reduced OCR but was not as effective as Ze 450 against erastin-mediated 
reduction of the ECAR (Figure 43D). Notably, the Aq. fraction, which consists of the 
phenolic acids, did not mediate protection against erastin-mediated damage. For the 
BuOH fraction, it was found that it had some similarities to the mode of action of total 
Ze 450, but especially at the level of mitochondria, the buthanolic fraction was not able 
to prevent erastin-mediated mitochondrial impairment. Interestingly, the isolated 
chemical triterpene glycosides did not mediate protection against oxidative damage in 
neuronal cells comparable to Ze 450, in a relevant concentration range. Moreover, the 
combination of different glycosides was only effective in concentrations higher than the 
concentrations in 100 µg/mL of total Ze 450 (Chapter 4.2.6.). The observed results 
suggest that neither sub-fractions nor single or combined components were as effective 
as total Ze 450 in the used model system of oxidative stress in HT22 cells. 
Conclusively, in the current study, Ze 450 was described as a plant extract with a 
complex mode of action, which, so far, cannot be attributed to a single component or a 
specific group of ingredients.  
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5.1.8. Ze 450 protects liver cells from oxidative damage 
 
Assessing cytotoxicity in liver cells was of particular interest in the present study since 
there is an ongoing debate whether Cimicifuga extracts may cause hepatotoxicity. There 
are reports in the literature that associated Cimicifuga racemosa extract to hepatic side 
effects in patients with possible yet unknown risk-factors [218–220]. Notably, none of the 
adverse liver effects was directly linked to Ze 450. Besides this, the causality in general, 
the exclusion of other causes and the consideration of the herbal constitution leading to 
the case reports, were criticized in the field [29,221]. Still, known liver damage is a 
contraindication for Cimicifuga racemosa preparations. At a very high dose (1000 mg/kg 
body weight) Ze 450 caused microvesicular steatosis in the liver of rats [222]. In this 
regard, the authors concluded that these high concentrations are very unlikely to be 
reached in humans treated with the recommended daily doses of 6.5-13 mg extract 
[222]. In the present study, two different liver cell lines were investigated and up to 
200 µg/mL of Ze 450, cytotoxicity was not detected in either cell line (Figure 55B and 
58B). In contrast, the results obtained in the cultured liver cells showed a pronounced 
protection against oxidative damage (Figure 55B and 58B) and further demonstrated that 
the concentrations leading to the enhanced cell death of liver cells (Figure 55A) are much 
greater (≥500 µg/mL) than the concentrations required for protective effects 
(50-200 µg/mL) (Figure 55B). In particular, in HepG2 liver cells, strong protective effects 
of Ze 450 on ATP depletion, lipid peroxidation, mitochondrial ROS formation and loss of 
mitochondrial membrane potential (Figure 56) were detected, which were consistent with 
the findings in neuronal cells. 
Regarding these findings, it might be suggested that Ze 450 shows beneficial effects on 
diseases related to oxidative liver damage, rather than causing liver toxicity.  
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5.1.9. Ze 450 extends the overall survival of Caenorhabditis elegans 
 
Moreover, it was of great interest to evaluate the effects of Ze 450 on a whole organism 
under basal and oxidative stress conditions.  
Therefore, Caenorhabditis elegans served as a model organism to study the effects of 
Ze 450 on survival in a real-time setting and under oxidative stress conditions in vivo. In 
the present study, it was demonstrated that 100 µg/mL of Ze 450 was capable to prevent 
PQ-mediated shorting of survival (Figure 51B). As described before in chapter 5.1.5., 
metformin was used as a control since it is used to treat patients with diabetes mellitus 
type II [165] and discussed as a potential agent promoting longevity in C. elegans 
[175,176]. In the current study, the heat shock assay demonstrated similar findings for 
25 mM metformin compared to 100 µg/mL of Ze 450 (Figure 52). Notably, 25 mM 
metformin enhanced survival in the heat stress resistance test, while 100 µg/mL of 
Ze 450 did not, highlighting mechanistical differences in the mode of action of Ze 450 
compared to metformin. In the real-time setting Ze 450 enhanced median and overall 
survival compared to its vehicle control, while metformin did not improve median survival, 
but overall survival (Figure 53).  
Metformin has been shown to improve survival of type II diabetic patients compared to 
healthy subjects [223]. In this context, the gut microbiota is of great interest since it was 
demonstrated that metformin mediated effects were regulated by interactions with the 
microbiota in C. elegans [224]. C.elegans is a good model to study drug microbiome 
interactions since C. elegans and humans share many gut microbes such as E. coli [225]. 
In a recent study, bacterial metabolites like agmatine were shown to mediate metformin 
related effects on longevity in C. elegans [224], which might explain the survival benefit 
in type II diabetic patients. A currently ongoing clinical trial (TAME, Targeting Aging with 
Metformin) is focusing on metformin mediated effects on aging and will give new insights 
into modulations of metformin beyond its impact on diabetes mellitus type II [223].  
Regarding Cimicifuga racemosa extracts, it remains open which exact cellular 
mechanisms are involved in the prolongation of survival. Moreover, it was previously 
stated that several pathways and molecular mechanisms interact and contribute to 
longevity in C. elegans [100,226,227]. daf-16 has been identified as a major regulator 
leading to lifespan extension [104,228], thereby involving a forkhead box O1 ortholog, 
which is regulated by the ortholog of Sirtuin 1 in C. elegans [229,230]. Additionally, AMPK 
was identified as another key player in longevity in C. elegans suggesting a link between 
lifespan extension and energy metabolism [227]. In C. elegans the AMP/ATP ratio 
increases upon aging. In this context, it was found that the AAK-2, which is the α subunit 
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of the C. elegans AMP-activated protein kinase, functions as an AMP sensor and 
modulates lifespan prolongation [227,231]. Metformin was shown to enhance lifespan in 
this study (Chapter 4.5) and previously [175,232]. Recently, it was demonstrated that 
activation of AMPK and inhibition of mTOR upon stimulation of the lysosomal pathway 
by metformin contribute to lifespan extension [232]. These mechanistical considerations 
might also account for Ze 450, but this needs to be confirmed in further experiments.  
Furthermore, the improvement of the chemotactic behavior of C. elegans due to Ze 450 
(Figure 54) implicates a potential effect on neuronal activity. Thus implying new 
mechanistical characteristics for Ze 450 involving the olfactory system of C. elegans.  
The in vivo setting with C. elegans emphasizes that Ze 450 has beneficial effects on a 
whole organism and might contribute to healthy aging. Alongside, PQ mimics an 
oxidative stress insult, which led to mitochondrial impairment. Hereby, Ze 450 
demonstrated protective effects, confirming the findings in vitro, that Ze 450 preserved 
mitochondrial function and integrity. Moreover, the results in C. elegans demonstrate that 
Ze 450 mediated advantageous effects in the paraquat model system of oxidative stress, 
which suggests a mode of protection involving mitochondria. These findings led to the 
conclusion that Ze 450 has a strong impact at the level of mitochondria, which was 
demonstrated in neuronal and liver cells, as well as in isolated mitochondria and in C. 
elegans.  
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5.2. Effects of Ze 339 on neuronal cells 
 
Petasites hybridus leaf extract is used to treat seasonal allergic rhinitis but the exact 
mechanism of action is not fully understood so far. Therefore, Petasites hybridus leaf 
extract, Ze 339 was investigated in regard to specify its mechanism of action and assess 
its potential protective effects against oxidative damage in HT22 neuronal cells, since 
inflammatory diseases like allergic respiratory diseases are often accompanied with an 
increase in reactive oxygen species [233,234].  
In this study, the model system of ferroptosis was used to induce oxidative stress in a 
well-established in vitro system of immortalized neuronal cells [59] as described in 
chapter 1.2.1. Interestingly, 50 µg/mL of Ze 339 enhanced lipid-peroxidation after 8 
hours of treatment, while mitochondrial ROS formation was induced upon 10 µg/mL 
Ze 339 (Figures 62 and 63). Annexin V/PI FACS measurement confirmed that this 
metabolic regulation was not accompanied by enhanced cytotoxicity (Figure 61A). These 
results demonstrated that Ze 339 induced mild oxidative stress via ROS formation 
(Figure 70), but was not harmful in these concentrations. Taken together, these results 
demonstrated that Ze 339 induced mitochondrial ROS formation and enhanced 12/15 
lipoxygenase activity in a concentration- and time-dependent manner.  
In line with this, it is known that mild oxidative stress mediates protection due to pre-
conditioning effects [235], and therefore, is relevant for aging and promotes disease 
resistance [137,236]. Whether Ze 339 mediates its anti-allergic and anti-inflammatory 
effects via (mito-) hormetic processes needs to be further investigated. In this context, it 
was demonstrated that besides an increase in (mitochondrial) ROS formation, 
autophagic processes were suggested to contribute to beneficial hormetic cytoprotection 
[235,237]. In this regard, it would be interesting to evaluate the effects of Ze 339 on 
autophagy, since it is known that mild mitochondrial or cellular stress induces (mito-) 
hormetic processes [238], which are accompanied by various molecular mechanisms 
involving, for example, unfolded protein response (UPR), but also impacts mito- and 
autophagy [239,240].  
 
Discussion 
129 
 
 
Figure 70. Proposed mechanism of action of Ze 339 
Ze 339 led to a mild increase in lipid-peroxidation and subsequent mitochondrial ROS formation. 
Mitohormetic adaptations might contribute to Ze 339-mediated protection against oxidative 
damage by enhancing mitochondrial resilience.  
 
Furthermore, in the current study, it was investigated if Ze 339 protects neuronal cells 
against oxidative stress-mediated cytotoxicity and mitochondrial impairment since an 
imbalance in redox homeostasis is linked to many diseases, including inflammatory 
diseases, like allergic respiratory disease [233]. 
In fact, it was found that Ze 339 mediates protection against erastin-mediated cytotoxicity 
in neuronal cells. Moreover, Ze 339 slightly induced lipid-peroxidation and mitochondrial 
ROS formation, but alongside abolished erastin-mediated oxidative insult (Figure 62-64). 
Hence, Ze 339 protected mitochondria from oxidative damage by preserving 
mitochondrial membrane potential (Figure 65B).  
Further, Ze 339 decreased ATP production compared to control conditions, which might 
be explained by a reduced mitochondrial respiration rate (Figures 65A and 66A). Notably, 
erastin-mediated ATP depletion was rescued by Ze 339 (Figure 65A). Analyzing 
mitochondrial respiration and glycolysis, upon 1 µg/mL Ze 339 the OCR was decreased 
but ECAR was maintained to ensure proper energy supply of the cells. Hereby, it would 
be of great interest to analyze energy supply at an early stage and therefore answer the 
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question, whether enhanced mitochondrial ROS formation is accompanied by an 
increase in mitochondrial respiration and hence superoxide production.  
 
Moreover, it was shown that Ze 339 acts via inhibition of STAT activation [119], leading 
to reduced transcription of cytokines and inflammatory effects. The authors proposed 
that Ze 339 acts upstream of STAT since cytokine-induced nuclear translocation was 
reduced for STAT 1, 3 and 6, suggesting interference with the assembly of the JAK/STAT 
complex. Whether STAT inhibition is essential for Ze 339 mediated protection in 
neuronal cells needs to be investigated in future studies more in detail.  
So far, it might be hypothesized that Ze 339 exerts multiple effects contributing to 
symptom relief of allergic rhinitis including reduced inflammatory responsiveness. 
Further (mito-) hormetic adaptions might mediate pre-conditioning effects supporting, for 
example, the endogenous antioxidant defense system, which protects against 
disturbances in redox homeostasis, but until now the exact mechanism of action remains 
to be clarified. In the current study, it was demonstrated that Petasites hybridus extract, 
Ze 339 reduced proliferation in a concentration-dependent manner, while cell viability 
until 50 µg/mL of Ze 339 was unaffected. Moreover, Ze 339 prevented lipid-peroxidation, 
mitochondrial ROS formation, loss of mitochondrial membrane potential and cell death 
in a model system of oxidative cell death. These effects might support the treatment of 
seasonal allergic rhinitis and likely in many other respiratory diseases with increased 
ROS formation. Further, Ze 339 might provide mitochondrial resilience via mild 
(mitochondrial) ROS formation at low concentrations and thereby promoting beneficial 
adaptions. 
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6. Summary  
 
The Cimicifuga racemosa extract Ze 450 is produced by a standardized procedure and 
well-established in the treatment of menopausal complaints; however, the underlying 
mechanism of action has not been clarified. In a recent study, Ze 450 mediated beneficial 
effects on glucose tolerance, insulin sensitivity and weight gain in diabetic ob/ob mice 
and on weight gain in a clinical study investigating therapeutic effects of Ze 450 on 
climacteric symptoms in menopausal women. Therefore, it was of great interest to study 
the effects of Ze 450 on cell metabolism in more detail. To address this issue, Ze 450 
was exposed to neuronal and liver cells alone, and in model systems of oxidative stress, 
since an imbalance in redox homeostasis was shown to be crucially involved in the 
pathogenesis of many age-related diseases, including, for example, diabetes mellitus 
type II, and further provides a molecular link towards menopause. In this context, a new 
concept of menopause is hypothesized, implying age-related metabolic disturbances 
rather than exclusively focusing on estrogen depletion. 
This study revealed that Ze 450 mediated remarkable effects on metabolism by reducing 
metabolic activity and the rate of cell proliferation in various cell types. Furthermore, it 
was demonstrated that Ze 450 provided protection against erastin- and glutamate-
mediated oxidative cytotoxicity in neuronal and liver cells. Notably, the findings on liver 
cells clearly demonstrated, that Ze 450 is rather protective than causing hepatotoxicity. 
Additionally, Ze 450 preserved mitochondrial integrity and function, while under oxidative 
challenge, Ze 450 prevented mitochondrial impairments by protecting against erastin- 
and glutamate-mediated lipid-peroxidation, mitochondrial ROS formation, loss of 
mitochondrial membrane potential and ATP depletion. Ze 450 exerted beneficial effects 
by directly inhibiting mitochondrial respiration and, thereby, reducing mitochondrial 
superoxide production. Moreover, Ze 450 preserved the energy supply of the cell by 
metabolic reprogramming towards glycolysis. In this context, it was demonstrated that a 
regulation of HIF1α and cMyc most likely contributed to the metabolic shift by enhancing 
the protein expression of key glycolytic enzymes. Further, it was demonstrated that 
Ze 450 enhanced glucose uptake to maintain cellular energy homeostasis by promoting 
glycolysis. These results demonstrated that Ze 450 affects energy metabolism by direct 
inhibition of mitochondrial respiration and metabolic reprogramming towards glycolysis, 
supporting a novel therapeutic concept describing Ze 450 as a metabolic regulator.  
Ze 450 is a plant extract, which consists of many different components. In former studies, 
triterpene glycosides were identified as active ingredients, but in neuronal cells, the 
isolated components (actein, 23-epi-26-deoxyactein, cimiracemoside C) were not able 
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to mediate effects comparable to Ze 450. Nevertheless, sub-fractions of Ze 450 were 
investigated and the EtOAc fraction turned out to act in a similar manner like Ze 450, but 
the effective concentrations were higher than contained in 100 µg/mL of Ze 450. 
Besides triterpene glycosides, Ze 450 also contains phenolic acids that mediate 
antioxidant effects. Indeed, Ze 450 showed moderate antioxidant properties compared 
to Trolox but this antioxidant effect is not mainly contributing to the observed protection 
by Ze 450. 
Taken together, Ze 450 offers promising therapeutic potential in diseases involving 
mitochondrial damage and increased ROS formation and provides first evidence for a 
novel mechanism of action involving metabolic reprogramming, which highlights a new 
perspective on menopausal transition.  
Besides Ze 450, a special extract of Petasites hybridus was investigated in the model 
systems of ferroptosis. Ze 339 is a CO2 extract obtained from leaves of Petasites 
hybridus and is used to treat seasonal allergic rhinitis. In this study, Ze 339 was 
investigated in order to specify its mechanism of action and assess its potential protective 
effects against oxidative damage in HT22 neuronal cells. Ze 339 induced mild ROS 
formation produced by lipid-peroxidation and by mitochondria but did not impair cell 
viability at concentrations up to 50 µg/mL of Ze 339. In the context of mitohormesis, 
Ze 339 might provide protection against mitochondrial impairment by a mild increase in 
ROS. Moreover, Ze 339 protected against erastin- mediated cytotoxicity and 
mitochondrial impairment in HT22 neuronal cells. In conclusion, it is hypothesized that 
Ze 339 provides mitochondrial resilience by a mild increase in ROS formation leading to 
beneficial metabolic adaptions or responses to allergens. In this study, it was 
demonstrated that (mito-) hormetic regulation processes might contribute to symptom 
relief of allergic rhinitis.  
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7. Zusammenfassung  
 
Cimicifuga racemosa Extrakte, wie Ze 450 werden zur Behandlung von 
Wechseljahresbeschwerden eingesetzt. Der zugrundeliegende Wirkmechanismus ist 
jedoch nicht bekannt. In einem diabetischen Mausmodell wurde gezeigt, dass Ze 450 
die Glucosetoleranz, Insulinsensitivität und Gewichtszunahme günstig beeinflusste. Die 
positiven Effekte auf das Körpergewicht wurden in einer retrospektiven klinischen Studie 
mit Frauen in der Menopause bestätigt. Die Menopause markiert die Zeit bis 12 Monate 
nach dem Ausbleiben der letzten Regelblutung und wird durch schwankende oder 
abfallende Östrogenspiegel eingeleitet. Die Akkumulation reaktiver Sauerstoffspezies ist 
maßgeblich an altersbedingten Erkrankungen, wie Diabetes mellitus Typ II, ebenso wie 
an der Entstehung typischer menopausaler Beschwerden beteiligt. In diesem 
Zusammenhang wurde postuliert, dass die Menopause nicht nur auf den Östrogenabfall, 
sondern vielmehr auf metabolische Veränderungen zurückzuführen ist, die zur 
Entstehung altersbedingter Erkrankungen mit beitragen.  
Diesbezüglich war die Untersuchung der Auswirkungen von Ze 450 auf den 
Zellstoffwechsel von großem Interesse. Daher wurden basale und potentiell protektive 
Effekte von Ze 450 in Modelsystemen des oxidativen Stresses untersucht, um den 
Einfluss von Ze 450 auf ein Ungleichgewicht der Redox-Homöostase zu untersuchen. 
Eine Beeinflussung des zellulären und mitochondrialen Metabolismus durch Ze 450 
wurde insbesondere durch eine vermindert mitochondriale Respiration und eine 
reduzierte Proliferationsrate gezeigt. Weiterhin schützte Ze 450 vor Erastin- und 
Glutamat-vermittelter Zytotoxizität in Neuronen und Leberzellen und induzierte in den 
relevanten Konzentrationsbereich keine Zellschädigung in den verwendeten Zelllinien. 
Darüber hinaus wurden in dieser Studie Einflüsse von Ze 450 auf mitochondriale 
Parameter untersucht, da diese Zellorganellen maßgeblich die Energiebereitstellung und 
die Thermoregulation steuern. Ze 450 schützte die Mitochondrien vor oxidativen 
Schäden und bewahrte so die Integrität der Mitochondrienmembran und die Funktion 
der Organellen. Ze 450 schützte vor Erastin- und Glutamat-vermittelter 
Lipidperoxidation, mitochondrialer ROS-Bildung, Verlust des mitochondrialen 
Membranpotenzials und dem Abfall der zellulären ATP Spiegel. Darüber hinaus 
verminderte Ze 450 die mitochondriale Atmung durch eine direkte Hemmung der 
Atmungskettenkomplexe. Der protektive Effekt von Ze 450 gegen die oxidativen 
Schädigung ist durch eine Verschiebung des Energiemetabolismus in Richtung 
Glykolyse begründet. Weiterhin tragen HIF1α und cMyc maßgeblich zur metabolischen 
Verschiebung bei, indem die Proteinexpression wichtiger glykolytischer Enzyme 
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hochreguliert wurde. Weiterhin erhöhte Ze 450 die Glukoseaufnahme in den Zellen und 
gewährleistete so die Energieversorgung über die verstärkte Glykolyse. Diese 
Erkenntnisse zeigen einen völlig neuen Wirkmechanismus von Ze 450 auf, wobei Ze 450 
als Regulator den Energiehaushalt vorteilhaft beeinflusst und so neben der effektiven 
Behandlung klimakterischer Beschwerden eine neue Sichtweise auf altersbedingte 
Erkrankungen eröffnet.  
Des Weiteren wurde die Frage nach den wirksamen Bestandteilen in Cimicifuga 
racemosa Extrakten adressiert. In früheren Studien wurden Triterpenglykoside als an 
der Wirkung beteiligte Stoffgruppe identifiziert, aber in den HT22 Zellen konnten Actein, 
23-Epi-26-Desoxyactein und Cimiracemosid C keine mit Ze 450 vergleichbaren Effekte 
vermitteln. Weiterhin wurden Subfraktionen von Ze 450 untersucht. Die EtOAc-Fraktion 
zeigte vergleichbare Effekte wie Ze 450, jedoch lagen die effektiven Konzentrationen 
höher als in korrespondierenden Konzentrationen des Gesamtextrakts. Ze 450 enthält 
neben Triterpenglykosiden auch Phenolsäuren, die antioxidative Effekte vermitteln. 
Tatsächlich zeigte Ze 450 im Vergleich zu Trolox moderate Eigenschaften als 
Radikalfänger, diese antioxidativen Effekten von Ze 450 tragen jedoch nicht 
hauptsächlich zum protektiven Mechanismus durch Ze 450 bei. 
Ze 450 zeigt großes Potential zur Behandlung von Erkrankungen, bei denen oxidative 
Schädigungen an der Pathophysiologie entscheidend mit beteiligt sind. Darüber hinaus 
wurde erstmalig ein neues Wirkprinzip herausgestellt, dass die metabolische 
Umprogrammierung und den damit verbundenen Schutz der Mitochondrien als zentralen 
Wirkmechanismus von Ze 450 hervorhebt.  
Neben Ze 450 wurde Ze 339, ein CO2-Extrakt aus Blättern von Petasites hybridus 
untersucht. Dieser wird zur Behandlung der saisonalen allergischen Rhinitis eingesetzt. 
Ziel dieser Studie war es den Wirkmechanismus von Ze 339 zu untersuchen und 
mögliche protektive Effekte gegen oxidative Schäden in HT22 neuronalen Zellen zu 
bewerten. Ze 339 induzierte eine milde Superoxidproduktion, beeinträchtigte aber die 
Zelllebensfähigkeit mit Konzentrationen bis zu 50 µg/mL von nicht. Im Rahmen der 
Theorie der Mitohormesis könnte Ze 339 durch einen leichten Anstieg der reaktiven 
Sauerstoffspezies vor mitochondrialer Beeinträchtigung schützen. Darüber hinaus 
schützte Ze 339 vor Erastin-vermittelter Zytotoxizität und mitochondrialen Schäden in 
HT22 neuronalen Zellen. Aus dieser Studie ergibt sich zusammenfassend die 
Hypothese, dass Ze 339 die Widerstandskraft der Mitochondrien durch moderate 
Superoxidinduktion stärkt und diese im Kontext der (mito-) hormetischen Regulation zu 
vorteilhaften Effekten, wie der Symptomlinderung bei der saisonalen allergischen 
Rhinitis beitragen können.  
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Abbreviations 
2-DG 2-deoxyglucose 
2-NBDG 2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-
deoxyglucose 
AD Alzheimers disease 
ADP  Adeonsinediphosphate 
AFDs Amphid neurons with finger-like ciliated endings  
AIF Apoptosis-inducing factor 
AMPK AMP-activated protein kinase 
AMR ATP monitoring reagent  
ANOVA Analysis of variance 
ATP Adenosinetriphosphate 
ARC Arcuate nucleus  
BID Bcl-2 interacting domain death antagonist 
BODIPY 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-
diaza-s-indacene-3-undecanoic acid 
bp Base pairs 
BSA Bovine serum albumin 
C. elegans  Caenorhabditis elegans 
C5a Complement component 5a 
Ca2+ Calcium 
CI, II, III, IV, V Mitochondrial complex I, II, III, IV, V 
Cl- Chloride 
CLSM Confocal laser scanning microscopy 
CNS Central nervous system  
CO2 Carbon dioxide 
COX Cyclooxygenase 
Cyt c  Cytochrome c  
DAPI 4',6-Diamidino-2-phenylindole 
DMEM Dulbecco's Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Desoxyribonucleic acid  
DNase Deoxyribonuclease 
DPN Diarylpropionitrile 
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DTT DL-Dithiothreitol 
e.g. Exempli gratia 
EBSS Earle's balanced salt solution  
ECAR Extracellular acidification rate  
EDTA Ethylenediamine-tetra-acetic acid 
EGTA Ethylene glycol-bis(2-aminoethylether)- 
N,N,N’,N’- tetraacetic acid 
EMA European Medicines Agency  
ER Estrogen receptor 
ETC Electron transport chain  
FACS Fluorescence-activated cell scanning  
FBS Fetal bovine serum 
FCCP Carbonyl cyanide-4-(trifluoromethoxy) 
phenylhydrazone 
FCS Fetal calf serum  
FoxOs Forkhead Transcription Factors 
fwd. forward 
GAPDH Glyceraldehyde-3-phosphatedehydrogenase 
GLUT Glucose transporter 
GPX4 Glutathione peroxidase 4 
GSH  Glutathione 
h Hour 
H2O2 Hydrogen peroxide  
HBSS  Hank´s balanced salt solution  
HCl Hydrogen chloride  
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIF Hypoxia-inducible factor 
HMPC Committee on Herbal Medicinal Products 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
HSP Heat shock protein  
HXKII Hexokinase II 
IFN Interferon 
IGF Insulin-like growth factor  
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IL Interleukin 
IL-8 Interleukin 8  
JAKs Janus kinases 
IMM Inner mitochondrial membrane 
IMS Mitochondrial intermembrane space 
kDa Kilo Dalton 
L. Carl von Linné 
LDHA Lactate dehydrogenase A 
LKB1 Liver kinase B1  
LOX Lipoxygenase 
LT  Leukotriene 
LTB4 Leukotriene B4 
mctx Mouse cortical neurons 
min Minute  
mL Milliliter 
mM Millimolar 
MM Mitochondrial matrix 
MOM Mitochondrial outer membrane 
MOMP Mitochondrial outer membrane potential 
mPTP Mitochondrial permeability transition pore 
mtDNA Mitochondrial DNA 
mTOR Mammalian target of rapamycin 
mTORC1 Mammalian target of rapamycin complex 1 
mTORC2 Mammalian target of rapamycin complex 2 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
n.s. Not significant  
NAC N-acetyl-L-cysteine 
NADH Nicotinamide adenine dinucleotide  
NADPH Nicotinamide adenine dinucleotide phosphate 
NaOH Sodium hydroxide 
nM Nanomolar 
nm Nanometer 
NMDA N-methyl-D-aspartic acid 
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NMDAR N-methyl-D-aspartic acid receptor 
Nrf2 Nuclear factor erythroid 2- related factor 2 
Nutt. Thomas Nuttal 
OCR Oxygen consumption rate  
OXPHOS Oxidative phosphorylation  
PA Pyrrolizidine alkaloids  
PAF Platelet-activating factor 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDK1 Pyruvate dehydrogenase kinase 1  
PEG Polyethylenglycole 
PEI Polyethylenimine 
Pen/Strep Penicillin + Streptomycin  
pH Potentia hydrogenii 
PI  Propidium iodide 
PI3K Phosphoinositide 3 kinase 
PPT 1,3,5-Tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole 
rctx Rat cortical neurons 
rev. reverse 
RNA Ribonucleic acid 
ROI Region of interest 
ROS Reactive oxygen species 
RT  Room temperature  
RTCA Real-time cell analysis 
s Second  
SD Standard deviation 
SDS Sodium dodecyl sulfate  
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis 
SGLTs Sodium-glucose linked transporter 
SLC2A Solute carrier family 2  
SOD Superoxide dismutase 
STAT Signal transducer and activator of transcription 
TBS Tris-buffered saline 
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TBST Tris-buffered saline and Tween 20  
TCA Tricarboxylic acid cycle 
TEMED Tetramethylenethylendiamine 
TMRE Tetramethylrhodamin ethyl ester 
U Units 
UbQ Ubiquinone 
UPLC TOF MS Ultra performance liquid chromatography time of flight 
mass spectrometry 
UV Ultra-violet 
V Volt 
WHO World Health Organization  
xCT Glutamine-cystine antiporter 
ΔΨm Inner mitochondrial membrane potential 
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